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Summary 
 
Respiratory syncytial virus (RSV) is a major respiratory pathogen, affecting the health of the 
very young and the elderly. RSV is the most important cause of lower respiratory tract 
infection in young children. Nearly all children will be infected by this virus at least once by 
two years of age [1]. Severe cases requiring hospitalization are not uncommon [2]. RSV-
related mortality rates range from 66,000-233,000 cases every year in children younger than 
five, of which most occur in the developing world [3, 4]. RSV infections cannot yet be 
prevented by vaccination or treated with an RSV-specific antiviral. Only children at high risk 
for developing a severe RSV infection are eligible for prophylactic treatment with 
palivizumab, a humanized mouse monoclonal antibody which reduces risk of hospitalization 
with 55% [5]. In this project, our aim was to develop a new RSV-specific antiviral. As target 
we chose for the fusion protein (F) of RSV for various reasons. This protein is membrane-
exposed, has an essential function in the RSV replication cycle (F mediates membrane 
fusion) and is highly conserved across the different RSV strains [6]. During fusion between 
virus and host membrane, the F protein transitions from a metastable prefusion 
conformation to a stable postfusion conformation. Most of the RSV-neutralizing activity in 
human serum is directed against the prefusion conformation of F [7, 8]. Therefore we aimed 
at developing an antiviral strategy against this conformation. To do so, we made use of the 
variable domain of heavy-chain only antibodies, an unconventional type of antibodies found 
in camelids and some cartilaginous fish [9, 10]. These variable domains are known as 
Nanobodies® or VHHs. VHHs are small, highly stable and soluble and can be cost-efficiently 
produced in microbial organisms. 
Immunization of a camelid with partially stabilized prefusion F followed by screening did not 
lead to very potent RSV-neutralizing VHHs. Therefore immunization was repeated with an 
improved version of prefusion-stabilized F. This time, after one round of panning on the 
prefusion F protein, two very powerful VHHs were isolated: F-VHH-4 and F-VHH-L66. These 
VHHs neutralize RSV A and B subtype viruses more potently than almost all of the previously 
described monoclonal F-specific antibodies. F-VHH-4 and -L66 are specific for the prefusion 
conformation of F, and bind this protein with very high affinity. Structural studies by X-ray 
crystallography showed that the two VHHs bind a cavity on the F surface formed by two F 
protomers. This site overlaps and is surrounded by antigenic sites from previously described 
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monoclonal antibodies. Furthermore, we could demonstrate that these VHHs protect mice 
from RSV infection and associated inflammation.  
Next to the development of a new potent antiviral, we also aimed at improving the mouse 
model for RSV research. Mice are not natural hosts for RSV and in fact they are poorly 
permissive for this virus. This means that very high doses of virus are needed to obtain an 
infection and even higher doses to induce some level of morbidity [11, 12]. This need for a 
high inoculum dose results in an infection process which is very different from that in man. 
To adapt the RSV A2 lab strain to the mouse as host, this virus was serially passaged in 
immune-depleted and later in immunocompetent mice. The resulting virus replicated more 
efficiently in mice and induced morbidity at a lower inoculum than the parental RSV strain. 
Deep sequencing analysis showed that the mouse-adapted virus consists of a pool of 
quasispecies containing different mutations. Five of these mutations, including a deletion in 
the gene coding for attachment protein G and a mutation in the gene coding for non-
structural protein 2, were present in more than 99% of the viruses. Single virus isolates were 
obtained from the mouse-adapted RSV pool, and these retained the mouse-adapted 
phenotype. Future research will be required to identify the mutations in the mouse-adapted 
RSV strain that are responsible for the higher replication in mice and to elucidate how these 
mutations contribute to mouse adaptation. 
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Samenvatting 
 
Het respiratoir syncytieel virus (RSV) is een belangrijk respiratoir pathogeen, dat een impact 
heeft op de gezondheid van vele kinderen en ouderen. RSV is de belangrijkste oorzaak van 
lagere luchtweginfecties in jonge kinderen. Bijna alle kinderen worden geïnfecteerd door dit 
virus voor de leeftijd van twee jaar [1]. Ernstige gevallen waarbij hospitalisatie nodig is, zijn 
niet uitzonderlijk [2]. RSV-gerelateerde sterfte varieert van 66.000 tot 233.000 gevallen per 
jaar, waarvan de meeste gevallen voorkomen in ontwikkelingslanden [3, 4]. RSV-infecties 
kunnen nog niet voorkomen worden door vaccinatie noch behandeld met een RSV-specifiek 
antiviraal middel. Alleen kinderen met een hoog risico op ernstige ziekte komen in 
aanmerking voor een profylactische behandeling met palivizumab, een gehumaniseerd muis 
monoklonaal antilichaam dat het risico op hospitalisatie met 55% vermindert [5]. Het doel 
van dit project was het ontwikkelen van een nieuw RSV-specifiek antiviraal middel. We 
kozen voor het fusie-eiwit (F) van RSV als doelwit voor verschillende redenen. Dit eiwit is 
zichtbaar op het membraan, het heeft een essentiële functie in de RSV replicatie cyclus (F 
medieert membraanfusie) en het is sterk geconserveerd tussen de verschillende RSV-
stammen [6]. Tijdens de fusie tussen het viraal- en gastheermembraan, gaat het F-eiwit over 
van een metastabiele prefusieconformatie naar een stabiele postfusieconformatie. Het 
meeste van de RSV-neutraliserende activiteit in menselijk serum is gericht tegen de 
prefusievorm van RSV F [7, 8]. Daarom hebben we ons gericht op het ontwikkelen van een 
antivirale strategie tegen deze conformatie van het F-eiwit. Hiervoor hebben we gebruik 
gemaakt van het variabele deel van zware-keten antilichamen, een onconventionele vorm 
van antilichamen gevonden in kameelachtigen en sommige kraakbeenvissen [9, 10]. Deze 
variabele domeinen zijn gekend als Nanobodies® of VHHs. VHHs zijn klein, erg stabiel en 
oplosbaar en ze kunnen kostenefficiënt geproduceerd worden in microbiële organismen.  
Immunisatie van een kameelachtige met een gedeeltelijk gestabiliseerd prefusie-F-eiwit 
gevolgd door screening resulteerde niet in potente RSV-neutraliserende VHHs. Daarom werd 
de immunisatie herhaald met een verbeterde versie van het prefusie-gestabiliseerde F- 
eiwit. Deze keer werden twee zeer krachtige VHHs geïsoleerd na één panningsronde op het 
prefusie-F-eiwit: F-VHH-4 en F-VHH-L66. Deze VHHs neutraliseren RSV A en B virussen op 
een meer efficiënte wijze dan bijna al de reeds beschreven monoklonale F-antilichamen. F-
VHH-4 en -L66 zijn specifiek voor de prefusievorm van het F-eiwit en binden dit eiwit met 
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zeer hoge affiniteit. Structurele studies toonden aan dat beide VHHs een holte op het 
oppervlak van het F-eiwit binden gevormd door twee F-protomeren. Dit gebied overlapt en 
is omringd door bindingsplaatsen van reeds beschreven monoklonale antilichamen. Voorts 
konden we aantonen dat deze VHHs muizen tegen RSV-infectie en geassocieerde 
inflammatie beschermen.  
Naast de ontwikkeling van een nieuw antiviraal middel, wilden we ook het muismodel voor 
RSV-onderzoek verbeteren. Muizen zijn geen natuurlijke gastheer voor RSV; ze zijn zeer 
weinig permissief voor dit virus. Dit betekent dat zeer hoge virusdosissen nodig zijn om een 
infectie te verkrijgen en zelfs nog hogere om enige morbiditeit te induceren [11, 12]. De 
noodzaak om een hoge inoculumdosis te gebruiken resulteert in een infectieproces dat sterk 
verschilt van dat in de mens. Om de RSV A2 labostam aan te passen aan de muis als gastheer 
onderging het virus seriële passages in immuungedepleteerde muizen en later in 
immuuncompetente muizen. Het resulterend virus repliceerde efficiënter in muizen en 
induceerde morbiditeit aan een lager inoculum dan de parentale RSV stam. Deep 
sequencing-analyse toonde aan dat het muisgeadapteerd virus uit een verzameling van 
quasispecies met verschillende mutaties bestaat. Vijf van deze mutaties, waaronder een 
deletie in het gen coderend voor aanhechtingseiwit G en een mutatie in het gen coderend 
voor het niet-structurele eiwit 2, waren aanwezig in meer dan 90% van de virussen. 
Virusisolaten verkregen uit deze muisgeadapteerde RSV-verzameling behielden het 
muisgeadapteerd fenotype. Verder onderzoek zal nodig zijn om de mutaties in de 
muisgeadapteerde RSV-stam te identificeren die verantwoordelijk zijn voor deze verhoogde 
replicatie in muizen en om te achterhalen hoe deze mutaties bijdragen aan de 
muisadaptatie. 
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Chapter 1 
Respiratory syncytial virus: an introduction 
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1.1 Discovery of RSV and history of RSV prophylaxis 
Respiratory syncytial virus (RSV) was first discovered in chimpanzees in October 1955 by 
Blount et al. who named the virus ‘Chimpanzee Coryza Agent’ [1]. A year after this report, 
the same pathogen was isolated from infants with severe lower respiratory illness [2]. The 
virus was renamed RSV due to its ability to induce the formation of syncytia (large cell 
fusions) in cell cultures. In the following years, the virus was isolated from patients of 
ranging ages, yet the most severe clinical illness was observed in young infants [3]. By the 
end of the 1960’s, an inactivated RSV vaccine was developed and tested in children. This 
vaccine however did not confer any protection and even resulted in enhanced clinical 
disease of vaccinees compared to the placebo group after a natural RSV infection [4-6]. This 
unexpected setback resulted in a delay in RSV vaccine development. Today, still no vaccine is 
available to control RSV. A prophylactic treatment based on intravenous injection of human 
RSV-neutralizing antibodies (Respigam®), was approved by the Food and Drug 
Administration in 1996 [7]. This therapy was replaced in 1998 by monthly intramuscular 
injections with palivizumab (Synagis®), a humanized mouse monoclonal antibody directed 
against the fusion protein (F) of the virus. This prophylactic treatment reduces 
hospitalization with 55%, yet its use is restricted to high-risk infants due to the high cost [8]. 
Despite many years of intensive research, still no RSV-specific therapeutic drugs are available 
in the clinic.  
1.2 Taxonomy and epidemiology of RSV 
 RSV is an enveloped, nonsegmented negative-sense RNA virus classified in the 
Paramyxoviridae family. This family has two subfamilies: Pneumovirinae and 
Paramyxovirinae. Human RSV belongs to the former together with the human 
metapneumovirus (hMPV) and their animal counterparts: bovine RSV, pneumonia virus of 
mice (PVM) and avian metapneumovirus. The Paramyxovirinae subfamily includes the 
measles virus, the mumps virus and the human parainfluenza viruses among others. Two 
antigenic RSV subtypes have evolved separately : RSV A and RSV B [9]. Strains of both 
subtypes can cocirculate, yet often one of the subtypes predominates [10, 11]. The subtype 
is defined by the attachment protein G, which displays high sequence diversity [12]. In 
temperate regions, RSV infections occur seasonally and last four to six months. The epidemic 
typically starts in autumn and ends in spring, the exact on- and offset varies between years 
and between locations [13, 14]. In tropical regions the epidemiology is less predictable, yet 
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some authors have reported that RSV outbreaks in these areas coincide with the rainy 
seasons [15, 16].  
1.3 Architecture of RSV 
RSV has a 15 kb long, negative-strand RNA genome, which codes for eleven different 
proteins: the non-structural proteins 1 and 2 (NS1 and NS2), the nucleoprotein (N), the 
phosphoprotein (P), the matrix protein (M), the small hydrophobic protein (SH), the 
attachment protein (G), F, M2-1, M2-2 and the large polymerase protein (L) (Fig.1a).  
 
Figure 1: Genome organization and schematic representation of RSV. (a) Genome diagram: each 
box represents a gene encoding a separate mRNA. The upper row of numbers (italicized) indicates 
amino acid lengths of the primary proteins. The numbers on the second row indicate the nucleotide 
lengths of the genes. The overlapping open reading frames of the M2 gene are indicated. The 
numbers under the diagram indicate the lengths of the leader, intergenic, and trailer regions 
(underlined) and the gene overlap (parentheses). Figure adapted from [17]. (b) Schematic 
representation of the RSV virion. 
As is visualized in Fig. 1b, RSV virions have three membrane proteins: G, F and SH. The G 
protein is a highly glycosylated type II transmembrane protein which mediates the 
attachment between the viral and the host membrane [18]. RSV G is found to bind to the 
glycosaminoglycan (GAG) heparan sulfate (HS) on immortalized cell lines [19, 20], yet this 
molecule is not present on the apical surface of primary human airway epithelial (HAE) cell 
cultures and is thus very likely not the actual attachment factor or receptor used in vivo [21, 
Fusion protein (F) Attachment protein (G)
Small hydrophobic protein (SH)
Nucleoprotein (N)
Large polymerase protein (L)
Phosphoprotein (P) Matrix protein (M)
a
b
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22]. The heparin-binding domain (HBD) is positioned next to a cysteine noose in the central 
region of the G protein, which is located in between two mucin-like domains (Fig. 2). The 
cysteine noose overlaps with the 13 amino acid long central conserved domain. Two 
cysteines in the cysteine noose represent the so-called CX3C motif that mimics a similar 
motif that is present in the CX3CL1 chemokine, also called fractalkine [23]. Tripp et al. 
showed that the G protein is able to bind to the CX3CR1 receptor and that fractalkine and 
anti-CX3CR1 inhibited RSV plaque formation in Vero cells (immortalized African green 
monkey kidney epithelial cells)[23]. They concluded that CX3CR1 is a possible receptor for 
RSV. This was supported by Johnson et al., who found that CX3CR1 is present on the apical 
surface of HAE cell cultures and is used by the virus to infect these cells [22]. This conclusion 
was based on three observations. (i) Soluble HS could only block infection of immortalized 
cell lines and not of the HAE culture,(ii) a so-called non-neutralizing G-binding antibody 
(which was found to block the interaction between G and CX3CR1) could prevent infection of 
the HAE culture but not of immortalized cells and (iii) RSV infection of HAE cultures is 
reduced when the G protein CX3CR1 motif is mutated. Interestingly, while the G protein is 
required for efficient virus replication in vivo [24], the central domain is dispensable [25]. 
Infection with RSV A2 deletion mutants lacking either only the cysteine noose or the cysteine 
noose and the conserved domain resulted in lung viral titers that are 3-10 fold lower 
compared to infection with wild type (WT) RSV A2, while 250-fold less virus was detected in 
the lungs of mice infected with RSV lacking the complete G protein. This surprising result 
indicates that CX3CR1 is probably not the only RSV receptor in mice. Still, the high 
conservation of the protein G central domain in human RSV isolates suggests that this region 
is important for infection of the human host. The RSV G protein can also bind to surfactant 
protein A (SPA) and annexin II, which therefore have also been suggested as possible RSV 
receptors [26, 27]. These receptor candidates have not yet been confirmed in HAE cultures 
or in vivo.  
An alternative translational initiation at Met48 results in a secreted form of the G protein, 
which is released from infected cells [28]. This protein functions as a decoy for the host 
humoral response [29, 30]. In mice, soluble G has an effect on Fc-receptor bearing 
leukocytes, in mice lacking the Fc receptor γ chain, there is no difference in susceptibility to 
WT RSV or RSV containing only membrane-bound G to passively transferred F-specific 
antibodies. However, in WT mice challenge infection with an RSV mutant virus that could not 
express secreted G was significantly better controlled by F-specific antibodies compared to 
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WT RSV [30]. The authors hypothesize that the secreted G protein might have an effect on 
the functioning or the influx of immune cells bearing an Fc receptor. This effect was later 
attributed to pulmonary macrophages and the complement system [29]. The CX3C motif 
may also have an effect on T cell influx, but the reports on this are contradictory. Harcourt et 
al. reported that soluble G reduces the migration of T cells to the mouse lung [31], while 
others reported that G has a chemoattractant activity through this motif both in vitro [23] 
and in vivo [32]. Anyhow, this effect does not greatly affect the replication of RSV in mice, as 
the presence or absence of the central domain does not impact viral replication much in 
mice [25]. 
 
Figure 2: Schematic of the RSV G protein. The transmembrane domain is shown as a black box. The 
amino acid sequence above the G protein shows the central conserved domain (underlined), the 
cysteine noose (cysteine residues are in bold, the disulfide bonding pattern is indicated by dotted 
lines) and the fractalkine CX3C motif (boxed). M48 is the translational start site for the secreted form, 
and the N-terminus of the mature secreted form is indicated with an arrow. (CT, cytoplasmic tail; TM, 
transmembrane domain; HBD, heparin-binding domain) 
The F protein is a type I transmembrane protein that is essential for the fusion between the 
viral and the host membrane. The fusion process is described in the next subchapter. Next to 
the fusion activity, several groups showed that F also displays some attachment activity. A 
cold-passaged attenuated RSV strain with a large deletion in the coding sequences of SH and 
G still replicated efficiently in tissue culture, indicating that another viral protein could take 
over the attachment function [33]. Feldman et al. showed that the F protein can use 
heparan-like molecules on the cell surface to facilitate attachment and infection of host cells 
[34], which was confirmed by Techaarpornkul et al. who developed a recombinant RSV 
lacking the G protein [35]. Others reported that RSV interacts with host-cell nucleolin via the 
F protein [36]. F-interacting partners can differ between RSV strains. For example, in contrast 
to F of the lab strain RSV A2, the F protein of a clinical strain (RSV 2-20) can interact with the 
epidermal growth factor receptor (EGFR), which is involved in airway mucin expression, 
thereby explaining the increased airway mucus production in mice infected with this strain 
TM CCT mucin-like mucin-like
Secreted form
HFEVFNFVPCSICSNNPTCWAIC
164
HBD
186
1
N
298
M48
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compared to other strains [37]. The authors thus considered EGFR to be a co-factor for 
infection.  
Following RSV infection, the human humoral immune response is primarily directed against 
the F and G proteins. Several epitopes have been characterized on the F protein. One is 
present only on the postfusion conformation (epitope I), two are present on both the pre- 
and the postfusion conformation (epitope II and IV, targeted by palivizumab and 101F 
respectively) and others are present only on the prefusion conformation (e.g. epitope Ø 
targeted by D25 and AM22) [38-40]. A more elaborate description of the F protein epitopes 
and F-specific antibodies is provided in the next chapter. 
SH is a small type II membrane protein which forms pentameric ion channels [41]. The 
function of this protein is not completely clear. Recombinant RSV strains missing this gene 
are not attenuated in vitro, and only slightly in vivo [42, 43]. This might be due to its effect 
on the host immune response as enhanced inflammation was observed after inoculation of 
mice with the SH gene knockout virus, suggesting an immunomodulatory role for SH [44]. On 
the contrary, SH is also found to be involved in inflammasome activation [45], like the matrix 
protein 2 of influenza A viruses [46]. Triantafilou et al. speculate that by being targeted to 
the Golgi, SH increases the membrane permeability resulting in imbalances in cellular ionic 
concentrations leading to inflammasome activation.  
An RSV particle is typically spherical, filamentous or a combination of the two [47]. The main 
determinant of this morphology is the M protein, which forms a layer below the viral 
membrane. This protein also has a key role in the assembly and budding of new viral 
particles [48, 49] .  
N binds to the viral RNA creating a viral ribonucleoprotein (RNP), which is the template for 
viral transcription [50]. Encapsidation by the helical N protein stabilizes and protects the viral 
genome from nucleases [51]. N also has an immunomodulatory role by associating with 
mitochondrial antiviral signaling protein (MAVS) and melanoma differentiation-associated 
gene 5 (MDA5) and sequestering them in viral inclusion bodies [52]. Interactions with the M 
protein results in a longitudinal organization of the RNP [47] and promotes the incorporation 
of the RNP into the budding virus [53].  
The P protein is an important part of the polymerase complex. It interacts with N, thereby 
opening the RNP structure and making the viral RNA accessible to the viral polymerase. P is 
9 
 
also able to bind free N protein monomers, preventing them from self-aggregating or 
binding nonviral RNA and delivering them to newly formed viral RNA [54].  
The L protein is the RNA polymerase, for which the RNP is the template. Together with N, P, 
M2-1 and M2-2, L forms the RNA-dependent RNA polymerase complex [55].  
The M2 mRNA contains two overlapping open reading frames (ORFs): the first one codes for 
M2-1 and the second one for M2-2 [56]. M2-1 functions as an essential transcriptional 
cofactor of the RSV polymerase [57]. It is an RNA-binding protein, yet it can also bind to P 
[58]. M2-1 also mediates the interaction between RNP and M [53]. M2-2 is involved in the 
regulation of the ratio between RNA replication and transcription [59].  
NS1 and NS2 are non-structural proteins which have an effect on the innate host immune 
response by counteracting the antiviral interferon (IFN) response [60, 61]. They do this very 
potently as RSV is a poor inducer of type I IFNs, while RSV lacking the NS1 and NS2 genes 
induces high levels of type I IFN [60]. The two proteins exert this effect independently, yet 
they act synergistically for the full inhibitory effect [60]. This regulation depends partly on 
the cooperative suppression by NS1 and NS2 of the activation and nuclear translocation of 
interferon regulatory factor 3 (IRF-3), an important transcription factor for the early IFN-α1 
and β response [62]. NS1 can reduce IKKε, a kinase which phosphorylates and activates IRF-3 
via a nonproteasomal mechanism [63]. NS2 blocks the activation of IRF-3 by inhibiting the 
association between retinoic acid-inducible gene 1 (RIG-I) and MAVS [64]. NS1 and NS2 may 
also induce suppressor of cytokine signaling 1 (SOCS1) which negatively regulates type I IFN 
expression [65]. Strangely, NS2 could activate NF-κB, a transcription factor also involved in 
the induction of the early type I IFN response [62]. This NF-κB-inducing activity can suppress 
premature apoptosis, which could therefore enhance viral replication and spread [66]. TNF 
receptor associated factor 3 (TRAF3), another key player in the IFN synthesis pathway, is 
reduced by both NS1 and NS2 by a nonproteasomal mechanism [63]. NS2 also inhibits 
signaling downstream of the type I IFN receptor by proteasome-dependent degradation of 
signal transducer and activator of transcription 2 (STAT2), an essential transcription factor 
for the expression of IFN-inducible antiviral genes [67, 68]. Next to the effect on type I IFN 
induction, it has been reported that NS1 has an inhibitory effect on viral transcription and 
replication, thereby avoiding the accumulation of viral RNA which could potentially activate 
the innate immune system [69]. NS2 also promotes shedding of infected epithelial cells, 
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leading to an accelerated reduction of viral titers and to acute distal airway obstruction [70]. 
Therefore, NS2 is a major contributor to severe disease in young children.  
1.4 The RSV fusion process 
After virion attachment, the viral membrane normally fuses with the host cell membrane. 
This process is non-reversible and is catalyzed by the energetically favorable transition of the 
F protein from a prefusion to a postfusion conformation. The fusion-competent F protein, a 
type I fusion protein, is present in a metastable prefusion conformation. This conformation is 
considered metastable because the transition to the postfusion state can be stimulated with 
either heat or a low-molarity buffer [71, 72]. Transition can even occur spontaneously on the 
viral membrane [47]. The F protein is expressed as an inactive precursor protein (F0) which is 
cleaved by furin-like proteases at two sites, releasing a 27 amino acid peptide (p27), 
resulting in a trimeric protein of which each protomer consists of F1 (C-terminal) and F2 (N-
terminal) protein fragments [73] (Fig. 3). F1 and F2 contain two intermolecular disulfide 
bridges. 
 
Figure 3: Schematic of the RSV F protein. Hydrophobic domains are shown as black boxes. HRA and 
HRB are indicated in grey. (SP, signal peptide; p27, peptide 27; FP, fusion peptide; HRA and HRB, 
heptad repeats A and B; TM, transmembrane domain; CT, cytoplasmic tail) 
In the prefusion state, the hydrophobic fusion peptide (FP) at the amino-terminus of F1 is 
followed by four short α-helices, connected to each other by short loops. Upon triggering, 
these connecting loops refold into α-helices that are in phase with the heptad repeat A 
(HRA) helix and thus combined form a single long HRA α-helix which presumably pushes the 
hydrophobic fusion peptide into the host membrane. The HRA α-helices of the resulting pre-
hairpin intermediate trimerize and the F protein collapses which causes the virion 
membrane proximal HRB α-helices to insert between the HRA α-helices, thereby creating a 
6-helix bundle (6HB) [74, 75] (Fig. 4). This conformational change brings the two membranes 
together resulting in hemi-fusion and eventually complete membrane fusion. This creates a 
pore that allows the release of the virion contents into the host cell. The crystal structure of 
pre- and postfusion F is shown in Fig. 5.  
SP FP TMHRA CTp27 HRB
1 25 109      136 574
F2 F1
N C
11 
 
 
Figure 4: Membrane fusion by RSV F refolding from pre- to postfusion state. The fusion peptide is 
indicated in turquoise and is followed by four short alpha helices indicated in blue. After triggering, 
the heptad repeat A (HRA) helices are completed and the fusion peptide inserts the host membrane. 
The protein folds and the HRA and HRB (in red) are combined, leading to the formation of the 6-helix 
bundle (6HB) and resulting in fusion. The central region of the F protein remains unchanged during 
the fusion process and is not depicted in this figure. Figure originating from [74].  
 
Figure 5: Structure of RSV F in the pre- and postfusion conformation. One of the three protomers is 
shown in color and ribbon presentation. The F1 and F2 domain are indicated in green and blue 
respectively, the fusion peptide is indicated in red. Figure adapted from [76].  
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1.5 Clinical impact of RSV infection 
RSV is the leading cause of lower respiratory tract infections (LRTI) in infants. Nearly all 
children in the world will be infected with RSV by two years of age [77]. In most cases this 
infection will remain asymptomatic or lead to common-cold like symptoms, yet in 1-2 % of 
cases severe bronchiolitis is developed and hospitalization is required [78, 79]. RSV is the 
most important cause of LRTI-related hospitalization in infants under the age of five and it is 
estimated that each year 66,000-233,000 children of this age group succumb to the 
consequences of an RSV infection [80, 81]. Most of these fatal cases occur in third world 
countries [80]. A severe RSV infection at young age increases the chance for long-term 
respiratory distress characterized by wheezing and/or asthma [82-84]. No durable immunity 
is developed after primary infection, which is why an individual can be infected with RSV 
multiple times throughout life. RSV is not only a dangerous pathogen for the very young, 
also the elderly are burdened with RSV-associated morbidity and mortality [85].  
The most important risk factor for severe RSV disease is young age, with 80% of hospitalized 
RSV-infected children under the age of two months being previously healthy [86]. Premature 
birth, HIV infection, an immunocompromised status, low birth weight and male sex are other 
known risk factors [87-90]. The household situation (crowded living conditions, indoor 
smoking) can also greatly impact the risk of a severe RSV infection [90, 91].  
In infants, severe RSV disease is characterized by robust virus replication in the bronchiolar 
and alveolar epithelium, with sloughing of infected cells into the airway. Together with 
infiltrating leukocytes, fibrin and mucus, sloughed infected cells form plugs that can obstruct 
the narrow airways of infants [70, 92]. RSV infection also impairs cilia function leading to 
reduced clearance of the obstructing debris [93]. This all results in labored breathing, 
tachypnea, hypoxia and wheezing [94]. Also in adults who have experienced multiple RSV 
infections, RSV can spread to the lower respiratory tract, but severe clinical symptoms are 
rare in this age group [95]. In the elderly RSV pathology is more complex and affected by 
underlying conditions [96]. Viral shedding begins on average five days after the infection and 
goes on during three to six days in adults, two to three weeks in infants and even several 
months in the immunocompromised [97-100]. Clinical symptoms parallel viral replication, 
with a peak at day seven after infection for both parameters in experimentally infected 
adults [101, 102]. This correlation was also observed in children, where higher viral loads 
strongly predicted prolonged hospitalization [103]. Additionally, disease severity correlates 
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with decreased innate immune cytokine responses, suggesting that certain elements of the 
immune response to RSV infection are impaired in children with more severe RSV [104]. This 
was reflected by a study by Mejias et al., who reported that the severity of disease in 
children was found to be inversely correlated with the level of expression of T and B cell 
genes [105], indicating that RSV severity is both correlated with viral titer and lack of RSV-
combating immunity.  
1.6 RSV antivirals 
Currently, there are only two licensed drugs for treatment of RSV infection: inhaled ribavirin 
and palivizumab. Ribavirin is an nucleoside analog antiviral with in vitro activity against 
several RNA and DNA viruses [106]. Its routine use is no longer recommended because of 
limited evidence of effectiveness [107, 108]. Palivizumab (Synagis®) is a humanized mouse 
monoclonal antibody targeting the RSV F protein, which is used for immunoprophylaxis in 
high-risk infants. Monthly intramuscular injections during the RSV season resulted in a 55% 
reduction in RSV-caused hospitalization [8]. Financial considerations limit its use to infants at 
high risk: those who are born prematurely or have serious underlying conditions [109-111]. 
Although a single infusion of palivizumab (15 mg/kg) given to hospitalized RSV-infected 
children could reduce viral titers in the tracheal secretions, it did not reduce any of the 
clinical symptoms nor the RSV concentration in the nasal aspirates [112]. An improved 
version of palivizumab has been developed, named motavizumab, with greater RSV-
neutralizing potency [113]. Despite promising in vitro results, clinical trials with 
prophylactically administered motavizumab did not reveal a significant improvement over 
palivizumab [114-116]. Also a 2% greater incidence of cutaneous adverse effects in 
motavizumab recipients compared with palivizumab recipients was observed [116]. 
Therefore, motavizumab was not approved for use in the clinic by the Food and Drug 
Administration. Its potential as a therapeutic agent was also tested in a phase 2 trial 
involving over one hundred hospitalized RSV-infected children [117]. A single intravenous 
dose of motavizumab (30-100 mg/kg) could not lower the RSV load in the upper respiratory 
tract nor relieve the symptoms of any of the infected children. A smaller study reported a 
small effect on viral titers at day one post administration [118]. 
The development of potent antivirals is necessary as vaccination is no option for newborns 
who are at highest risk for severe RSV infection due to their low immune responsiveness. 
Several compounds are being tested in clinical trials (Table 1). 
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Table 1: Overview of RSV antivirals in clinical trials 
 Format Target Company Development status 
MEDI-8897 Antibody F MedImmune Phase 1b/2a 
RI-002 Antibody various ADMA biologics Phase 3 
REGN-2222 Antibody F Regeneron Phase 3 
ALX-0171 Antibody fragment F Ablynx Phase 1b/2a 
GS-5806 Small molecule F Gilead sciences Phase 2 
JNJ-53718678 Small molecule F Janssen Phase 1 
AK0529 Small molecule F Ark Biosciences Phase 2 
BTA-C585 Small molecule F Aviragen Therapeutics Phase 2 
Danirixin Small molecule CXCR2 GlaxoSmithKline Phase 2 
ALS-008176 Nucleoside analogue RSV polymerase Alios Biopharma Phase 2 
ALN-RSV01 siRNA N Alnylam 
Pharmaceuticals 
Phase 2b 
 
Multiple immunoglobulins are being developed as new anti-RSV agents: MEDI-8897, RI-002, 
REGN-222 and ALX-0171. Except for ALX-0171, these antibodies are developed for 
prophylactic treatment to prevent RSV disease. MEDI-8897 is a human monoclonal antibody 
with extended half-life (derived from AIMM's D25 [119]) which targets the prefusion F-
specific epitope Ø. RI-002 is an intravenous immunoglobulin (IVIG) treatment consisting of 
polyclonal RSV-neutralizing antibodies obtained from human plasma. This formulation was 
developed as an immunoglobulin replacement therapy to treat infants with primary immune 
deficiency disease [120]. ALX-0171 consists of three linked single-domain antibodies, the 
variable parts derived from camelid heavy chain-only antibodies (named Nanobody® by 
Ablynx or VHH). This trivalent VHH which targets epitope II of the F protein is administered 
directly to the respiratory tract via nebulization and is tested as a therapeutic in adults and 
children [121].  
Another group of RSV antivirals being developed in the clinic are the small molecule RSV 
inhibitors, most of which inhibit viral fusion. GS-5806, an RSV fusion inhibitor is a promising 
candidate. This small molecule was tested in adults in a clinical challenge study which 
showed that oral administration of this compound reduced viral load and severity of 
symptoms [122]. Danirixin is the only drug in the list which has no activity against RSV itself. 
This compound is a CXCR2 antagonist and inhibits neutrophil activation, which is an 
important part of RSV pathogenesis [123]. A phase 1 trial was finished in which was 
determined what concentration of danirixin is required to inhibit neutrophil activation in 
blood obtained from RSV-infected children and healthy adults. ALS-008176 is a nucleoside 
analog which inhibits RSV by terminating RNA strand elongation, thereby interfering with 
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viral transcription and replication. Promising results were obtained from a challenge study in 
adults and clinical trials are continued in infants [124]. ALN-RSV01 also targets the viral 
transcription and replication machinery. This therapeutic is based on RNA interference, it 
consists of a small interfering RNA which targets the mRNA coding for N [125]. Intranasal 
administration of ALN-RSV01 in lung transplant patients showed a great reduction in the 
development of bronchiolitis obliterans [126].  
So far, none of the above antivirals has been approved for clinical use. Therefore, treatment 
of RSV-hospitalized children is limited to administration of respiratory support and 
intravenous fluids [127]. Hopefully, these basic treatments will soon be complemented with 
an effective antiviral drug.  
1.7 RSV vaccine strategies 
The development of an effective RSV vaccine has had a rough start, with the unfortunate 
outcome of a formalin-inactivated (FI) RSV vaccine trial in the 1960s. RSV-naive children 
vaccinated with this vaccine experienced worse symptoms upon RSV infection compared to 
the control group [4-6]. Multiple hypotheses to explain this disease exacerbation were 
formulated. The formalin treatment supposedly altered the antigenic sites of the RSV 
membrane proteins leading to the induction of non-neutralizing antibodies which resulted in 
immune complex deposition and enhanced inflammation upon RSV infection [128, 129]. 
Others suggested that the exacerbated disease was due to an exaggerated Th2 response 
resulting in a strong pulmonary eosinophilic response during RSV infection [130].  
A second complication in the development of an effective RSV vaccine is the fact that a 
natural RSV infection does not provide long-lasting immunity, a property which an effective 
vaccine should of course have. People are reinfected throughout their entire lives even 
though there is only limited genetic diversity between the strains [131, 132].  
Another challenge is the successful immune evasive strategy used by RSV. RSV has evolved 
several mechanisms to escape or modulate innate immune responses. Type I IFN responses 
are effectively disrupted by NS1 and NS2, through various mechanisms [62, 64, 65, 67]. Also 
by mainly infecting the superficial epithelium of the respiratory tract, RSV avoids the host 
immune response effectively. Serum immunoglobulin G (IgG) has difficulty accessing the 
respiratory lumen, mainly the upper respiratory tract, while the local IgA is only short-lived 
[133]. Due to these elements, the upper airway is vulnerable to RSV infection and spread to 
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the lower airways is possible before adaptive immunity is active. The challenge is to develop 
a safe vaccine which is immunogenic enough to induce a proper protective immune 
response, while avoiding a possible exacerbation of disease symptoms. 
 To circumvent the problem of protecting newborns, whose immunity is too immature for 
vaccination and who are at risk for enhanced disease, researchers are investigating the 
possibility of maternal vaccination. Through active placental transfer of immunoglobulins, 
newborns would be protected from a serious RSV infection by their mother's antibodies 
[134]. Also breastfeeding was found to be a protective factor against severe RSV disease 
[135]. The half life of maternal IgG is approximately one to two months [136, 137], resulting 
in about six weeks to three months of protection after birth. Low levels of maternal antibody 
inhibit the infant's own RSV-specific antibody responses [138, 139]. So only when these 
immunosuppressive antibodies start to wane, vaccination is possible to protect the children 
from serious RSV-related illness in later infancy.  
To be able to assess the protective capacity of a new vaccine, the correlates of protection 
against RSV infection should be understood. Vaccination strategies often focus on inducing 
neutralizing serum antibodies. RSV-neutralizing serum antibodies can be protective against 
RSV, Piedra et al. found that people with naturally acquired serum neutralizing antibody 
levels at least equal to the minimal protective threshold titer were approximately three 
times more likely not to have an RSV-associated hospitalization compared to people having 
lower titers [140]. Others did not observe this protective effect of serum-neutralizing 
antibodies [141-144]. Experimental human infection models showed that mucosal IgA 
antibodies correlated better with protection than serum IgG [141, 145]. This is not 
unexpected, as mucosal IgA, unlike serum IgG, is readily available at the site of RSV infection. 
A prolonged protection by IgA antibodies is difficult to achieve by natural RSV infection as 
the development of IgA-specific memory against RSV is defective [146]. Although being 
protective, a fully protective level for any of the antibody types could not be defined [147]. 
RSV infections are possible no matter how high an individual's antibody titer, although 
incidence is lower in persons with higher levels [132, 147]. Another determinant important 
for protection is cellular immunity. It was shown that an increased level of RSV-specific CD8+ 
cytotoxic T lymphocytes in children correlated with a decreased risk of secondary RSV 
infection [148]. CD8+ T cells are also implicated in RSV clearance in mice, yet, unlike in 
humans, this is associated with lung pathology [149]. Despite this, vaccines based on 
inducing a cellular response rather than a humoral response are found to be protective in 
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mice. Administration of a vaccine consisting of a peptide representing the immunodominant 
M282–90 CD8
+ T cell epitope, the Toll-like receptor agonist poly(I:C) and a costimulatory anti-
CD40 antibody resulted in the induction of protective effector CD8+ T cells. The memory 
CD8+ T cells elicited by this vaccine however were only moderately antiviral [150]. The 
induction of protective memory T cells could be achieved by immunization with a live viral 
vector, based on a recombinant influenza virus expressing the F85–93 cytotoxic T cell epitope, 
as was reported by our group [151]. To maximize the chance for protection, an RSV vaccine 
should not only induce neutralizing antibodies, it should also induce protective T cell 
memory responses. A review on CD8+ T cell immunity against RSV is included in addendum. 
Multiple vaccine strategies are currently being tested in the clinic: live-attenuated RSV, 
vector-based, particle-based and subunit vaccines (Table 2).  
Table 2: Overview of RSV vaccines in clinical trials 
 Format Company Development 
status 
RSV-MEDI-ΔM2-2 
RSV-LID-ΔM2-2 
Live-attenuated NIAID Phase 1 
RSV cps2 Live-attenuated NIAID Phase 1 
RSVΔNS2Δ1313/1314L Live-attenuated NIAID Phase 1 
RSV001 Vectored ReiThera Phase 1 
ChAd155-RSV Vectored GSK Phase 1 
VXA-RSV-f Vectored Vaxart Phase 1 
MVA-BN-RSV Vectored Bavarian Nordic Phase 1/2 
Ad35.RSV.FA2 
Ad26.RSV.FA2 
Vectored Crucell Holland Phase 1 
RSV-F nanoparticles Particle Novavax Phase 3 
MEDI-7510 Subunit (F) MedImmune Phase 2 
F-protein vaccine Subunit (postfusion F) Novartis Phase 1 
GSK3003891A Subunit (prefusion F) GSK Phase 2 
RSV-DPX Subunit (SH) Immunovaccine Phase 1 
 
Live-attenuated vaccines are viruses which are modified in a way that they are unlikely to 
cause disease, yet still induce a protective immune response. An attenuated phenotype used 
to be obtained by serial passaging of the virus in vitro. Nowadays attenuation can be easily 
achieved by reverse genetics, introducing attenuating mutations with limited chance for 
reversion and mutations which enhances the vaccine's immunogenicity [152]. Such live-
attenuated vaccines for RSV are administered intranasally, avoiding the use of needles, and 
inducing both systemic and local mucosal immunity. Other advantages are that they do not 
cause enhanced disease, they broadly stimulate innate, humoral and cellular immunity and 
18 
 
they replicate in the presence of preexisting maternal antibodies [153, 154]. A disadvantage 
is that they might cause disease in the immunocompromised. Also, considering the 
immunological immaturity of young children, such vaccines may be incompletely attenuated 
in this population [153]. Three live-attenuated candidates with deletions of non-essential 
genes are currently being tested in clinical trials, one with the M2-2 gene deleted, one with a 
deletion of the SH gene combined with other attenuating mutations and one with a deletion 
of the NS2 gene combined with two mutations in the L gene. The former one (RSV-MEDI-
ΔM2-2) was evaluated in adults, RSV-seropositive and -seronegative children [155]. The 
deletion in M2-2 resulted in a shift of the balance between genome replication and viral 
gene transcription towards the latter, leading to an increase in synthesis of immunogenic 
viral proteins, yet a decrease in replicating virus [59]. Vaccination led to the induction of 
RSV-neutralizing titers in the RSV-seronegative children and these children seemed to be 
protected from RSV infection during the RSV season. These children did however have a 
somewhat increased risk of developing rhinorrhea upon immunization compared to the RSV-
seropositive children [155]. RSV cps2 is derived from a cold-adapted RSV strain, which was 
further attenuated by removing the SH gene and adding other mutations [156]. A phase 1 
clinical trial in healthy seronegative children was already completed, but no results have 
been published. RSVΔNS2Δ1313/1314L at last was derived from the same cold-adapted 
virus, but here instead of SH, NS2 was removed. The phase 1 trial with this vaccine is still 
ongoing, no results have been published yet. This attenuated virus is temperature-sensitive 
yet phenotypically stable at physiological temperature [157]. 
Another strategy is the use of vectored vaccines. Using vectors to deliver RSV antigens has 
the advantage of stably presenting the desired antigen and having the adjuvant effect of the 
vector. Yet it also has the disadvantage of inducing anti-vector immunity which could be 
problematic for later immunizations. The RSV001 vaccine for example consists of two 
independent vectors, simian adenovirus and modified vaccinia virus Ankara (MVA), which 
both express the viral proteins F, N and M2-1 [158, 159]. These vectors are considered to be 
safe and potent inducers of immunity. The simian adenovirus was selected because of the 
low prevalence of pre-existing anti-vector immunity, however more than 3% of the 
volunteers presented with pre-existing antibody directed against the adenoviral vector. The 
F protein was included for elicitation of neutralizing antibodies, while N and M2-1 were 
included for induction of T-cell immunity. Different prime-boost combinations were tested in 
healthy adults and all regimens were found to be safe and well tolerated. Vaccination 
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elicited both humoral (IgG and IgA) and cellular responses, without detectable Th2 cytokines 
which are associated with enhanced disease. Another vaccine, MVA-BN-RSV, based on the 
MVA vector expressing the RSV F and G protein and some undisclosed internal proteins, was 
also well tolerated in adults, and provided both B- and T-cell immunity. This vaccine could 
also boost RSV-specific immunity in elderly subjects. A phase 2 trial with this vaccine in 
elderly will be initiated in the near future [160].  
Multiple subunit RSV vaccines are currently being tested. A subunit vaccine is based on 
purified protein, usually F or G for RSV. These vaccines could be of use to immunize older 
children, adults and elderly, for who live-attenuated vaccines might be too attenuated to 
induce a proper immune response. A disadvantage associated with these vaccines is the 
need for boosters to elicit sustained immunity which is not always needed with replication-
competent vectored or live-attenuated vaccines. Also, in contrast to replication-competent 
vaccines, no endogenous antigen expression is induced, resulting in low CD8+ T cell induction 
[161]. Subunit vaccines will thus primarily induce B cell and CD4+ responses, which is 
associated with a higher risk for vaccine-enhanced disease in seronegative children [162]. 
This concern however doesn't prevent the testing and use of such vaccines in other target 
groups.  
The smallest membrane protein of RSV is also considered as a vaccine target: SH. An 
antibody response raised against the SH ectodomain would mainly be directed to infected 
cells, as the SH protein is hard to detect on the virion itself [163]. In an experimental mouse 
model, protection by these antibodies is based on clearance of infected cells through Fcγ 
receptor-dependent antibody-dependent cellular cytotoxicity and phagocytosis [164]. A 
vaccine based on this SHe antigen (RSV-DPX) is currently being tested in a phase 1 
randomized, observer-blind, controlled, dose escalation trial in healthy adults that are 
younger than 50 years. Preliminary results of this trial were positive in terms of safety and 
the observed immunogenicity. 
RSV antigens can also be presented through nanoparticles. For example the vaccine 
developed by Novavax, consisting of recombinant F-proteins which are self-assembled into 
nanoparticle constructs approximately the size of RSV [165, 166]. According to the 
manufacturer this conformation enhances the immune response. Phase 2 clinical trials in 
elderly individuals showed that this vaccine could significantly induce palivizumab-
competing antibodies and could reduce the amount of RSV infections in this population up 
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to one year after immunization. Also maternal immunization with this nanoparticle vaccine 
was tested in a phase 2 trial. The vaccination seemed to be well-tolerated and could induce 
antibodies which were robustly transferred to the infants, supposedly protecting the 
newborn for a minimum of 90 days [167]. A phase 3 clinical trials with this vaccine in elderly 
adults was recently finished. Preliminary results of this trial show however that the vaccine 
could not lower the chance of RSV-associated lower respiratory tract disease in this age 
group [168]. A phase 3 clinical trial with this vaccine in pregnant women has already been 
initiated. 
1.8 Studying RSV in animal models 
A great obstacle in the development of new antivirals and vaccines is the lack of a proper 
animal model reflecting the human RSV infection and disease process. 
Mice. Rodents are by far the most widely used lab animals in biomedical research. Also for 
studying RSV they have been instrumental. Mice are easy to manipulate, are available at low 
cost and allow statistically relevant group sizes. The study of biological processes in this 
species is straightforward due to the large availability of mouse-specific reagents. 
Unfortunately, for RSV this model comes with many limitations. Mice are only semi-
permissive for RSV infection, to obtain an infection these animals have to be inoculated with 
at least 105 plaque forming units (PFU) and to induce morbidity close to 107 PFU is necessary 
[162, 169]. The high inoculum volume and viral antigen load results in an unnatural temporal 
progression of the infection and initial immune response. RSV replication in mice is very 
restricted, negative-sense viral RNA does not rise after infection and slowly starts to decline 
after 24 hours [170]. Therefore it is very challenging to test the therapeutic efficacy of 
antivirals in this model, it is hard to block replication when almost no replication occurs. 
Lung pathology differs significantly between mice and men. Unlike in humans, lung 
pathology in mice is mainly mediated by a strong CD8+ T cell response, although these cells 
are essential for clearance of the RSV infection [171, 172]. Another difference with infection 
in humans is that in mice RSV mainly infects alveolar pneumocytes, while in humans 
infection occurs in both alveolar and bronchial epithelium [92, 173]. Only in mice in which 
the type I IFN pathways are interrupted, infection of the murine bronchiolar epithelium can 
be demonstrated [174]. This finding possibly implies that the type-I evading mechanisms are 
not effective in mice. Despite all these differences, the mouse model is still a popular model 
for studying RSV-induced immune responses and allergic inflammation.  
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Many vaccines are tested in mice, although being effective in mice does not always mean 
they are effective in men. Therefore, the mouse model is mainly useful as a negative 
selection of vaccine candidates; excluding the vaccines for further studies which have a 
negative outcome in mice.  
Another option in studying RSV in mice, is using a pneumovirus that naturally infects mice: 
PVM. Infection with PVM shows the pathogenesis of a natural respiratory virus infection, a 
low inoculum dose results in robust replication in the bronchial epithelial cells and 
symptomatic disease [175]. Also here, T cells contribute to both virus elimination and 
disease. Mortality upon a high-dose PVM infection however is independent of T cells [176]. 
PVM infection in mice reproduces many of the clinical features of severe illness caused by 
RSV infection in human infants [177]. PVM and RSV have only low amino acid identity (12-
43% for G and F respectively), thus this model can only be used to evaluate vaccine concepts 
and to study the immune response.  
Cotton rats. Cotton rats have often been used in the evaluation of RSV therapeutics and 
pathogenesis. The efficacy of antibody prophylaxis in preventing RSV disease was first shown 
in these animals. Both RSVIg and palivizumab advanced to clinical trials based on the cotton 
rat studies [178, 179]. The same disadvantages of using mice as a model can be applied to 
cotton rats except that cotton rats are found to be more permissive for RSV infection than 
mice [180]. Both mice and cotton rats mimic the enhanced disease that occurred in the FI-
RSV trials [181, 182]. A limitation of using cotton rats as lab animals is the limited availability 
of cotton rat-specific reagents and antibodies.  
Non-human primates (NHPs). Being discovered in chimpanzees, RSV obviously infects this 
species. Experimentally infected chimpanzees shed a large quantity of virus and showed 
upper respiratory tract disease symptoms like rinorrhea, sneezing and coughing, yet no 
symptoms linked to lower respiratory tract disease [183]. RSV vaccines also have been tested 
in African green monkeys [184, 185], because they allow efficient RSV replication. African 
green monkeys also showed enhanced pathology to RSV infection upon vaccination with FI-
RSV [186]. The great similarity between NHPs and man is a major advantage, but this does 
not outweigh the ethical, logistical and economical concerns. 
Calves. Human RSV is closely related to bovine RSV (bRSV), both antigenically and 
genetically. The epidemiology and pathology of these viruses are similar, bRSV being an 
important cause of respiratory disease in young calves [187]. Despite some obvious 
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limitations (their size, housing, difficulty to test large groups), calves could be a valuable 
preclinical animal model to evaluate the safety and efficacy of RSV vaccines. The RSV001 
vaccine has been tested in this animal model and has now moved on to phase 1 clinical 
trials, supporting the use of calves as RSV animal model [158, 188]. This model was also 
valuable in the research on the vaccine-enhanced illness caused by the FI-RSV vaccine [189].  
Sheep. Also sheep, and more specific lambs can function as an RSV animal model. Lambs are 
naturally infected by ovine RSV and they are also susceptible to experimental bRSV and 
human RSV infection [190, 191]. Human RSV infection of perinatal lambs leads to pulmonary 
pathology similar to a moderate RSV infection in infants [191, 192]. RSV mRNA significantly 
increased from day three to six after infection and dropped again at day 14 in newborn 
lambs, indicating active replication. This peak in viral load also coincided with a peak in 
pulmonary pathology and clinical symptoms [191]. Just like in infants, effectiveness of viral 
clearance depended on age, with reduced clearance in preterm lambs compared to neonatal 
ones [190]. The lungs of newborn lambs and human infants are similar on developmental, 
structural, cellular, physiologic and immunologic level. Just as in the cotton rat and the calve 
model, molecular tools to deal with sheep are limited. Another clear disadvantage which it 
shares with the calve model is the housing, small size of experimental groups and the need 
for veterinary expertise. 
1.9 Conclusion 
RSV is a highly infectious pathogen, infecting nearly all children at least once by the time 
they're two years old. In a small percentage of cases, RSV infection leads to serious 
bronchiolitis requiring hospitalization. Once hospitalized, RSV-infected children receive only 
supportive care to ease their symptoms. Still, despite many years of research, no RSV-
specific antivirals are available to treat these infants, nor a vaccine to prevent the infection. 
The unfortunate outcome of the inactivated RSV vaccine, the lack of sustained immunity 
induced by a natural RSV infection, the immune-evasive nature of RSV and the difficulty of 
doing RSV-related research in mice complicate the development of an effective vaccine and 
antiviral against RSV. Prophylactic administration of palivizumab lowers the chance of 
hospitalization in high-risk children, demonstrating the protective potential of F-binding 
antibodies. Other antibodies binding the F protein have been isolated which neutralize RSV 
more potently. These antibodies target specifically the prefusion conformation of F. 
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Treatments, prophylactic or therapeutic, based on these antibodies are potentially more 
effective than treatment with palivizumab. These prefusion-F binding antibodies are 
described in the next chapter.  
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2.1 Introduction 
Human respiratory syncytial virus (RSV) is a single-stranded negative-sense RNA virus which 
belongs to the Pneumovirus subfamily of the Paramyxoviridae family. Infection with this 
virus causes symptoms ranging from a mild cold to severe bronchiolitis and pneumonia [1]. 
Mainly in the very young and the elderly, RSV poses a serious health risk. RSV infection is the 
leading cause of infant hospitalization, with a peak occurring at two to four months of age 
[2]. Globally, RSV accounts for almost 7% of mortality in children between 1 month and 1 
year of age [3]. In the elderly, RSV has a disease burden similar to that of seasonal influenza 
A [4]. The only licensed RSV-specific antiviral is palivizumab (Synagis®), a humanized mouse 
monoclonal antibody which is administered prophylactically during the RSV season and can 
reduce RSV-associated hospitalization of high-risk infants by 55% [5]. Due to its high cost, 
use of palivizumab is restricted to high-risk infants [6]. The need for an effective vaccine or 
antiviral is high. Development of such compounds has proven to be challenging, many years 
of research has still not led to RSV-specific pharmaceuticals available in the clinic. In this 
chapter, we provide an overview of antibody-based candidate anti-RSV drugs that are 
directed against the fusion protein. 
2.2 The F protein as ideal target 
Three proteins are exposed on the outer surface of RSV: the attachment protein G, the 
fusion protein (F) and the small hydrophobic protein (SH). SH is small, sparsely present on 
the virion, poorly immunogenic and has an unclear function [7]. Therefore it is not yet clear 
if SH could be a valuable option as antiviral target. Although the G protein has an important 
function in the attachment of the virus to the host cell, it is not indispensable for viral 
infection in vitro nor in vivo. An RSV mutant expressing only the F protein on its viral 
membrane could still replicate efficiently in Vero cells and was attenuated in humans [8]. 
The loss of the G protein can be compensated by F, which is capable of facilitating 
attachment to the target cells [9-11]. Based on these observations, it is fair to state that F is 
the only RSV membrane protein that is essential for viral infection. Therefore, F is the most 
logical target for the development of RSV-neutralizing antibodies. F-targeting antibodies are 
indeed to some extent associated with protection against disease caused by RSV. A study by 
Kasel et al. showed that the level of F-binding antibodies in immune sera of children 
correlates with protection against reinfection and illness severity [12]. A correlation between 
RSV-binding serum antibodies and protection is however not always evident. In hospitalized 
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infants, Wright et al. could not detect a correlation between severity of illness and serum 
neutralizing antibodies [13]. In elderly, no correlation was found between RSV-specific 
immunoglobulin G (IgG) levels and clinical symptoms [14]. RSV infections in infants are still 
possible despite high levels of maternal F-binding antibodies, although the level of maternal 
serum antibody titer is positively correlated with reduced level of severe disease [15, 16]. 
Individuals with high levels of F- and G-binding antibodies directed against a particular strain 
of RSV could still become reinfected with the same virus strain within one year [17]. Mucosal 
RSV-binding IgA show a better correlation with protection [18-20], however also here no 
fully protective level could be defined [20]. So although no complete protection can be 
conferred by F-binding antibodies, they are linked to at least a degree of protection in 
humans. Treatment with F-targeting antibodies can be protective. This was validated by the 
use of the F-binding palivizumab, the only RSV-specific antiviral currently used in the clinic. 
Palivizumab reduces the risk of RSV-related hospitalization with 55% in high-risk infants [5]. 
In contrast to the G protein, the F protein is also highly conserved among RSV A and B 
subgroups, with amino acid sequence identities of 90% or higher [21]. In conclusion, of all 
RSV membrane proteins, the F protein is the most optimal target protein for the 
development of RSV-neutralizing antibodies.  
2.3 Pointing the arrows towards prefusion F 
The F protein is a type I membrane protein that is expressed as a 574 amino acid precursor 
F0 and is cleaved twice by furin-like host proteases in the Golgi complex [22, 23]. Possibly, 
the second cleavage occurs only after uptake of virions into macropinosomes by the host 
cells [24]. The result of this dual processing is the release of a 27 amino acid long peptide 
(p27) and the formation of the N-terminal 84 amino acid long F2 fragment that is disulfide-
linked to the C-terminal 438 amino acid long F1 fragment, which together form the fusion-
competent prefusion F protein [25-27]. The F protein is present as a trimer, but the exact 
timing of this trimerization is not known. F1 has two hydrophobic regions at its termini: the 
fusion peptide (FP), which is inserted in the host membrane upon fusion, at the N-terminal 
side and the transmembrane domain (TM), which anchors the protein in the viral 
membrane, at the C-terminal side. The FP is followed by four short α-helices (α2-5) which 
are connected by three short loops, that together make up the heptad repeat A (HRA) 
domain in F1. This configuration changes dramatically upon triggering: the loops adapt an α-
helical secondary structure that is in phase with the adjacent α-helices. The result is the 
formation of one long α-helix and the accompanying insertion of the FP in the target 
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membrane. In this pre-hairpin intermediate state, the HRAs positioned next to the FP, are 
arranged as a trimeric coiled coil and the protein collapses resulting in the joining of the HRA 
trimer and the HRB α-helices which are present at the other end of F1 next to the TM 
domain. This results in the formation of a stable six-helix bundle (6HB), the signature of 
postfusion F (Fig. 1 and 2) [28, 29]. Through this process, host and viral membranes are 
brought together and fuse.  
 
Figure 1: Membrane fusion by RSV F refolding from pre- to postfusion state. The fusion peptide is 
indicated in turquoise and is followed by four short alpha helices indicated in blue. After triggering, 
the heptad repeat A (HRA) helices are completed and the fusion peptide inserts the host membrane. 
The protein folds and the HRA and HRB (in red) are combined, leading to the formation of the 6-helix 
bundle (6HB) and resulting in fusion. The central region of the F protein remains unchanged during 
the fusion process and is not depicted in this figure. Figure originating from [28].  
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Figure 2: Comparison of RSV F in pre- and postfusion conformation. Structure of an F protomer in 
either prefusion (left) and postfusion (right) conformation, showing the change in secondary 
structure. Figure adapted from [30]. 
Electron cryotomographic characterization of RSV demonstrates that there are two types of 
spikes on the virion surface that represent F (Fig. 3) [31]. This is in line with imaging by high 
resolution electron microscopy of full-length F protein, which revealed cone-shaped and 
lollipop-shaped protein rods [32]. The cone-shaped rods represent the fusion-competent 
protein, present in a metastable prefusion conformation. This metastable form easily flips to 
the postfusion conformation under influence of heat or exposure to a low-molarity buffer 
[33, 34]. Due to this instability, it was for a long time more straightforward to recombinantly 
produce the F protein in the postfusion rather than in the prefusion conformation. The 
epitopes of the neutralizing antibodies palivizumab and 101F that have been mapped to 
linear regions in the F1 subunit, antigenic site II and IV respectively [35], were shown to be 
preserved in this postfusion conformation [36, 37]. This preservation explains why 
immunization with postfusion F protein is able to induce RSV-neutralizing antibodies [36]. 
Although some RSV-neutralizing antibodies do bind to postfusion F, it was found that human 
Ig preparations depleted from antibodies binding to soluble G and postfusion F still 
contained most of the RSV-neutralizing activity [38]. This was not linked to SH-binding 
antibodies, because depletion using live cells expressing the F and G glycoproteins was able 
to remove RSV-neutralizing activity from the Ig preparation [38]. The same group later 
Prefusion F Postfusion F
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published that these neutralizing antibodies could also be obtained from rabbits immunized 
with recombinant vaccinia viruses expressing a full-length RSV F [39]. They found that the 
rabbit and human neutralizing anti-F antibodies, depleted of those binding to postfusion F, 
bound to the prefusion form of RSV F [39]. These studies show that to obtain highly RSV-
neutralizing antibodies, the fusion-competent prefusion conformation should be targeted.  
 
Figure 3: F spike structures in pre- and postfusion conformation. Electron cryotomograph pictures 
of the fusion protein in the prefusion conformation (a) and the postfusion conformation (b) of RSV 
A2. (Scale bar = 10 nm.) Figure adapted from [31].  
2.4 The quest for stable prefusion F  
The stabilization of the fusion protein in the prefusion conformation was very challenging 
but of great importance for the development of a more potent vaccine antigen. Several 
groups attempted to recombinantly produce the prefusion F protein, with varying success. In 
a study by Chaiwatpongsakorn et al. soluble RSV F was produced in a pretriggered state by 
replacing the transmembrane and cytoplasmic domains with tags to ease purification and 
detection (Fig. 4b) [34]. The resulting protein appeared mainly in a spherical form as judged 
by electron microscopy, yet some molecules displayed a ''hat-pin'' shape with a thin, long 
body, which represents the postfusion conformation of F. Dialysis to a low-molarity buffer 
converted all the spherical molecules into elongated shapes, suggesting that those 
molecules were in a prefusion-like state [34]. The group of Concepción Palomo attempted to 
stabilize F in the prefusion form by the introduction of intermonomeric disulfide bridges to 
try to prevent refolding after solubilization, and the removal of the furin-cleavage sites (Fig. 
4c) [39]. The disulfide bonds were designed using a model of prefusion RSV F based on the 
structure of the parainfluenza virus 5 (PIV5) F protein. The resulting disulfide bonds can only 
be formed if the F protein is present in the prefusion conformation. Electron microscopy 
showed that the resulting molecules were heterogeneous in morphology yet a significant 
a b
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proportion had a more rounded structure, similar to the shape reported for the prefusion 
form of the F protein of PIV5 [40] and the prefusion RSV F obtained by Chaiwatpongsakorn 
et al. [34].  
Two years later, in a joint effort, the groups of Barney Graham and Peter Kwong managed to 
express soluble prefusion F protein stabilized by the prefusion specific antibody D25, that 
had been isolated shortly before [30, 41]. D25 bound to a F construct comprising of residues 
1-513 (leaving out the TM and cytoplasmic tail (CT) domain) C-terminally fused to a T4-phage 
fibritin trimerization domain (Fig. 4d). By co-expressing this F construct with antibody D25, 
the F protein was successfully captured in the prefusion conformation and the crystal 
structure of this complex could be determined. This structure revealed that although the 
overall shape differed dramatically between pre- and postfusion F, the majority of the 
secondary and the tertiary structure was preserved in both states. The large conformational 
change mainly results from the repositioning of the N- and C -terminal regions of the F1 
subunit [30]. Later, the same group succeeded in stabilizing the F protein in the prefusion 
conformation without the help of an antibody [42]. To achieve this, the researchers 
introduced cysteine pairs and/or cavity-filling hydrophobic substitutions at positions that 
were guided by the structure of the prefusion F protein in complex with D25, and again 
made use of the fibritin trimerizing domain. The construct with the most favorable 
characteristics related to yield, stability and antibody binding affinity was the so-called 'DS-
Cav1' construct, containing S155C-S290C substitutions introducing disulfide bridges ('DS'), 
and S190F-V207L cavity-filling hydrophobic substitutions ('Cav1') (Fig. 4e) [42]. Immunization 
with this protein elicited high neutralizing activity in the serum of both mice and rhesus 
macaques, which were respectively 8 to 70 times higher than those elicited by recombinant 
postfusion F. The fibritin domain used to trimerize DS-Cav1 is derived from the T4-
bacteriophage. To avoid this phage-derived domain which could result in off-target effects, it 
was replaced by a cysteine zipper in a next step [43]. Cysteines were introduced on strategic 
places in the native RSV F coiled coil so they would form disulfide ''rings''. The resulting 
designed RSV F protein, stabilized by four disulfide rings, elicited neutralizing titers in mice 
equivalent to those of DS-Cav1 (Fig. 4f) [43]. Recently, structure-based design led to a 
further improvement of DS-Cav1 [44]. Genetic linkage of the F subunits, deletion of the 
fusion peptide and an additional disulfide bond resulted in a second-generation DS-Cav1, 
''DS2'' (Fig. 4g). Immunization of naive mice with this new molecule with increased stability 
led to the induction of fourfold higher neutralizing titers compared to DS-Cav1 [44].  
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Another prefusion-stabilizing strategy was applied in the study by Widjaja et al. Here the 
HRB-regions were replaced with a GCN4 trimerization domain and the furin cleavage sites 
were mutated (Fig. 4h) [45]. The authors speculated that changing or deleting the HRB 
region would prevent 6HB formation and thus postfusion F formation. Merely introducing 
substitutions in HRB which prevent formation of 6HB was not sufficient to inhibit the binding 
with a postfusion-specific antibody. Antibody recognition profiles showed that the GCN-4-
extended F protein lacking HRB had prefusion-like characteristics [45].  
Additional strategies to stabilize the F protein in the prefusion conformation were reported 
by the group of Johannes Langedijk [46]. These strategies are based on the stabilization of 
the N-terminal part of the F1 fragment (containing the FP and HRA), the elimination of 
proteolytic exposure of the FP and the addition of a trimerizing domain (Fig. 4i). The TM was 
replaced with a fibritin trimerization domain and p27 with a short linker leaving out the furin 
cleavage sites. To prevent the rearrangement of the FP and HRA region, a proline residue at 
position 215 was introduced in the loops between the secondary structure elements. 
Another mutation was inserted at position 67, for further stabilization and at position 487 
for increased expression levels. The resulting prefusion F proteins outperform DS-Cav1 on 
expression levels and stability and induce high titers of neutralizing antibodies in cotton rats 
[46].  
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Figure 4: Schematic representations of prefusion stabilized F constructs. Letters below the F 
fragment indicate amino acid substitutions. Red crosses indicate mutations of the furin cleavage 
sites. (a) wild type F gene. (b) Prefusion F construct from [34]. (c) Prefusion F construct from [39]. (d) 
Prefusion F construct from [30]. (e) Prefusion F construct from [42]. (f) Prefusion F construct from 
[43]. (g) Prefusion F construct from [44]. (h) Prefusion F construct from [45]. (i) Prefusion F construct 
from [46]. (SP, signal peptide; p27, peptide 27; FP, fusion peptide; HRA and HRB, heptad repeats A 
and B; TM, transmembrane domain; CT, cytoplasmic tail; Thrombin, thrombin site; Fibritin trim, 
fibritin trimerization domain) 
2.5 The antigenic landscape of RSV F epitopes 
In the eighties and nineties, RSV F epitopes were discovered by competition binding 
immunoassays, isolation and sequencing of monoclonal antibody (mAb) escape mutants and 
the use of synthetic peptides to examine the binding of mAbs [35, 47-50]. These techniques 
led to the identification of various RSV F epitopes located in two to five antigenic sites. The 
inconsistencies in reported antigenic sites can be attributed to the different mAbs and 
techniques used. The epitopes found in these studies are clustered around three sites: site I, 
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II and IV (B, A and C in [49]), represented on Fig. 5. In contrast to sites II and IV, the epitopes 
of site I, bound by antibody 131-2a, are not very conserved among RSV strains and 
antibodies binding to this site have only marginal or no neutralizing activity [50, 51]. This site 
is only present in the postfusion conformation of RSV, explaining the very poor neutralizing 
activity of antibodies directed against this site [37, 52]. Site II and IV have been mapped to 
linear regions in the F1 fragment and are bound by the neutralizing antibodies palivizumab 
and 101F respectively [35]. These sites are present in both pre- and postfusion conformation 
of RSV F. Epitope II forms a helix-loop-helix structure which is found to be important for 
antibody recognition and elicitation [53], as immunization with the epitope peptide failed to 
elicit neutralizing antibodies while immunization with the helix-loop-helix grafted on a 
scaffold protein did elicit neutralizing activity [54, 55]. This site is also bound by 
motavizumab, an improved version of palivizumab, with enhanced in vitro neutralizing 
activity [56]. Motavizumab only differs by 13 amino acids from palivizumab, yet it has a 70-
fold higher affinity for the F protein and a 20-fold higher neutralizing activity [56]. An X-ray 
crystal structure of the peptide representing site IV bound to antibody 101F revealed that 
this peptide adopts a mostly linear conformation [57]. However, modeling and the low 
affinity 101F has for the epitope IV peptide, suggest that antigenic site IV is larger and more 
complex than the simple linear peptide [57]. This antigenic site is conserved in human 
metapneumovirus (hMPV), another member of the Paramyxoviridae family, which is 
exemplified by site IV-specific antibody 54G10, having neutralizing activity against both RSV 
and hMPV strains [58].  
 
Figure 5: Representation of RSV F with antigenic sites Ø, I, II and IV. Hydrophobic domains are 
shown as black boxes. HRA and HRB are indicated in grey. (SP, signal peptide; p27, peptide 27; FP, 
fusion peptide; HRA and HRB, heptad repeats A and B; TM, transmembrane domain; CT, cytoplasmic 
tail) 
As most neutralizing activity is retained in human serum depleted for antibodies against 
postfusion F and G, it follows that more epitopes are present on the prefusion conformation 
of F [38]. The elucidation of the structure of prefusion F [30] led to the identification of 
prefusion F-specific antigenic sites. The antibody (D25) used to stabilize prefusion F was 
SP FP HRA CTp27 HRB
1 25 109      136 574
F2 F1
N C
157 199 488 516 550
II (254-277) I (389)         IV (422-436)  
TM
530
Ø (62-69)  Ø (196-209)  
43 
 
found to bind antigenic site Ø ('zero'). This is a quaternary site including regions of F2 
(residue 62-69) and F1 (196-209) at the membrane-distal apex of the RSV F glycoprotein (Fig. 
5) [30]. Other prefusion specific epitopes were uncovered at the side of the F trimer, bound 
by antibodies MPE8, AM14 and 2E1. These prefusion specific antibodies, and the antigenic 
sites they bind to, are discussed more elaborately in the next paragraph. Recently an effort 
was done to identify all possible epitopes of the F and G protein by use of genome-fragment 
phage display libraries [59]. The phages in these libraries displayed protein segments ranging 
in size from 15 to 250 amino acids, thereby supposedly presenting all possible linear and 
conformational epitopes of either protein. Quaternary epitopes or epitopes for which post-
translational modifications are important for recognition by antibodies will however be 
missed by this strategy. Nevertheless this approach revealed that the antibody repertoire of 
young children before and after primary infection was similar, with antibodies binding to 
fragments from the N-terminus of F, encompassing site Ø, fragments covering antigenic site 
II and fragments from the C-terminus of F. A total of 18 antigenic sites were defined, 
containing seven large and eleven smaller ones. Interestingly a novel antigenic site was 
mapped to p27, the peptide that is absent in the mature F protein and only found in 
uncleaved F0. Antibodies that bind this site may have been elicited by exposure to immature 
virus or dying RSV-infected cells. The p27-specific antibodies probably do not confer much 
protection as this site is not present in the mature protein on the infectious virus. Two 
antigenic sites specific for prefusion F (one covering the p27 region and one covering site II 
and a part of site Ø) were uncovered that were not previously identified. Overall 
characteristics of F-binding antibodies are displayed in Table 1 and 2. 
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Table 1: Neutralizing potential and F-binding characteristics of RSV F-specific monoclonal 
antibodies 
Name Antigenic site Affinity for preF 
(KD) 
IC50 RSV A IC50 
palivizumab 
Ref. 
Postfusion F specific 
131-2a I >1000 nM No neutralization ND [42, 60] 
Post- and prefusion specific 
Palivizumab II 23 nM 100 ng/mlL  [42, 61] 
Motavizumab II 0.041 nM 44.6 ng/ml  504 ng/ml [42, 56] 
101F IV 3.2 nM 190 ng/ml 100 ng/ml [42, 62] 
54G10 IV ND 14.2 µg/ml  2.4 µg/ml [58] 
Prefusion specific 
D25 Ø 0.15 nM 2.1 ng/ml  209 ng/ml [41, 42] 
AM22 Ø 0.01 nM 1.15 ng/ml  209 ng/ml [42, 63] 
5C4 Ø 13 nM 15 ng/ml 800 ng/ml [30, 42] 
MPE8 Between II-IV ND 50 ng/ml  188 ng/ml [64] 
RSE4 II ND 175 ng/ml  188 ng/ml [64] 
AM14 Overlapping IV 0.18 nM  2.1 ng/ml  209 ng/ml [41] 
2E1 Around IV 13 nM  11.4 ng/mlL 200 ng/mlL [65] 
RSV A2 IC50 values are shown, unless these were not available than RSV A long values are mentioned, 
indicated with L.  
To compare the different RSV neutralizations assays, the RSV A2 IC50 values of palivizumab obtained 
in the same assay are mentioned. 
ND: not determined 
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Table 2: Characteristics of RSV F-specific monoclonal antibodies 
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131-2a      
Palivizumab      
Motavizumab      
101F      
54G10      
D25      
AM22      
5C4      
MPE8      
RSE4      
AM14      
2E1      
*Stabilization of the wild type fusion protein in prefusion conformation 
If no  or  sign is present, the trait was not yet investigated 
2.6 Antibodies specific for the prefusion conformation 
D25, AM22 and 5C4  
D25 and AM22 were retrieved from immortalized B cells from a human donor, selected for 
their high RSV-neutralizing activity [41, 63]. Antibody 5C4 was isolated from hybridomas 
derived from mice immunized with gene-based vectors expressing the F protein [30]. These 
antibodies potently neutralize RSV with half maximal inhibitory concentrations (IC50s) of 1 - 
15 ng/ml (Table 1). Despite having little sequence homology, these antibodies all bind the 
prefusion-specific antigenic site Ø, present at the membrane-distal apex of F [30]. The 
localization of this site on prefusion F is shown in Fig. 6. During the transition from prefusion 
to postfusion F, the secondary structure of this antigenic site remains mostly unchanged 
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while the tertiary structure of this antigenic site changes substantially, explaining the 
prefusion specificity of these antibodies (Fig.6). By binding this site, D25, AM22 and 5C4 
prevent the collapse to the postfusion conformation, thereby preventing RSV fusing with the 
host cells. The binding site of D25 is not confined to one protomer. The D25-light chain binds 
both the protomer that is bound by the heavy chain and the neighboring one [30]. 
Surprisingly, D25 also can bind monomeric RSV F, which apparently retains some prefusion-
like features [66, 67]. Despite the high conservation between F proteins from human RSV A 
and B subtypes, antigenic site Ø contains six naturally occurring amino acid variations. This 
sequence diversity may be linked to immune pressure on the RSV F apex, as this site is easily 
accessible on the surface of the virion or the infected host cell. In vivo prophylactic 
protection by antibody D25 could be demonstrated in cotton rats. Intramuscular injection 
with this antibody one day before challenge protected these animals from an RSV infection 
with higher efficacy than palivizumab [30]. A D25 variant with extended half-life, named 
MEDI-8897, is currently being tested in clinical trials. As the antibodies binding site Ø are so 
potently RSV-neutralizing, immunogens were developed based solely on the head region of F 
containing this antigenic site (amino acid 51-306) [68], hoping to induce mainly site Ø-
binding antibodies with high neutralizing activity. Immunization of mice with these 
immunogens resulted in the induction of RSV-neutralizing titers comparable to those of DS-
Cav1 immunization, and boosting of DS-Cav1-primed mice resulted in more site Ø-binding 
antibodies compared to boosting with DS-Cav1. These smaller vaccine candidates have 
increased stability compared to DS-Cav1 and could be used to direct the immune response in 
non-naive people to the attractive antigenic site Ø [68]. 
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Figure 6: Structure of prefusion F and postfusion F with epitopes indicated. The separate protomers 
are indicated in shades of grey. Antigenic site Ø is indicated in yellow, site II is indicated in blue, site 
IV is indicated in magenta. Upper panels: prefusion F. Lower panels: postfusion F. (a) Residues which 
interact with MPE8 are indicated in red, determined by isolation of antibody resistant mutants. (b) 
Site bound by AM14 is indicated in lime green, determined by crystallization studies (c) Site bound by 
antibody 2E1 is indicated in orange, determined by hydrogen/deuterium exchange mass 
spectrometry. Only site II and site IV are conserved in both prefusion and postfusion F. 
MPE8 and RSE4 
MPE8 is a human antibody developed by the group of Antonio Lanzavecchia, which has 
broadly neutralizing activity against four paramyxoviruses: human RSV, hMPV, bovine RSV 
(bRSV) and pneumonia virus of mice (PVM) [64]. An antibody neutralizing both RSV and 
a b c
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hMPV is rather rare, as antisera generated against either human RSV or hMPV does not 
contain any cross-neutralizing activity [69]. The fusion proteins of human RSV and hMPV also 
only share 33% amino acid identity [70]. The researchers rightfully believed that repeated 
exposure to both viruses, which is the case in humans [71], could lead to such cross-
neutralizing antibodies. MPE8 was isolated from immortalized B cells from human donors 
displaying high serum neutralizing antibody titers against both viruses. Next to MPE8, they 
picked up an antibody named RSE4 which also had cross-neutralizing activity against both 
RSV and hMPV. This antibody however was less potent against RSV and did not exhibit 
neutralizing activity against hMPV B, PVM and bRSV. The epitope of MPE8 was mapped on 
two highly conserved anti-parallel β-strands just below the helix-loop-helix bound by 
palivizumab, leading to cross-competition between the palivizumab and the MPE8 antibody 
(Fig. 6). This region does not undergo major conformational changes during transition from 
pre- to postfusion F, yet the antibody is prefusion specific, indicating that a more subtle 
transformation of this region takes place. Cross-competition studies with all the prefusion-
specific antibodies obtained in this study, led to the identification of 7 antigenic sites (S1-S7) 
on prefusion F, among which antigenic site II, IV and Ø. As MPE8 and RSE4 competed with 
palivizumab, they were considered to bind to antigenic site II (named S1 in this study) [64]. 
So although an antigenic site may contain an epitope that is present in both the pre- and 
postfusion conformation, this does not mean that this is true for all epitopes in this site. Like 
D25, MPE8 could also bind monomeric F [67]. MPE8 was more potent than palivizumab in 
reducing RSV titers in mice when given intravenously before infection. The antibody was also 
found to be protective in a therapeutic setting (administration at day one after infection), 
yet comparable to the effect of palivizumab [64]. Protective activity of MPE8 was also 
observed against hMPV and PVM. Also a mutant MPE8 without antibody effector functions 
(complement and Fc-receptor binding), could protect mice when administered after 
infection with PVM [64]. MPE8's therapeutic efficacy against PVM thus mainly relies on 
neutralization and inhibition of viral spread.  
AM14 
Gilman et al. reported on the prefusion F-specific antibody AM14 [67]. AM14 was selected 
from the same pool of immortalized human B cells as D25 and AM22, and was retained 
based on its high RSV-neutralizing activity [41]. Like the other prefusion-specific antibodies, 
AM14 potently neutralizes RSV (Table 1). AM14 recognizes a quaternary epitope at the side 
of the RSV trimer, which undergoes a dramatic conformational change during the pre- to 
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postfusion transition (Fig. 6). Unlike D25, of which the epitope is located for 90% on a single 
protomer, the epitope of AM14 is evenly distributed across two protomers, explaining the 
absence of AM14-binding to monomeric F. Thanks to this feature, AM14 is able to stabilize 
the fusion protein in the prefusion conformation without a trimerizing domain. Another 
property that distinguishes AM14 from D25 and MPE8 is its dependence on cleavage for 
binding, as no binding is possible to F with mutated furin sites [67]. Two reasons are put 
forward to explain this: the presence of p27 could result in steric hindrance or the uncut F 
protein does not fold into a proper prefusion conformation. This conformation however 
would still have some prefusion-like characteristics to allow D25 and MPE8 binding. 
2E1 
The 2E1 antibody was derived from a commercial, synthetic human antibody phage library 
(Morphosys HuCAL GOLD®) [72]. A specific panning strategy led to the isolation of a 
prefusion-specific antibody, 2E1. Peculiarly, 2E1 bound prefusion F only weakly as bivalent 
Fab fragment, while it bound prefusion F strongly as a full-length IgG. Although the RSV A-
neutralizing activity improved similarly when the bivalent Fab was converted to IgG (from an 
IC50 of 53.4 ng/ml to 11.4 ng/ml), the RSV B-neutralizing activity remained weak at an IC50 of 
520 ng/ml. A possible explanation of this inconsistency is the expression system used, being 
E. coli for the bivalent Fab and CHO cells for the IgG, resulting in differing posttranslational 
modifications. Competition studies showed that this antibody does not bind to site Ø or II. 
Shotgun mutagenesis revealed four residues on RSV F critical for binding to 2E1: N426, K433, 
G446, K465. Hydrogen/deuterium-exchange mass spectrometry analysis showed that 2E1 
probably binds in the proximity of antigenic sites IV/V/VI described in Lopez et al., around 
the binding site of AM14 [51] (Fig. 6).  
2.7 Conclusion 
RSV poses a major worldwide threat for both the very young and the elderly. Palivizumab, 
binding both pre- and postfusion F, gives limited protection to the weakest babies [5]. Yet 
most children hospitalized with RSV, were previously healthy [73]. No vaccine nor RSV-
specific antiviral is available to relieve these infants. Specific targeting of the active prefusion 
form of F, could result in such highly needed antivirals. The prefusion F-specific antibodies 
described in this chapter are all more potent than palivizumab. While palivizumab can bind 
to prefusion F, it also binds to the non-active postfusion F, diluting the antibody's 
neutralizing activity. Various binding sites of the prefusion-specific antibodies are described. 
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Not only antibodies binding to a site which undergoes a large conformational transformation 
(like site Ø) display potent neutralizing activity, also the antibodies binding to sites 
undergoing only subtle transformations can exhibit high neutralizing activity. By tightly 
binding to these sites, these antibodies probably fix the structure in the prefusion 
conformation, thereby preventing RSV fusion. The exact mechanism of stabilization is not 
clear. While probably most prefusion-specific neutralizing antibodies prevent the 
conformational change altogether, it is also possible that some function by preventing the 
collapse from pre-hairpin intermediate to postfusion state. Further development of these 
antibodies may lead to new tools for vaccine development or a new antiviral for either 
prophylactic or therapeutic treatment.  
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VHHs: New ammunition to battle viruses, follow-up 
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3.1 Introduction 
Members of the Camelidae family possess two kinds of antibodies, the conventional and a 
distinct antibody type. The latter type is composed of two identical heavy chains and are 
called heavy chain-only antibodies. Besides the absence of the light chain, these antibodies 
also lack the first constant heavy domain. Heavy chain-only antibodies were discovered by 
the group of Raymond Hamers at the Free University of Brussels and first reported upon in 
1993 by Hamers-Casterman et al., who already saw the biotechnological potential of 
isolating the variable part of these antibodies [1]. These variable domains of the heavy chain-
only antibodies (VHHs, or Nanobodies®) retain the full antigen-binding specificity of heavy 
chain-only antibodies and hold many advantages over regular antibodies. VHHs are very 
stable and typically soluble, allowing multiple ways of administration like inhalation or 
topical use for which regular antibodies are less suited [2-4]. They can also be easily 
produced in high levels in microbial or plant systems [5-7]. Their small size (around 14 kDa) 
and typically extended complementarity determining region 3 (CDR3) allows VHHs to 
recognize antigenic sites which are more difficult to access by conventional antibodies [8, 9]. 
Thanks to their small size, VHHs can also rapidly penetrate tissue [10]. Finally, the single-
domain nature of VHHs facilitates formatting into bi- or multivalent constructs with single or 
multi-target specificity [11]. 
This chapter describes the advances that have been made during the last five years in the 
development of VHHs as antiviral agents. Earlier developments are described in [12].  
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Table 1: Overview of recently described VHHs directed against viruses 
Virus Immunogen Camel
id 
Prod. Mechanism In vitro* In vivo* Specificity Ref 
Influenza A M2 Camel E. coli Neutralization  minimal inhibitory 
concentration at 1.2 
µM (12.5 µg/mL) 
200 µg VHH IN at 1 and 2 DPI 
resulted in 80% survival 
WT and 
amantadine 
resistant influenza 
A  
[13] 
Influenza A Total virus 
(H5N2) 
Camel E. coli Neutralization Minimal inhibitory 
concentration at 0.1 
µg/ml (4.2 nM) 
100 or 200 µg of VHH IP 2h 
before challenge resulted in 
complete protection. 
50 µg of VHH IN 1 DPI also 
resulted in complete 
protection  
H5N2 [14] 
Influenza A HA (H1N1) Alpaca E.coli Neutralization IC50 3.2 nM  Seasonal and 
pandemic H1N1, 
several H5N1 
strains, H2N2 and 
H9N2 (+ H2N2 if 
bivalent) 
[15] 
Influenza A NA (H5N1) Alpaca E. coli 
A. Thaliana 
Inhibition of 
viral release 
IC50 bivalent VHH: 
7.6 nM 
100 µg IN 4h before infection 
results in protection from 
morbidity , no difference in 
viral titers. 
H5N1 clade 1 and 
clade 2 
[16] 
Influenza A Inactivated 
H1N1 
Alpaca E. coli 
MDCK cells 
293T cells 
A549 cells 
Blocking of 
nuclear import 
of vRNP 
Intracellular 
expression 
disrupted infection 
of influenza virus 
 H1N1 (PR8) [17] 
Influenza A 
VSV 
Inactivated 
H1N1 and VSV 
Alpaca A549 cells 
E. coli 
Influenza VHHs 
block nuclear 
import of vRNP 
and viral mRNA 
transcription. 
VSV VHHs block 
viral mRNA 
transcription 
Intracellular 
expression blocked 
more than 90% of 
infection of either 
influenza virus or 
VSV 
 H1N1 (A/WSN/33) 
VSV Indiana 
[18] 
RSV F + RSV A Llama P. pastoris Neutralization  IC50: 0.1 nM  1 mg/kg IN on 2 and 3 DPI 
resulted in 50-fold lower 
lung viral titers 
RSV A and RSV B, 
several clinical 
strains 
[19] 
Rabies G Llama E. coli Neutralization 16.6 µg/ml can 
neutralize 95 % of 
all rabies 
pseudotypes. 
A mixture of rabies virus and 
VHH was injected IM, IP 
vaccination at day 0, 3 and 7. 
Death rate of VHH treated 
mice was 50%. 
Rabies aG strain [20] 
Rabies G Llama E. coli Neutralization IC50: 0.14 nM Intra-cerebral administration 
of 33 µg VHH 1 DPI could 
protect 60% of mice from 
lethality. 15 mg IP of half-life 
extended VHH 1 DPI can 
protect 71% of mice from 
lethality. 
Rabies genotype 1 
and 5 
[21, 
22] 
Poliovirus Polio virus 
Sabin strain 
Drome
dary 
E. coli Neutralization IC50: 7nM  Type I 
polioviruses 
[23] 
Rotavirus Rotavirus G3 
strain 
Llama Yeast VWK 
18gal1 
Neutralization IC50: 0.63 µg/mL 50 µg significantly reduced 
the number of days with 
diarrhea per pup 
Rotavirus strains 
Wa, RRV, WI61, 
69M, F45, VA70, 
RV4, DS1, ST-3 
and P 
[24] 
[25] 
Rotavirus Rotavirus VP6 
protein 
Llama Baculovirus
-infected 
insect 
larvae 
Neutralization 0.2 µg/mL reduces 
>80% of focus 
forming units 
Daily administration of VHH 
via milk, until 9DPI, 
protected piglets from 
diarrhea and could reduce 
virus shedding 30-fold 
Bovine rotavirus 
C48, IND and 
B223, Human 
rotavirus Wa, 
DS1, SA11, 
Gottfried, ST3, 
H1, 69M, F45, 
Arg720; Equine 
rotavirus H2, G3 
RRV strain 
[26-
28] 
 
58 
 
Table 1 continued 
Virus Immunogen Came
lid 
Prod. Mechanism In vitro* In vivo* Specificity Ref 
HIV gp140CN54 
gp140UG37 
Llama E. coli Neutralization IC50: 0.02-50 µg/mL  Group I: subtype A, C 
and B'/C. Group II: 
subtype B and C. Group 
III: subtype A, A/G, B, 
B/C and C 
[29] 
HIV-1 gp140CN54 
gp140UG37 
Llama E. coli Neutralization IC50: 0.023- 6.5 
µg/mL 
 Subtypes A, B, C, D, BC, 
AE, AG, AC, ACD, CD, 
and G 
[30] 
HIV-1 DNA encoding 
gp160 
followed by 
this DNA in 
combination 
with VLP 
bearing gp145, 
followed by 
soluble gp140 
Llama E. coli Neutralization Median IC50: 0.53 
µg/mL 
 Subytpe A, AC,AG,AE, B, 
BC, C, CD and G 
[31] 
HIV-1 gp140 or 
gp140 
crosslinked to 
a CD4 
derivative 
Llama E. coli Neutralization IC50: 0.2-57.3 µg/mL  HIV-1 subtype B, A, C, G, 
CRF01_AE and 
CRF02_AG 
[32] 
HIV-1 gp41 
proteoliposom
es 
Llama E. coli Neutralization IC50: 0.2-29.3 µg/mL  HIV-1 subtype A and B [33] 
HIV-1 Nef Llama E. coli Neffin 
counteracts 
effect of Nef on 
virus replication 
Neffin inhibits Nef 
function in 
macrophages and T 
lymphocytes 
 Neffin has broader 
inhibitory activity than 
VHH alone, against large 
panel HIV-1 Nef proteins 
[34, 
35] 
HIV-1 Rev Llama E. coli VHH binds 
multimerization 
domain of Rev 
and inhibits its 
oligomerization. 
Expression in cell of 
VHH leads to 
inhibition of HIV-1 
viral production  
 HIV-1NL4-3 molecular 
clone 
[36, 
37] 
HIV-1 No 
immunization. 
Panning on 
LFA-1, CD11a 
Alpaca E. coli VHH can inhibit 
HIV-1 
transmission 
VHH reduced 
transepithelial 
transmission 
 HIV-1Ba-L [38] 
Human 
norovirus 
GII.10 VLP 
protein 
Alpaca E. coli VHH binding 
causes VLP 
particles to 
disassemble 
VHH binding causes 
VLP particles to 
disassemble 
 Several GII genotypes 
(GII.4, GII.10 and GII.12) 
[39] 
Human 
norovirus 
GI.1 or GII.4 
VLP 
Llama E. coli  VHHs function in 
surrogate 
neutralizing assays 
(HBGA blocking and 
hemagglutination 
inhibition).  
 GI.1 and GI.3 or GII.4 
and other GII genotypes 
[40] 
HCV No 
immunization, 
panning on 
NSB5 protein  
Camel E. coli VHH inhibits 
RNA-dependent 
RNA polymerase 
20 µg of VHH could 
reduce HCF foci in 
HCV RNA 
transfected cells.  
 Genotype 3a, possible 
cross-genotype activity 
[41] 
HCV No 
immunization, 
panning on 
NS3-C protein 
Camel E. coli VHH inhibits HCV 
helicase 
25 µg of VHH could 
interfere with HCV 
replication  
 Genotype 3a and 2a [42] 
HCV No 
immunization, 
pannnig on 
NS3/4A fusion 
protein 
Camel E. Coli VHH inhibits HCV 
protease 
25 µg of VHH could 
reduce HCF foci in 
HCV RNA 
transfected cells. 
 Genotype 3a and 2a [43] 
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Table 1 continued 
Virus Immunogen Came
lid 
Prod. Mechanism In vitro* In vivo* Specificity Ref 
HCV No 
immunization, 
pannnig on 
NS4B 
Camel E. coli VHH inhibits 
NS4B function 
20 µg of VHH could 
reduce HCF foci in 
HCV RNA transfected 
cells. 
 Genotype 2a [44] 
HCV E2  Alpaca E. coli Neutralization IC50: 1-10 µg/mL  Neutralization across all 
HCV genotypes 
[45] 
HPV No 
immunization, 
panning on L1-
VLPs (Gardasil 
vaccine) 
Camel E. coli Neutralization 50 nM of VHH could 
inhibit HPV 
replication 
 HPV-16 [46] 
PRRSV Nsp9 Camel MARC-145 
cells 
VHH inhibits 
function of 
Nsp9 
VHH could inhibit 
cytopathic effect and 
block replication at a 
MOI of 0.01 or lower 
 PRRSV strain SD-16, 
VR2332, JXA1 and GD-HD 
[47] 
PRRSV Nsp4 Camel MARC-145 
cells 
VHH inhibits 
function of 
Nsp4 
VHH could inhibit 
cytopathic effect and 
block replication at a 
MOI of 0.001 or 
lower 
 PRRSV strain SD16 [48] 
*If multiple VHHs were described, only the neutralizing activity of the most potent one is provided. 
3.2 Therapeutic antiviral VHHs 
Influenza virus  
The influenza virus is a negative-sense RNA virus belonging to the family of the 
Orthomyxoviridae. The current vaccination strategy is able to prevent seasonal influenza 
relatively successfully. however, still as many as 250,000-500,000 people die due to influenza 
each year [49]. Pandemic outbreaks are unpredictable, precluding the possibility of providing 
a matching vaccine in time [50]. Since 2011, several VHHs have been developed which could 
serve as influenza A virus-specific therapeutics. Wei et al. described a VHH selected from a 
synthetic camel-based VHH library, that binds to the influenza M2 protein [13]. M2 is a small 
conserved membrane protein functioning as an ion channel which is required for uncoating 
the influenza virion in the host cell [51]. VHH M2-7A could inhibit viral replication of the 
A/PR/8/34 influenza virus in vitro by blocking the proton influx through this ion channel [13]. 
This is remarkable because usually M2-specific antibodies do not have in vitro activity 
against this virus. Conventional M2-specific antibodies typically exert their protective 
function by eliminating infected cells through their Fc-effector functions [52, 53]. 
Intraperitoneal (IP) administration of the VHH at 24 and 48 hours after infection with a lethal 
dose of influenza virus resulted in 80% of survival while all controls died, indicating that M2-
inhibitory VHHs can provide protection in vivo without an Fc tail.  
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Tillib et al. described a technique to efficiently and rapidly generate protective VHHs against 
any influenza virus, using the mouse-adapted H5N2 influenza A strain as an example [14]. In 
order to obtain neutralizing VHHs, a camel was immunized with an inactivated virus 
preparation, which was then panned on immobilized virus. After selection of individual VHHs 
which bind to the virus, a spacer and isoleucine zipper domain was added to the selected 
VHHs, promoting formation of trivalent VHHs. The higher avidity of trivalent VHHs is often 
associated with substantially higher biological activity [22]. The most powerful of the 
formatted VHHs, aHA-7 (which binds to the attachment and fusion protein hemagglutinin 
(HA)), neutralized H5N2 with a minimal concentration of 4.2 nM. This construct was tested in 
vivo. IP doses of 100 or 200 µg of formatted VHH administered two hours before infection 
protected mice from lethal H5N2 virus challenge. A lower dose of 20 µg only gave 50% 
protection. Also therapeutically, this VHH was protective. Intranasal (IN) administration of 50 
µg of aHA-7 24 hours after challenge resulted in survival of all treated mice. The researchers 
wanted to develop a time-efficient strategy to obtain influenza-neutralizing VHHs. 
Immunization with entire inactivated virus has the advantage that all structural proteins are 
potentially targeted by the heavy chain-only repertoire of the immunized camelid. On the 
other hand, immunization with recombinant HA, as was performed in the study by Hultberg 
et al., resulted in VHHs that neutralized H5N1 influenza viruses with much greater potency 
(IC50s of 3-9 pM for the bi- and trivalent constructs) [22]. Tutykhina et al. explored a passive 
immunization strategy for prolonged VHH delivery that was based on a recombinant 
adenovirus, using the anti-HA VHHs developed by Tillib et al. as proof of concept [54]. 
Delivery of these VHHs as transgenes encoded by an adenoviral vector, could potentially 
overcome the rapid renal clearance of the small VHHs in vivo. The gene encoding the 
formatted aHA-7 was inserted into a replication-deficient adenoviral vector, which was then 
tested in mice. Intranasal (IN) administration of 107 and 108 plaque forming units (PFU) of 
this recombinant vector 48 hours before lethal challenge with influenza virus completely 
protected the mice from mortality. Protection could only be established when the treatment 
was performed before the challenge (14 days to 24 hours in advance), while the VHHs 
administered as purified recombinant proteins protected only when administered between 
24 hours before and 24 hours after H5N2 infection. Mixing the adenoviral vector and the 
formatted VHH therefore gave the most optimal protection ranging from 14 days before to 
24 hours after influenza virus challenge. VHH aHA7 binds to the globular head of HA. A major 
limitation of using VHHs with HA head-specificity is the high mutation rate that is tolerated 
in most of the sequence encoding this region of HA, leading to a narrow species-specificity 
and rapid viral escape. VHHs that bind the stem region of HA have much broader neutralizing 
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activity, like the ones described in a study by Hufton et al. [15]. To obtain HA stem-specific 
VHHs, an alpaca was immunized with recombinantly produced HA derived from the 
pandemic H1N1 influenza virus and the resulting VHH phage-display library was subjected to 
panning on the immobilized immunogen. Binding studies showed that several VHHs bound 
to multiple influenza A virus subtypes. One VHH (R1A-B6) could even bind to both seasonal 
and pandemic H1N1, different H5N1 strains, an H2N2 and an H9N2 strain. VHH R1A-B6 could 
neutralize H1N1, H5N1 and H9N2 viruses, yet it did not neutralize H2N2. The specificity of 
the cross-neutralizing antibodies for the stem region of HA was shown by their lack of 
hemagglutination inhibition activity and the loss of binding to HA after low-pH treatment, 
which converts HA to the postfusion state. Activation of membrane fusion competency of 
HA by lowering the pH is associated with substantial conformational changes in the HA stem 
region, while the head domain remains intact [55]. Interestingly, formatting the VHHs as a 
bivalent construct broadened the cross-neutralizing activity displayed by two of the VHHs 
even more. For example, bivalent VHH R1A-B6 gained the ability to neutralize H2N2, while 
its H1 and H5 virus-neutralizing activity was not improved compared to its monovalent 
counterpart. In vivo, stem-specific antibodies strongly depend on Fc-receptor functions to 
exert their protective effect [56]. Only high doses of such antibodies can have a direct 
antiviral effect in vivo [57]. As VHHs lack an Fc tail, a high dosage may therefore also be 
needed to obtain in vivo protection, this could be achieved by direct administration to the 
lung via nebulization. 
VHHs directed against the second major influenza membrane protein, neuraminidase (NA), 
were described by our group [16]. NA is essential for the release of virus from infected cells 
by its sialidase function. Recombinant soluble NA derived from a clade 1 H5N1 virus was 
produced for the immunization of an alpaca and for the panning steps. VHHs were selected 
based on NA-binding and inhibition. To improve the biological activity of these VHHs, 
bivalent constructs were made by either using a camelid IgG2c hinge domain or a mouse 
IgG2a-derived Fc domain. Bivalency greatly increased the antiviral potential of the VHHs 
(500-2000 fold lower IC50s compared to monovalent VHHs). The Fc-domain fusion constructs 
were produced in a plant seed-based expression system in order to comply with their higher 
complexity. Some of the monovalent and bivalent VHHs could protect against influenza-
associated morbidity when administered prophylactically, yet this protection was not 
associated with reduced lung viral titers. This is perhaps not so surprising as the NA-VHHs 
can prevent viral budding but poorly hinder virus entry. Analysis of the viral titer in the 
broncho-alveolar lavage (BAL) fluid to assess the presence of free viral particles, might be a 
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better way to more specifically monitor virus release than assessing the viral load in total 
lung. Two IN doses (one before challenge and one six days later) of the bivalent VHHs could 
prevent H5N1-induced mortality. The Fc domain-linked VHHs were found to provide better 
protection against morbidity than their bivalent counterparts without an Fc domain, based 
on the observation that ten to fifty-fold less protein of the VHH-Fc fusions was needed for 
survival of treated mice.  
Ashour et al., developed VHHs targeting an intracellular influenza virus target, the 
nucleoprotein (NP) [17]. They immunized an alpaca with an inactivated H1N1 influenza A 
virus after which seven influenza-specific VHHs were selected by phage display or by 
selection using staphylococcal surface expression. Six of these seven VHHs were specific for 
the influenza NP protein and two distinct epitopes in NP were bound to. Intracellular 
expression of the VHHs could successfully disrupt viral replication in these cells. 
Mechanistically these VHHs all functioned by interfering with nuclear import of viral 
ribonucleoproteins (vRNPs) and one of them had an additional inhibitory activity at the level 
of genome replication. Later the same group applied a novel screening technique to isolate 
VHHs that bind to an intracellular protein of either the influenza A virus or vesicular 
stomatitis virus (VSV) a negative-strand RNA virus belonging to the Rhabdoviridae family 
[18]. Hereto, two alpacas were immunized with a mixture of inactivated H1N1 influenza A 
virus and inactivated VSV. A lentiviral plasmid VHH library was constructed, which was used 
to transduce A549 cells. These cells were infected by either virus and surviving cells were 
expanded and analyzed. This screening technique resulted in more hits than the phage-
display technique used before. Antiviral VHHs were then isolated that could block either 
influenza A virus infection or VSV infection by more than 90%, when expressed 
intracellularly. The targets were identified as either the influenza virus NP or the VSV 
nucleocapsid protein. Functional assays showed that the influenza-VHHs could block the 
nuclear import of the vRNPs and some also blocked the viral mRNA transcription. This latter 
mechanism was confined to the VSV-VHHs. Such VHHs, binding intracellular viral targets may 
help the development of small molecule inhibitors or could possibly be applied directly as 
antiviral by fusing them to cell-penetrating peptides.  
Respiratory syncytial virus (RSV) 
RSV, a negative-sense RNA virus belonging to the Paramyxoviridae family, is an important 
pathogen in both infants and the elderly. It is the main cause of lower respiratory tract 
infections in young children worldwide and there are no RSV-specific therapeutics available 
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to treat RSV patients [58]. Prophylactic treatment with palivizumab, a humanized mouse 
monoclonal antibody directed against the RSV fusion (F) protein, can reduce the risk of RSV-
related hospitalization with 55% [59]. This treatment, consisting of monthly intramuscular 
injections during the RSV season, is in practice limited to high-risk children due to its high 
cost. To further reduce the risk of hospitalization motavizumab was developed, a version of 
palivizumab with enhanced biological activity [60]. Clinical studies however did not show a 
sufficient increase in protection and a slight increase in adverse effects compared to 
palivizumab; further development of this antibody was therefore halted [61-63]. RSV-
neutralizing VHHs could serve as alternative, antibody-based therapeutics to treat RSV 
infections because their high stability and solubility allows administration via inhalation, 
delivering the molecules directly to the infected lungs. Ablynx, a biotech company 
specialized in the development and commercialization of VHHs, has a VHH, named ALX-
0171, against RSV in its product pipeline [19]. This is a trimeric VHH comprising of three 
Nb017 moieties linked tail to head to each other by glycine-serine linkers, which binds to 
antigenic site II of the RSV F. Site II is present on F in both the pre- and postfusion 
conformation and is also the target of palivizumab. Nb017 was selected from a VHH phage-
display library derived from a llama which had been immunized with soluble postfusion F 
protein and inactivated RSV A. Adapting Nb017 to a trivalent format increased its affinity to 
the prefusion conformation only 160-fold, while it increased its neutralizing activity roughly 
6000-fold for RSV Long and even more than 10,000-fold for the RSV B strain 18537. Escape 
viruses are less prone to emerge in the presence of the trivalent VHH compared to its 
monovalent counterpart [64]. Still, escape mutants could be selected which contained amino 
acid changes in antigenic site II. Some mutations (like N262I and N276Y) had a major effect 
on VHH neutralization while leaving the palivizumab neutralization unaffected, indicating 
that although Nb017 and palivizumab bind the same antigenic site, their respective epitopes 
are somewhat different. ALX-0171 neutralizes RSV with higher potency than palivizumab, an 
effect that might be attributed to either the smaller size and extended CDR loops of the VHH 
or to the higher flexibility of the GS-linker compared to a full-length antibody hinge or the 
different binding modes of a trivalent VHH [19]. This difference depends on the tested strain; 
while ALX-0171 is 130- to 400-fold more potent than palivizumab in neutralizing RSV A, this 
increased potency ranges between 6- and 650-fold for different RSV B strains. The in vivo 
efficacy of ALX-0171 was tested in cotton rats, in which RSV replicates somewhat better 
compared to mice. IN administration on day two or three after infection resulted in 
significantly lower lung viral titers at day four after infection. This reported effect could 
however be an artifact from remaining VHHs in the lung which then go on to neutralize the 
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virus in vitro, as the lung titers were determined through plaque assay and not by the 
quantification of the viral RNA. ALX-0171 could withstand the effects of nebulization because 
its prophylactic administration via whole-body exposure nebulization could still block RSV 
replication [19]. The protective effect of ALX-0171 was later confirmed in a neonatal lamb 
model. Administration of ALX-0171 by nebulization at day three to five post infection 
resulted in a strong (10,000-fold) reduction of viral titers determined by plaque assay and a 
more limited reduction (5-fold) on viral RNA in the BAL fluid at day six post infection, 
reflecting again the in vitro neutralization effect of remaining VHH in the sample [65]. Overall 
health scores were significantly better in the VHH-treated lambs compared to the control 
group and a strong reduction of viral lung lesions was reported in the VHH-treated lambs 
[65, 66]. The safety of ALX-0171 was confirmed in different animal models (cotton rat, rat, 
dog and bovine model) before the drug was tested in clinical studies. After successful trials in 
adults [67], the VHH moved on to a phase 1/2a clinical trial in which its safety was tested in 
children hospitalized due to an RSV infection [68]. This study showed that daily treatment 
with ALX-0171 for three days was considered safe and tolerable. Anti-VHH antibodies were 
found in 23% of patients, but there was no relation seen with any adverse effects nor did 
this affect the pharmacokinetics. However, it is unclear if such anti-VHH antibodies could 
alter the RSV neutralization activity. Although the primary goal of this study was to assess 
safety, also a significant improvement of the clinical symptoms could be observed indicating 
that treatment with VHHs can have a clinical effect in RSV-hospitalized children. 
Rabies virus 
Rabies virus is a negative-sense RNA virus belonging to the Rhabodviridae family. In humans 
it is a neurotropic virus which causes either furious rabies with symptoms like aggressive 
behavior and hydrophobia or paralytic rabies characterized by ascending paralysis [69]. Post-
exposure treatment with the rabies vaccine combined with highly expensive rabies 
immunoglobulin is the most effective way in preventing rabies virus-caused lethality. 
However, this treatment is completely ineffective upon the manifestation of the first 
symptoms. Once symptoms appear, rabies is always fatal. Each year about 70,000 persons 
die due to the consequences of a rabies infection [70]. VHH therapy could function as a more 
cost-effective means to prevent rabies-induced mortality. Boruah et al. selected VHHs 
against the outer envelope glycoprotein (G) of the rabies virus from a naïve llama-derived 
antibody library [20]. To increase the binding avidity of the VHHs they were fused with a 
coiled-coil assembly peptide, resulting in pentavalent VHH structures. In vitro neutralization 
potential rabies virus could be established using rabies pseudotypes. A combined vaccine-
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VHH treatment reduced mortality in a lethal mouse model for rabies with 50% compared to 
vaccine treatment alone. In the positive control group however, in which mice received a 
combined vaccine-equine rabies immunoglobulin treatment, no mice died. In this study the 
VHHs were administered together with the rabies virus, which is not so relevant for real life 
circumstances. VHHs that protect mice from rabies virus-induced mortality when 
administered 24 hours after infection were described by Terryn et al. [21]. The tested VHHs 
were directed against the rabies G protein, and the first development of these VHHs was 
described by Hultberg et al. [22]. Two different strategies of therapeutic administration were 
tested, treatment by direct intra-cerebral administration or treatment by systemic 
administration with or without half-life extension. Intra-cerebral administration of 33 µg of 
bivalent VHH (Rab-E8/H7) 24 hours after infection led to protection of 60% of mice; lower 
amounts of VHH were not protective. Intra-cerebral treatment with 100 µg of Rab-E8/H7 
could also significantly reduce viral spread to the posterior parts of the brain. Administering 
the bivalent VHH at later time points however resulted in progressively less protection. IP 
administration of 100 µg Rab-E8/H7 24 hours after infection could not protect the mice, and 
a dose of 10 mg was required to increase the time before death. The fusion or Rab-E8/H7 
with an anti-serum albumin VHH to extend the half-life, did increase the protective effect 
substantially. An IP dose of 15 mg of this half-life extended VHH could protect 71% of mice 
from mortality outperforming the highest available dose of commercially available human 
anti-rabies immunoglobulins, which could only prolong the survival time with two days when 
administered in the same way. In a more recent study the same group tested if combination 
therapy consisting of the half-life extended VHHs and the rabies vaccine resulted in a better 
outcome than VHH treatment alone in the mouse model [71]. Combined therapy (IP 
administration of 1.5 mg VHH and IM administration of the vaccine at 24 hours post 
infection, repeated vaccination three days later) resulted in the best prognosis with 60% 
survival. Vaccination alone could not protect the mice and VHH therapy alone saved only 
19% of the mice. Also in this setting the VHHs outperformed the human anti-rabies 
immunoglobulin as this, even in combination with vaccination, could not prevent mortality 
at all. Being more effective and cheaper in production, the VHHs described in these studies 
offer a very good alternative for the expensive and scarce anti-rabies immunoglobulins 
currently used in the post-exposure prophylaxis therapy. 
Poliovirus 
Poliovirus is a positive-stranded RNA virus belonging to the Picornaviridae family and can 
cause poliomyelitis. Eradication of this virus through vaccination was not yet achieved 
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although its incidence decreased substantially from an estimated 350,000 cases in 1988 to 
74 reported cases in 2015 [72]. To eradicate the poliovirus and to be able to treat possible 
new outbreaks, an effective antiviral is necessary. Further research was done on the five 
type I-poliovirus-neutralizing VHHs that were previously described by Thys et al. [23]. 
Mechanistic studies showed that these VHHs neutralize poliovirus by inhibiting attachment 
of the virus to the cell and by stabilizing the capsid and thus interfering with viral entry and 
uncoating [73]. Cryo-electron microscopy images showed that the binding sites of the VHHs 
overlap with the binding site for the poliovirus receptor located in a channel (called the 
canyon) on the viral capsid [73, 74]. To assess the possible emergence of drug-resistant 
strains, escape mutants were selected and analyzed [75]. These VHH-resistant mutants 
contained amino acid substitutions in the four viral capsid proteins. These substitutions are 
located at both the edge of the VHH binding sites and further away from the canyon and 
hidden beneath the capsid surface. The mutant viruses were found to be equally stable and 
have similar replication kinetics as the parental strains, indicating that they might continue 
to replicate next to the parental strain even in the absence of VHH. The resistant strains 
could still be neutralized by at least two of the other VHHs, thus combination therapy might 
prevent the selection of these resistant variants.  
Rotavirus  
Rotavirus, a double-stranded RNA virus belonging to the Reoviridae family, is the main cause 
of severe diarrhea in infants resulting in 453,000 deaths each year [76]. Vaccines are 
available, but they are expensive and lack consistent efficacy [77]. Treatment consists mainly 
of supportive symptom-based care as there is no rotavirus-specific therapy available. Anti-
rotavirus VHHs previously developed by van der Vaart et al. [24], were further characterized 
in a study by Aladin et al. [25]. It was shown that two VHHs (ARP1 and ARP3) could neutralize 
many cell culture-adapted strains of rotavirus and could bind different clinical strains. The 
target of these VHHs, which were obtained from a rhesus rotavirus-immunized llama, was 
identified as the rotavirus inner capsid protein VP6, containing many cross-reactive epitopes. 
A clinical study in rotavirus-infected infants showed that oral ARP1 therapy could 
significantly reduce diarrhea (a 22.5% reduction in stool output) [78] encouraging the use of 
VHHs to treat rotavirus-induced gastroenteritis. The ARP1 formulation consisted of freeze-
dried yeast supernatant of which 35% of the protein content was VHH. An alternative option 
for administering the VHHs directly to the patient is using the commensal bacterium 
Lactobacillus as a vehicle for VHH delivery directly to the gastrointestinal tract mucosa. A 
Lactobacillus paracasei bacterium was engineered in two different ways resulting in either 
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expression of mono- or bivalent ARP1 or ARP3 on the bacterium surface [79] or the 
production of the monovalent ARP1 and ARP3 VHH as secreted and/or surface displayed 
proteins [80]. The first strategy led to Lactobacilli which could reduce the rate of diarrhea in 
mice in both a prophylactic and a therapeutic setting with a slight improved efficacy for the 
bivalent VHH- compared to the monovalent VHH-expressing bacterium. Using the second 
strategy, the researchers could show that when the rotavirus was captured by one VHH on 
the surface of the bacterium, another secreted VHH from the same bacterium could bind to 
another epitope. Co-expression of two VHHs binding to different epitopes reduces the risk 
for development of resistance. This strategy is not yet tested in vivo. Another strategy to 
present the ARP1 VHH was developed by Álvarez et al. [81]. In this study Lactobacillus 
rhamnosus GG was modified to display ARP1 on its surface. The use of this Lactobacillus 
strain has the advantage that it's one of the best characterized probiotic bacteria, it has 
intrinsic anti-rotavirus activity and it colonizes the small intestine only transiently [82, 83]. 
Only a variant which had a defect in exopolysaccharide production was able to display ARP1 
on its surface. Analysis of the engineered strain in a mouse pup model showed that the 
ARP1-expressing bacterium could reduce (although not significantly) the prevalence, 
duration and severity of diarrhea compared to the control strain.  
Garaicoechea et al. also developed VHHs directed against the rotavirus VP6 protein [26]. 
These have now been tested in a neonatal gnotobiotic piglet model [28]. VP6-VHH (3B2), 
produced in baculovirus-infected insect larvae [27], was administered to the piglets via their 
daily milk during nine days after infection with a human group A rotavirus strain. Compared 
to treatment with milk supplemented with a preparation of control larvae, VHH treatment 
resulted in complete protection against diarrhea and reduced viral shedding 30-fold, thereby 
proving to be more effective than porcine IgG antibodies or VP6-specific IgY antibodies 
which failed to completely protect against rotavirus-induced diarrhea. Just like the VHHs 
described by Aladin et al. [25], this 3B2 VHH is reactive against many different human 
rotavirus strains, yet lower amounts of the 3B2 VHH were necessary to obtain the same 
neutralizing effect [28].  
Human immunodeficiency virus (HIV) 
HIV is a lentivirus belonging to the Retroviridae family and causes acquired 
immunodeficiency syndrome (AIDS). Although the currently available antivirals effectively 
suppress the virus, they still can't completely eradicate the virus from an infected person. 
Scientists are continuing the search for new HIV-specific antivirals because the current drugs 
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are expensive, have to be taken lifelong and can elicit side effects. Their low production 
costs and high stability make VHHs a good format for new anti-HIV strategies. During the last 
five years, many VHHs were developed against HIV. 
Strokappe et al. described the development of VHHs against the HIV envelope protein (Env), 
which mediates attachment and fusion [29]. Env consists of a complex constituted of surface 
gp120 and transmembrane gp41 glycoproteins and binds to the primary receptor, CD4, 
followed by a chemokine co-receptor [84, 85]. To obtain broadly HIV-neutralizing Env-
targeting VHHs, a llama was immunized with a mixture of gp140s (cleaved, soluble versions 
of the ectodomain of trimeric Env) from two HIV subtypes (A and C). After two panning 
rounds on Env using competitive elution with a soluble version of CD4, a competition assay 
was performed to selectively pick up the VHH clones that bind to the CD4bs (CD4 binding 
site). Ten selected VHHs were tested in a neutralization assay against a panel of 26 HIV 
strains from different subtypes. Based on the neutralization profiles, three groups of VHHs 
could be discriminated: group I (efficient against HIV subtype A, C and B'/C), group II 
(efficient against HIV subtype B and C) and group III (efficient against HIV subtype A, A/G, B, 
B/C and C). VHH 2E7, belonging to group III, had the broadest cross-subtype neutralization 
activity, neutralizing 21 out of 26 tested viruses. While determining which amino acids of the 
CDR1 and CDR3 region of 2E7 were most important for Env binding, it was found that a 
single amino acid substitution back to the germ-line sequence could enhance the binding 
activity of VHH 2E7 to the gp140 of HIV subtype B/C. McCoy et al. also aimed at developing 
anti-Env VHHs [30]. Hereto, they immunized a llama with the same mixture of gp140 
proteins used by Strokappe et al. The resulting VHH-phage library was immediately screened 
for HIV-1 neutralization to avoid enrichment of non-neutralizing VHHs which do bind to the 
antigen. A broadly-neutralizing VHH (J3) was isolated which had activity against 96 of the 
100 tested HIV-1 strains representing a wide range of HIV-1 subtypes. The epitope of the J3 
VHH was mapped to a region covering the CD4bs. The interaction with conserved residues in 
Env allows its broadly neutralizing nature. VHH J3 could also block cell-cell HIV spread, in a 
more potent way than any CD4bs-directed antibody tested. Full-length reconstituted VHH 
(J3-Fc) neutralized HIV-1 infection more effectively than the individual VHH [86]. The 
addition of an Fc tail may be advantageous for use in vivo as it has been shown that in vivo 
protection by broadly neutralizing HIV monoclonal antibodies depends mainly on Fc-
receptor mediated functions [87], which is reminiscent of the broadly neutralizing HA-stem 
specific antibodies against influenza virus. The J3 VHH is currently being tested in macaque 
challenge studies. The same group identified three other broadly neutralizing VHHs binding 
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to gp120 obtained after a new llama immunization [31]. The immunization process consisted 
of three steps. First the llamas were injected with DNA encoding gp160 from two HIV-1 
strains from subtype B and C, followed by twice the same DNA in combination with virus-like 
particles bearing the corresponding gp145 proteins and at last both llamas were injected 
four times with soluble recombinant gp140 from the same two strains. The third step was 
necessary because no HIV-neutralizing activity was found in the serum obtained after the 
first two steps. The three obtained VHHs each target a different area of the CD4bs, so using 
them together increased both breadth and potency of neutralization. Deep sequencing 
analysis showed that these VHHs and VHH J3 were elicited by the immunization indicating 
that the llama immunization model reproducibly can develop multiple broadly HIV-
neutralizing antibodies [31].  
Matz et al. aimed at developing VHHs specifically for the CD4bs or the co-receptor binding 
site of the Env protein, because these sites are highly conserved among HIV strains [32]. The 
epitopes of the co-receptor binding site are inaccessible before virion attachment, yet this 
changes after CD4 binding. To induce antibodies binding to these sites, a llama was 
immunized with trimeric gp140 with or without cross-linking to a small CD4 mimic and 
panning was performed on monomeric gp120, again with and without the CD4 mimic. A 
panel of broadly-neutralizing VHHs was selected that bound to either the CD4 or the co-
receptor binding site. One of the selected VHHs presented neutralizing activity against HIV-1 
subtypes A, B, C and CRF01_AE. After multimerization, all tested subtypes, including subtype 
G could be neutralized by this VHH. The recognition between a co-receptor-specific VHH 
(JM4) and gp120 was further characterized by Acharya et al. [88]. They showed that the JM4 
VHH targets a hybrid epitope that combines elements from both the CD4bs and the co-
receptor binding region, although its binding is compatible with CD4 binding to gp120. JM4 
was grafted onto an IgG2b scaffold, to test if antibody size has an effect on the 
neutralization. Previous studies showed that the CD4-induced co-receptor antigenic site is 
only accessible to antibody fragments and small molecules [89]. Surprisingly, the full-size 
IgG2b had much more potent and broad neutralizing activity than the VHH itself. Lutje-Hulsik 
et al., focused on another highly conserved region, the membrane proximal external region 
of gp41 [33], which is targeted by the broadly neutralizing antibodies 2F5 and 4E10. 
Immunization of a llama with the gp41 region formulated as proteoliposomes led to the 
isolation of a VHH (2H10) whose epitope overlaps with that of the 2F5 antibody. Just like this 
antibody, the VHH contains hydrophobic residues in the CDR3, which although they do not 
contact the antigen directly, are required for virus neutralization. The hydrophobic residues 
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are probably involved in the membrane interaction thereby facilitating antigen binding. The 
membrane proximal external region of gp41 possibly becomes membrane-embedded during 
the fusion reaction, so the antibodies binding this site should recognize it in the context of a 
membrane. Therefore the immunization was performed with the target as part of a 
proteoliposome. Also here, formatting the VHH into a bivalent construct resulted in 
increased and more broad biological activity.  
The VHHs obtained in these studies could function as microbicides or be valuable in the 
development of an HIV vaccine. Formulation as intravaginal microbicide (either in the form 
of a gel, tablet or vaginal ring) is possible thanks to their high stability [4]. Like the 
researchers point out themselves: ''VHHs are very stable under conditions they might 
encounter during transport, storage, or use by women''.  
Wang et al. developed an alternative antiviral strategy based on liposomes coated with anti-
gp120 VHH J3 (described in [30]) containing the antiviral hydrophobic drug dapivirine [90]. 
The VHHs were linked to the liposome either via non-covalent metal chelation or a covalent 
linkage. In vitro testing showed that although the binding avidity was enhanced, the 
neutralizing activity of the covalently bound VHHs was diminished. This was not the case for 
the non-covalently bound VHHs where surprisingly no increase in avidity was observed. The 
liposomes containing dapivirin could reduce viral replication more efficiently than free 
dapivirin irrespective of the presence of J3 VHH on the liposome surface. This combined 
approach could form an effective anti-HIV strategy.  
Bouchet et al. decribed VHHs against HIV Nef, a small protein which can manipulate the host 
vesicular transport and the intracellular signaling pathways to allow HIV infection and 
replication [34]. A more recent study reports further development of this anti-Nef VHH [35]. 
The Nef-binding VHHs were fused to modified SH3 domains creating so-called Neffins. Nef 
interacts with SH3 domains, present in some cellular proteins, like tyrosine kinases of the Src 
family. These Neffins could effectively inhibit all the functions of Nef including alterations of 
T lymphocyte and macrophage functions, in contrast to the Nef-VHHs which could not block 
the Nef-mediated downregulation of MHC-I molecules. Targeting Nef using these molecules 
could represent a promising new antiviral strategy.  
A third HIV protein that is targeted by the VHH technology is Rev, a protein important for 
nucleocytoplasmic export and expression of the late viral mRNAs. Vercruysse et al. 
previously identified a VHH (Nb190) which functions intracellularly and inhibits Rev 
multimerization causing a strong reduction in HIV-1 production [36]. More recent research 
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from the same group characterized the interaction between Nb190 and Rev using mutational 
and docking studies [37]. Cell lines have been generated which stably express Nb190 [91]. No 
virus-induced cytopathogenic effects were apparent in these cells, not even when cells were 
infected with a high multiplicity of infection (MOI). The replication of HIV-1 subtype A, B, C, 
D, G, H and O is impaired in these VHH-expressing cell lines demonstrating broadly 
protective properties of Nb190. A large-scale sequence analysis showed that the residues 
constituting the Nb190 epitope are well conserved across many HIV-1 subtypes [91]. A 
possible clinical application of this VHH would be in gene therapy, as this VHH needs to be 
expressed in the cell for its activity. New small-compound antivirals could also be developed 
which bind to the Nb190 epitope. 
Guedon et al. developed a VHH-based antiviral strategy directed against the virus-acquired, 
host-encoded protein leukocyte function associated antigen 1 (LFA-1), which plays an 
important role in cell recruitment to the site of infection [38]. The receptor of LFA-1, 
intercellular adhesion molecule-1 (ICAM-1) is expressed on both cervical and vaginal 
epithelium [92], possibly facilitating transmigration of HIV-1 infected lymphocytes and 
monocytes. An LFA-1-binding VHH, isolated from a naive alpaca, was picked up after panning 
on the LFA-1 CD11a domain. It could prevent the transmigration of HIV-1-infected cells in an 
in vitro transwell assay as well as an anti-LFA-1 monoclonal antibody [38]. A strategy where 
the VHH would be secreted by a commensal vaginal bacterium could be applied to prevent 
HIV1-transmission in the female genitourinary tract.  
Norovirus 
The norovirus is a positive-stranded RNA virus from the Caliciviridae family. Norovirus 
infections are an important cause of viral gastroenteritis. The development of norovirus-
specific vaccines and antivirals is cumbersome due to difficulties in growing human 
noroviruses in cell culture and the continuously evolving strains. Koromyslova et al. 
developed a VHH binding to a conserved epitope of the lower region of the norovirus capsid 
protein protruding domain [39]. This region is occluded on intact particles. This VHH was 
found after immunization of an alpaca with a virus-like particle (VLP) containing the capsid 
protein from norovirus GII.10. By binding to a conserved epitope, the VHH recognized 
antigenically distinct capsid proteins belonging to several GII genotypes. Interestingly, 
binding with the VHH caused the VLPs to disassemble in vitro. Next to a function in 
diagnostics, this VHH could be very useful as a broadly reactive norovirus antiviral. Also 
Garaicoechea et al. developed VHHs with therapeutic potential against norovirus [40]. They 
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immunized two llamas with VLPs containing either GI.1 or GII.4 capsid proteins. After a 
panning strategy to obtain VHHs highly specific for either GI or GII, VHHs were isolated which 
bind to a conformational epitope in the capsid protein protruding domain, except one which 
binds a linear epitope. The selected VHHs had varying specificities, the GI.1 VHHs were 
specific for the GI.1 genotype with only one VHH cross-reacting with GI.3. the GII.4 VHHs 
reacted with multiple GII genotypes. Some of the VHHs functioned in neutralization 
surrogate assays of which the outcome correlates with protection against norovirus disease, 
indicating that they may be successful as a prophylactic or therapeutic antiviral.  
Hepatitis C virus (HCV) 
HCV is a positive-stranded RNA virus belonging to the Flaviviridae family which causes 
hepatitis C. Chronic HCV infection may lead to progressive liver disease and cirrhosis. No 
vaccine is available to prevent HCV infection. Hepatitis C treatment is possible, however this 
is not straightforward due to different HCV genotypes which manifest differently, induction 
of HCV resistance, drug-drug interactions, side effects and contraindications for certain 
target groups [93, 94]. There is still a need for broadly effective and safe antivirals. Thueng-in 
et al. developed a VHH-based antiviral strategy targeting the HCV RNA-dependent RNA 
polymerase (named NS5B) [41]. Blocking this protein interrupts HIV replication and 
therefore also the HCV infection cycle. A naïve camel VH/VHH library (containing both the 
variable domains from the heavy-chain only antibodies and the conventional antibodies) was 
used to select VHHs binding to the NS5B protein. Four of the selected molecules were able 
to inhibit the RNA-dependent RNA polymerase activity. To be able to reach the intracellular 
target, the VHHs were made cell penetrable by linkage to a 16 amino acid cell-penetrating 
peptide (penetratin). Simple addition of these cell-penetrating VHHs to culture medium of 
cells transfected with HCV RNA could suppress HCV replication. The high dissimilarity 
between host polymerases and the viral RNA-dependent RNA polymerase would allow 
clinical use of these VHHs without fear for off-target effects. The same group also considered 
the NS3 helicase/NTPase as a possible target candidate for VHH therapy [42]. This enzyme 
both unwinds and separates RNA intermediate strands and eliminates secondary structures 
of the HCV RNA to facilitate transcription. NS3-binding VHHs were extracted from the same 
VH/VHH library, and again a cell-penetrating peptide was added. The resulting molecules 
could inhibit the activity of recombinant helicase and could also significantly reduce HCV 
replication. The epitope of one of the NS3-binding VHHs lays in a region of the helicase that 
is not shared by human helicases, therefore this compound should be safe to use in humans. 
In combination with NS4A, NS3 also has serine protease activity, which processes the viral 
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polyprotein during replication and has an important function for host immunity evasion. The 
same strategy was applied to develop VHHs specifically targeting the HCV serine protease 
[43]. Hereto, a HCV NS3 and NS4A fusion protein was produced which was used for panning. 
The selected VHHs could also suppress HCV replication when added to cell medium after the 
penetratin peptide was added. The latest update in the anti-HCV VHH studies published by 
this group encompassed a VHH targeting the NS4B protein, a multifunctional HCV protein 
which is important for the formation of the viral replication complex and which inhibits 
innate antiviral immunity [44]. The same strategy led to the development of cell-permeable 
VHHs which could abrogate the NS4B function and thereby inhibit HCV replication. The 
researchers propose to use a combination of all these cell-penetrable VHHs, specific for 
multiple sites of the HCV key enzymes as a new antiviral therapy against HCV. 
The HCV E2 glycoprotein, which is the host receptor binding protein and one of the two 
major targets for neutralizing antibodies, was chosen as a target for VHH therapy by Tarr et 
al. [45]. They isolated VHHs from a phage-display library obtained after immunizing an 
alpaca with recombinant HCV E2 lacking the HVR1 region which is the main target for strain-
specific antibodies. One particular VHH had cross-neutralizing activity against all six major 
HCV genotypes. It could also inhibit cell-to-cell HCV transmission, a process resistant to 
several broadly neutralizing antibodies. The epitope of this VHH overlaps with the epitopes 
of known cross-neutralizing antibodies at the receptor-binding site.  
Herpes simplex virus 2 (HSV-2) 
HSV-2 is a double-stranded DNA virus belonging to the Herpesviridae family which causes 
genital herpes. It is one of the most prevalent sexually transmitted infections. Despite its 
omnipresence, there is still no vaccine or antiviral available in the clinic. Geoghegan et al. 
developed a VHH which binds to the viral surface glycoprotein D [95]. After panning, only 
one D-binding VHH could be picked up, possibly due to the high number of panning rounds 
used (six rounds). This VHH however was not capable of neutralizing HSV-2. Therefore, the 
researchers linked the cytotoxic domain of exotoxin A to the VHH. The resulting molecule 
specifically neutralized HSV-2-infected cells at high potency. This VHH immunotoxin could be 
used preventive or therapeutically to treat HSV-2 infections. 
Human papillomavirus (HPV) 
HPV, a double-stranded DNA virus belonging to the Papillomaviridae family, is the main 
cause of cervical cancer which is the second most common female cancer in the world, 
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resulting in more than 200,000 deaths annually [96]. A HPV vaccine is available, yet it is not 
routinely administered [97]. Minaeian et al. isolated VHHs binding to the HPV-16 capsid 
protein L1 from a naive camel library after panning with the Gardasil vaccine consisting of 
VLPs carrying the L1 capsid protein [46]. These VHHs could effectively neutralize HPV-16 in 
vitro. The VHHs described in this study could be used, alone or in combinational therapy, 
topically in vaginal gels or washing solutions for the prevention of HPV infection.  
Porcine reproductive and respiratory syndrome virus (PRRSV) 
PRRSV is a positive-stranded RNA virus belonging to the Arteriviridae family which causes 
PRRS, a disease affecting the swine industry worldwide. No therapeutics are available to 
treat infection. Liu et al. developed a VHH against the PRRSV nonstructural protein 9 (Nsp9) , 
a conserved protein essential for the viral replication [47]. They immunized a camel with 
recombinant Nsp9 and after three rounds of panning, Nb6 was selected for its high binding 
activity. A cell line stably expressing this VHH could block viral replication by inhibiting 
genome replication and transcription. The same group later isolated VHHs against PRRSV 
Nsp4, a protease responsible of the maturation of certain PRRSV viral proteins and the 
modulation of host antiviral responses [48]. A similar set-up was followed like they used 
before. The resulting VHHs could potently suppress PRRSV replication when expressed as 
intrabodies. Both VHHs directed against either Nsp9 or Nsp4 have potential as an anti-PRRSV 
agent once the problem of the intracellular targeting has been overcome. 
3.3 Conclusion 
In the last five years, the number of VHHs developed against viral infections has greatly 
expanded. Their small size, high solubility and stability and ease of production and 
formatting makes them good candidates for antiviral strategies. Many of the VHHs were 
developed against viruses targeting mucosal sites. VHHs are better suited for use in these 
regions than full size antibodies because rapid penetration is possible due to their small size 
and harsh conditions (either during administration or at the site) can be easily endured 
thanks to the VHH's high stability and solubility. Topical administration of VHHs at these 
regions also avoids the otherwise rapid clearance of systemically applied VHHs.  
Multivalency often increases both potency and breadth of virus neutralization of a VHH. The 
flexibility of the linker could have an important influence. This is exemplified by bispecific 
anti-HIV1 antibodies of which the neutralizing activity substantially improved by engineering 
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the IgG3 hinge domain on the IgG1 structure to increase Fab domain flexibility while 
retaining the IgG1-Fc functional properties [98]. 
At low concentrations broadly neutralizing antibodies against HIV and influenza virus largely 
depend on Fc receptor-mediated functions for protection in vivo [56, 87]. Being single 
domain antibodies, VHHs as such cannot engage Fc receptor-mediated functions. Therefore, 
it could be necessary to administer the VHHs at high concentrations directly to the region 
where they are needed to obtain a protective effect. This can be achieved for example by 
nebulization for lung viruses, or gels or tablets for vaginal use for sexually transmitted 
viruses. If local administration is not possible, the VHH could be linked to Fc domains, if this 
does not abrogate the VHH function. 
Many of the described VHHs target intracellular viral proteins. Linkage to a cell-penetrating 
peptide or administration via gene therapy using lenti- or adenoviral vectors will be needed 
to deliver these VHHs intracellularly, if possible, selectively to virus-infected cells. Linkage to 
a cell-penetrating peptide could be useful if the VHH can be administered locally, as systemic 
administration could lead to the uptake of the VHH in cells were it has no function. Using 
gene therapy has the advantage that the treatment can be targeted to a certain cell type, 
but comes with the disadvantage of the induction of anti-vector immunity.  
Viral vectors can also be used for prolonged VHH delivery, illustrated by the adenoviral 
vector expressing a VHH directed against influenza HA [54]. Bacterial carriers can also be 
applied to deliver VHHs. The commensal bacterium Lactobacillus for example was used as 
carrier of anti-rotavirus VHHs in the gastrointestinal tract [79, 81]. This probiotic strategy 
could also be applied to battle viral infections in the female genitourinary tract. Prolonged 
delivery could possibly also be achieved by use of self-replicating RNA coding for the VHH of 
interest.  
Several VHHs are being tested in clinical trials. A trivalent anti-RSV VHH has recently 
successfully finished phase 1-2a trials in RSV-infected children. This VHH treatment appeared 
safe and could reduce RSV-associated symptoms. Also rotavirus-infected children benefited 
from the application of rotavirus-specific VHHs with a clear reduction in diarrhea. These 
positive results encourage the further development and testing of new antiviral VHHs, to 
reduce human and animal suffering caused by viral infections worldwide. Although not so 
new anymore, VHH technology has proven itself as powerful ammunition to battle many 
viral infections. 
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RSV is the most important cause of lower respiratory tract infections in young infants. The 
virus is so omnipresent that by the age of two nearly all children will have experienced at 
least one RSV infection [1]. In a small percentage of cases this results in severe bronchiolitis 
and hospitalization [2]. The incidence of RSV-caused fatalities has been estimated to be as 
high as 66,000-520,000 children under the age of five each year [3, 4]. Despite many years of 
research still no licensed vaccine or RSV-specific therapeutic is available in the clinic. 
Prophylactic administration of the monoclonal antibody palivizumab provides some 
protection, but this treatment is restricted to high-risk infants due to its high cost and 
somewhat cumbersome administration [5].  
Development of a potent new antiviral against RSV 
The prime aim of this PhD project was to isolate and characterize single-domain antibodies 
(VHHs) that selectively bind to the prefusion conformation of the RSV fusion protein (F) and 
that could suppress RSV replication in vitro and in the mouse model. RSV F was chosen as 
target because it is the only RSV membrane protein that is essential for infection. We 
specifically aimed at targeting the fusion-competent prefusion conformation of RSV F. It was 
demonstrated that most of the RSV-neutralizing antibodies present in human serum are 
specifically directed to prefusion F [6, 7]. In addition, monoclonal antibodies targeting this 
conformation were shown to be more potent than antibodies that also bind to postfusion F 
[8, 9]. To obtain prefusion-specific VHHs, immunization of a camelid with prefusion-
stabilized F was followed by biopanning of the VHH library and a screening on RSV-
neutralization. The VHHs with promising antiviral activity were further characterized on 
multiple levels:  
- In vitro neutralization against lab strains 
- In vitro neutralization against clinical strains 
- Binding studies 
- Epitope determination by competition analysis 
- Escape mutant analysis 
- Epitope determination by X-ray crystallography 
- Prophylactic and therapeutic efficacy in mice  
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Development of an improved mouse model for RSV 
A second objective of this PhD project was to improve the mouse model for RSV. The lack of 
a proper RSV mouse model is a major obstacle in the development of new RSV vaccines and 
therapeutics. Mice are poorly permissive for RSV, infection of BALB/c mice with RSV requires 
a very high inoculum dose and even then only limited morbidity is observed [10]. In our lab, 
extensive passaging of RSV A2 in immune-depleted mice has resulted in a viral strain that 
replicates far better in mice than the parental RSV strain. As a second aim of this thesis work, 
we aspired to continue the in vivo adaptation in immunocompetent BALB/c mice in order to 
also establish the enhanced replication in these immunocompetent mice. The resulting 
mouse-adapted RSV was subsequently deep-sequenced, plaque-purified and thoroughly 
analyzed in vivo and in vitro. 
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4.1 Introduction 
VHHs are single-domain antibodies consisting of the variable domain of heavy-chain only 
antibodies, found in all camelids. Several intrinsic features make these VHHs attractive 
antiviral candidates. Their small size allows VHHs to recognize antigenic sites that stay 
hidden for conventional antibodies and to efficiently penetrate tissue [1, 2]. Their high 
solubility and stability also allows a long shelf-life and pulmonary administration to the 
patient [3, 4]. Furthermore, production of VHHs can be performed cost-efficiently in 
microbial or plant expression systems, in which no animal-derived products are involved. At 
last, formatting these VHHs into multimeric molecules is straight-forward thanks to their 
simple single-domain nature.  
Because of all these properties, and in particular the possibility of pulmonary administration, 
VHHs have great potential for the treatment of respiratory viral infections, for example 
caused by respiratory syncytial virus (RSV). RSV is the most important cause of lower 
respiratory tract infections in children around the world. In 1-2 % of children, infection leads 
to severe bronchiolitis where hospitalization is required [5]. Currently, only supportive care 
is provided to these hospitalized children. There is no escape from an RSV infection, by the 
age of two all children have been infected at least once with this virus [6]. No vaccine is 
available to prevent infection, only monthly administration of a humanized mouse-
monoclonal antibody (palivizumab, Synagis®) can reduce the risk of hospitalization in high-
risk infants [7]. With an increased risk for wheezing and asthma, a serious RSV-infection can 
have a life-long impact on a person's health [8-10]. Effective antiviral therapeutics to battle 
these infections are highly needed. 
In this chapter the development of VHHs specific for the prefusion conformation of the 
fusion protein (F) of RSV is described. Due to its conserved nature and its essential function 
for viral entry, the F protein is an ideal target. The F protein presents itself in two 
conformations on the viral membrane, the pre- and postfusion form [11]. In order to obtain 
potent RSV-neutralizing VHHs, our aim was to target the prefusion form of F, because this is 
the fusion-competent conformation and because most of the RSV-neutralizing activity in 
human serum is directed to this conformation [12, 13].  
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4.2 Results 
Isolation of prefusion F-specific VHHs from a Cav1-immunised alpaca 
An alpaca was immunized six times with weekly intervals with 150 µg recombinant soluble F 
protein, stabilized in the prefusion conformation by the introduction of a trimerization 
domain and cavity-filling mutations (named Cav1) [14]. Alpaca plasma samples obtained 
before the first and after the last immunization were checked for the presence of RSV-
neutralizing activity (Fig. 1). Although the immunogen was based on the RSV A2 sequence, 
equal neutralizing activity was observed against RSV A and B strains. Low neutralizing activity 
was already present in the pre-immune plasma sample.  
 
Figure 1: Alpaca Cav1-immune plasma neutralizes RSV A2 and RSV B. RSV neutralizing activity in 
plasma isolated from an alpaca before the first immunization and after six immunizations with Cav1 
was determined by plaque reduction assay using RSV A2 (a) and RSV B (clinical strain RSV 
BE/5649/09) (b). Monolayers of Vero cells seeded in 96-well plates were infected with RSV A2 or RSV 
B (20 PFU/well) in the presence of different dilutions of alpaca plasma. Three days after infection, the 
plaques in each well were stained and counted (Y-axis).  
VHH sequences were extracted from the peripheral blood mononuclear cells and a VHH 
phage-display library was constructed. To obtain VHHs specific for the prefusion F, two 
panning strategies were tested. In strategy A, one round of panning was performed on 
immobilized Cav1. This resulted in a 22-fold enrichment of phages binding to the Cav1 
protein. In panning strategy B, the library was subjected to two rounds of panning on DS-
Cav1, a Cav1 variant which is further stabilized by the introduction of disulfide bridges [14], 
combined with counter-selection against postfusion F (FΔFP described in [15]) before the 
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second round of panning. While the first round only led to a 2-fold enrichment, the second 
round of panning resulted in a 1022-fold enrichment.  
Ninety-five clones were picked from the enriched library obtained after panning strategy A 
and tested for binding to Cav1 in an ELISA. Of these 95, 63 colonies scored positive and 
sequence analysis revealed that these represent 38 unique VHHs. To estimate how many of 
these bind specifically to the prefusion conformation, an ELISA using bacterial periplasmic 
extracts (PE-ELISA) was performed to compare their affinity to either post- and prefusion F 
(DS-Cav1) (Fig. 2a). Ninety-two clones picked up randomly after panning strategy B were 
immediately examined by this differential PE-ELISA (Fig. 2b). VHHs obtained after panning 
strategy A were named R1RSVF (obtained after one round of panning on RSV F), and VHHs 
obtained after panning strategy B are named R2RSVF (obtained after two rounds of panning 
on RSV F). 
None of the clones obtained after panning strategy A were found to be specific for the 
prefusion conformation. Of the 92 clones derived from panning strategy B, on the other 
hand, 52 were found to be specific for the prefusion conformation. After a second PE-ELISA 
experiment, 42 of these 52 clones were confirmed to bind specifically to the prefusion 
conformation. Sequence analysis showed that 29 of these 42 clones were unique.  
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Figure 2: Selection of VHHs that bind to purified recombinant F protein. ELISA plates were coated 
with DS-Cav1 (white bars, prefusion F), postfusion F (black bars) or bovine serum albumin (BSA). The 
plates were incubated with bacterial periplasmic extracts prepared from pHEN4-VHH transformed 
TG1 E. coli cells that had been obtained after either one round of panning against Cav1 (a) or two 
rounds against DS-Cav1 with postfusion F counter-selection (b) with the VHH-displaying phage library 
generated from the PBMCs of the Cav1-immunized alpaca. In the graphs, the binding to the F protein 
is depicted as the ratio of OD450 values over binding to BSA. 
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RSV-neutralizing activity of F-binding VHHs 
It was not possible to evaluate the RSV-neutralizing activity in the bacterial periplasmic 
extracts that were used for the prefusion/postfusion F PE-ELISA because the buffer used to 
make these extracts was neutralizing by itself. Therefore the sequences coding for VHHs 
obtained after both panning strategies were cloned into the pKai61 expression vector for 
subsequent transformation in and expression by the yeast Pichia pastoris. A selection of 
VHHs was purified from the P. pastoris supernatant by affinity chromatography and tested 
for their neutralizing activity against both RSV A and B (Fig. 3). Only two of the VHHs 
obtained after panning strategy A displayed RSV neutralizing activity, R1RSVF 71 and R1RSVF 
60 with IC50s of 0.11 µg/ml and 0.17 µg/ml respectively. While palivizumab neutralizes RSV 
with an IC50 in the same range of these VHHs when expressed in µg/ml, it has a tenfold lower 
IC50 when expressed in nM, due to the difference in size between the VHH and the antibody. 
Panning strategy B resulted in more neutralizing candidates. Almost all VHHs displayed some 
neutralizing activity, however with lower potency than R1RSVF 71 and R1RSVF 60. 
 
Figure 3: Comparison of RSV-neutralizing activity of VHHs obtained after panning strategy A and B. 
RSV A2 (left panels) or RSV B (clinical strain RSV BE/5649/09) (right panels) was preincubated with 
different concentrations of Pichia pastoris produced VHH obtained after panning strategy A (a) or 
after panning strategy B (b) before infection of Vero cells. Three days later the viral plaques were 
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stained with polyclonal anti-RSV serum. Palivizumab was included as positive control. The Ctrl-VHH is 
specific for an irrelevant target. Candidates with the least neutralizing activity are indicated in black.  
Binding activity of purified RSV-neutralizing VHHs 
The affinity chromatography-purified VHHs were next evaluated by ELISA to determine their 
affinity for immobilized prefusion F and postfusion F (Fig. 4). In an ELISA read-out affinity is 
defined by the concentration at which the VHH displays its half-maximum binding (Table 1). 
Only the two neutralizing candidates from panning strategy A were included in this assay. 
Palivizumab binds to antigenic site II, which is available in both pre- and postfusion 
conformations, and was used as a positive control. R1RSVF 71 also binds the two 
conformations, in line with the PE-ELISA results. Surprisingly, only binding to prefusion F was 
evident for R1RSVF 60, whereas the PE-ELISA suggested that this VHH could bind to both F 
conformations. 
 
Figure 4: Comparison of binding affinities of VHHs obtained after panning strategy A and B. ELISA 
plates were coated with DS-Cav1 (left panels) or postfusion F (right panels). The plates were 
incubated with a 1/3 dilution series of purified VHHs from either panning strategy A (a) or panning 
strategy B (b) starting from 10 µg/ml. The OD450 values are depicted. The Ctrl-VHH is specific for an 
irrelevant target. 
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Table 1: Summary of neutralizing and binding activity displayed by VHHs obtained after panning 
strategy A and B. 
 IC50  (nM) 50%  max binding (nM) 
RSV A2 RSV B49 Prefusion F Postfusion F 
R1RSVF 60 14.0 34.0 3.38 / 
R1RSVF 71 8.8 20.3 4.45 8.41 
R2RSVF 21 3830.0 / / / 
R2RSVF 27 / 217.80 / / 
R2RSVF 39 298.48 8440 139.92 / 
R2RSVF 42 74.88 147.68 57.20 / 
R2RSVF 50 / 1279.00 / / 
R2RSVF 67 184.72 84.64 / / 
R2RSVF 69 1594.4 490.40 408.24 / 
R2RSVF 85 / 508.32 1.4 / 
 
As expected, none of the VHHs obtained after panning B bound to postfusion F. The lack of 
binding to prefusion F displayed by four of the tested VHHs was however not anticipated. 
The ELISA results revealed that VHHs R1RSVF 60 and 71 bound with higher affinity to 
prefusion F than all the strategy B VHHs, which may explain their higher neutralizing activity.  
In vivo protection by F-binding VHHs 
Next, the protective potential of the most potent VHH obtained from each strategy, i.e. VHH 
R1RSVF 71 and R2RSVF 42, was analyzed in vivo. Four hours before RSV infection, mice were 
treated intranasally with 30 µg of VHH R1RSVF 71, R2RSVF 42, Ctrl-VHH or palivizumab. Six 
days after challenge, the mice were weighed and then sacrificed to determine the RSV levels 
in the lungs (Fig. 5).  
Treatment with the pre- and postfusion F binding VHH, R1RSVF 71, significantly reduced viral 
replication. In three of the six mice no virus could be detected at day six after infection. VHH 
R2RSVF 42 and palivizumab were also protective, reducing viral titers 8- and 80-fold 
respectively. This protective effect is also reflected by the RT-qPCR data, where almost no 
viral RNA could be observed in the group treated with R1RSVF 71 and intermediate amounts 
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in the groups treated with R2RSVF 42 and palivizumab. Limited weight loss was observed on 
day six in the mice which received the irrelevant VHH (Ctrl-VHH). Treatment with either RSVF 
VHH or palivizumab prevented this symptom of RSV-induced morbidity. 
 
Figure 5: R1RSVF 71 protects against RSV A2 challenge. Groups of six BALB/c mice were treated 
intranasally with 1.5 mg/kg of R1RSVF 71, R1RSVF 42, palivizumab or Ctrl-VHH four hours before 
infection with 1 x 106 RSV A2. (a) Six days after infection, the pulmonary RSV load was determined by 
plaque assay. the dashed line represents the detection limit, the horizontal lines indicate medians. *P 
< 0.05, **P < 0.01 (Mann-Whitney U-test). (b) Pulmonary RSV load of each group was also 
determined by quantification of the amount of lung viral RNA using RT-qPCR. (c) Percentage of body 
weight six days after infection. Horizontal lines indicate medians. **P < 0.01, *** P < 0.001, ****P < 
0.0001 (One-way ANOVA).  
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4.3 Discussion 
In this chapter we describe the isolation of RSV-neutralizing VHHs following the 
immunization of an alpaca with prefusion F and two different panning strategies. The alpaca 
was immunized with Cav1, a soluble prefusion F protein stabilized by a trimerizing domain 
and cavity-filling mutations. This protein is less stable in situations of extreme temperature, 
pH or osmolality than DS-Cav1 in which cysteine pairs were introduced that can form 
stabilizing disulfide bridges [14]. This more stable prefusion F protein was however not yet 
available at the time of immunization. Interestingly the pre-immune plasma of the alpaca 
already contained some neutralizing activity against RSV. This pre-existing RSV-specific 
immunity might have been caused by an earlier infection with bovine RSV (bRSV). The 
presence of bRSV-specific antibodies in alpacas has been reported before [16]. BRSV 
infection could induce cross-neutralizing antibodies, effective against both bRSV and human 
RSV (hRSV) because of the relatively close relatedness between the fusion protein of bRSV 
and hRSV (81% amino acid identity) [17]. This pre-existing immunity might hold the 
advantage of contributing to a more broadly neutralizing immune response upon 
immunization with the RSV A2-derived Cav1 protein.  
Two panning strategies were applied. In strategy A, the phage library was simply subjected 
to one round of panning on the Cav1 protein. In strategy B, two rounds of panning were 
performed on DS-Cav1 protein, with a counter-selection on postfusion F before the second 
round of panning. Counter-selection was applied because the PE-ELISA performed after 
panning strategy A showed that none of the selected VHHs was specific for prefusion F. This 
counter selection was effective as it did result in quite some VHHs specifically binding to 
prefusion F. However, none of the selected VHHs had high RSV-neutralizing potency, 
indicating that prefusion F-specificity is no guarantee for potent neutralizing activity. In fact, 
the most neutralizing candidate that was picked up, R1RSV F71, bound to both pre- and 
postfusion F. The relatively high neutralizing activity of this VHH is probably linked to its 
higher affinity for prefusion F compared to the other candidates. R1RSVF 71 was found to be 
about 80-fold more potent than the monovalent VHHs binding the palivizumab epitope 
described by Hultberg et al. and Detalle et al. [18, 19]. These poorly RSV-neutralizing, 
epitope II-binding VHHs still outperformed some of the prefusion-specific VHHs picked up 
after panning strategy B. 
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Based on the initial selection using PE-ELISA, VHHs R1RSVF 71 an R1RSVF 60 obtained after 
panning strategy A displayed affinity for both pre- and postfusion F. Once purified however, 
R1RSVF 60 only seemed to bind prefusion F. Also many VHHs picked up after panning 
strategy B for their prefusion F binding activity based on PE-ELISA seemed to behave 
differently once evaluated as purified recombinant proteins. This inconsistency is probably 
caused by the underestimated background binding of samples tested in the PE-ELISA, which 
are after all crude bacterial periplasmic extracts. Many contaminating proteins are present in 
these extracts, and the amount of VHH is highly variable between samples. The PE-ELISA 
technique should thus only serve as a rough screening technique to exclude VHH candidates 
that do not display any binding affinity to either of the F proteins. 
Mice challenge experiments showed that R1RSVF 71, which was the most potent in vitro, 
was protective in vivo. A dose of 30 µg could almost completely protect mice from an 
ensuing RSV infection, while this was not the case with palivizumab or R2RSVF 42 where a 
reduced but clearly detectable virus level was still observed at day six post infection. All 
three molecules however could protect against the RSV-induced weight loss, which was 
obvious in the group treated with the irrelevant Ctrl-VHH, indicating that even a limited 
reduction in RSV can already result in protection against morbidity. This is probably due to 
the restricted permissiveness of RSV in mice, which implies that high titers are necessary to 
observe signs of morbidity [20, 21].  
R1RSVF 71 can neutralize both RSV A and B, yet it has no enhanced in vitro potency 
compared to palivizumab. By the immunization with F protein stabilized in the prefusion 
conformation, we aimed at inducing VHHs specific for prefusion F with greater neutralizing 
potency than palivizumab. Such highly potent VHHs could not be isolated. Possibly the Cav1 
protein was not stable enough, resulting in triggering over time followed by its transition to 
the postfusion conformation. It was previously reported that immunization of mice with the 
more stable DS-Cav1 resulted in three times more neutralizing activity than immunization 
with Cav1 [14]. Therefore it was decided to perform an immunization with the DS-Cav1 
protein. This immunization and the resulting potently RSV-neutralizing VHHs are discussed in 
the next chapter.  
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4.4 Materials and methods 
Immunization, library construction, panning and selection 
An alpaca was immunized subcutaneously six times with 150 µg Cav1 emulsified with Gerbu 
LQ#3000 each time at weekly intervals. Four days after the last immunization 100 mL 
anticoagulated blood was collected for the preparation of peripheral blood lymphocytes. 
Total RNA from peripheral blood lymphocytes was used as template for first strand cDNA 
synthesis with oligodT primers. Using this cDNA, the VHH encoding sequences were 
amplified by a nested PCR using first the call 01 and call 02 primers (5’ 
GTCCTGGCTGCTCTTCTACAAGG3’, 5’GGTACGTGCTGTTGAACTGTTCC3’) and next the A6E and 
38 primer (5’GATGTGCAGCTGCAGGAGTCTGGA/GGGAGG3’; 
5’GGACTAGTGCGGCCGCTGGAGACGGTGACCTGGGT3’). The resulting PCR fragment was 
digested with PstI and NotI, and cloned into the PstI and NotI sites of the phagemid vector 
pHEN4. Electrocompetent E. coli TG1 cells were transformed with the recombinant pHEN4 
vector. The resulting TG1 library stock was infected with VCS M13 helper phage to obtain a 
library of VHH-presenting phages. 
Panning strategy A: One round of panning was performed on 20 µg of immobilized prefusion 
F (Cav1) in one well of a microtiter plate (type II, F96 Maxisorp, Nunc). After blocking the 
prefusion F-coated well and an uncoated well used as a negative control, phages (1 x 1012 
particles) were applied to these wells and incubated for one hour at room temperature. 
After washing, the retained phage particles were eluted by applying a TEA-solution (14% 
triethylamine (Sigma) pH 10) for 10 minutes. Dissociated phages were transferred to a tube 
with 1 M TRIS-HCl pH 8.0. Tenfold serial dilutions of the phages were used to infect TG1 
cells, after which the bacteria were plated on LB agar plates with 100 μg/mL ampicillin and 
1% glucose.  
Panning strategy B: Analogous to strategy A. Panning was performed during two rounds on 
20 µg of DS-Cav1 instead of Cav1. To initiate a second round of panning, the rest of the 
eluted phages was added to exponential growing TG1 cells which were next incubated at 
37°C for 30 minutes without shaking, allowing infection of the TG1 cells. After the addition of 
growth medium containing 100 µg/ml ampicillin and 1% glucose, M13VCS helper phages 
(less than 1 x 107 particles) were added and the cells were again incubated at 37°C for 20 
minutes without shaking. The culture was pelleted and resuspended in growth medium 
containing 100 µg/ml ampicillin and 100 µg/ml kanamycin. After an overnight incubation at 
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37°C, phages were prepared by PEG precipitation and a second round of panning was 
initiated. In this second round of panning, the phages were first added to a well coated with 
20 µg of postfusion F (FΔFP) before being added to the well coated with 20 µg of prefusion F 
(DS-Cav1).  
ELISA for the detection of F-specific VHHs in bacterial periplasm (PE-ELISA) 
After panning, colonies were randomly selected for further analysis by ELISA for the 
presence of F-specific VHHs in their periplasm. The colonies were used to inoculate two mL 
of Terrific Broth (TB) medium with 100 µg/mL ampicillin in 24-well deep well plates. After a 
five-hour incubation step at 37°C, VHH expression was induced by adding isopropyl β-D-1-
thiogalactopyranoside (IPTG) at a concentration of 1 mM. The plates were subsequently 
incubated overnight at 37°C while shaking. The next day, bacterial cells were pelleted, 
resuspended in 200 µL TES buffer (0.2 M TRIS-HCl pH 8, 0.5 mM EDTA, 0.5 M sucrose) and 
incubated at 4°C for 30 minutes. Next, periplasmic extracts were prepared by adding water 
to induce an osmotic shock. After one-hour incubation at 4°C and subsequent centrifugation, 
the supernatants were collected. Microtiter plates were coated overnight with either 100 ng 
F protein in the postfusion conformation (FΔFP), 100 ng prefusion F (DS-Cav1) or 100 ng 
Bovine Serum Albumin (BSA, Sigma-Aldrich). The coated microtiter plates were blocked with 
1% milk powder in phosphate-buffered saline (PBS) and 100 µL of the periplasmic extract 
was added to the wells. Bound VHHs were detected with anti-HA (1/2000, MMS-101P 
Biolegend) mAb and horseradish peroxidase (HRP)-linked anti-mouse IgG (1/2000, NXA931, 
GE Healthcare). After washing, 50 µL of TMB substrate (Tetramethylbenzidine, BD OptEIA™) 
was added to every well. The reaction was stopped by addition of 50 µL of 1M H2SO4 after 
which the absorbance at 450 nM was measured with an iMark Microplate Absorbance 
Reader (Bio Rad). For all periplasmic fractions for which the OD450 values obtained for 
prefusion F were at least two times higher than the OD450 values obtained for BSA, and for 
which this was not the case for postfusion F, the corresponding colonies were selected and 
grown in 3 mL of LB medium with 50µg/ml ampicillin for plasmid isolation using the QIAprep 
Spin Miniprep kit (Qiagen). The cDNA sequence of the VHH was determined by Sanger 
sequencing using the M13RS primer (5’CAGGAAACAGCTATGACC3’). 
Cloning of VHH into Pichia pastoris expression vector and transformation of Pichia pastoris 
To clone VHH sequences into a yeast expression vector, the VHH coding sequences were PCR 
amplified from the respective pHEN4 plasmids using the following forward and reverse 
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primers (5’ GGCGGGTATCTCTCGAGAAAAGGCAGGTGCAGCTGGTGGAGTCTGGG3’; 
5’CTAACTAGTCTAGTGATGGTGATGGTGGTGGCTGGAGACGGTGACCTGG3’). The resulting PCR 
products were digested with XhoI and SpeI and ligated into XhoI/SpeI-digested pKai61 
backbone. The origin of the pKai61 vector is described in Schoonooghe et al. [22]. The VHH 
sequences are cloned in frame with a slightly modified version of the S. cerevisiae a-mating 
factor signal sequence. The encoded genes contain a C-terminal 6XHis tag and are under 
control of the methanol inducible AOX1 promoter. The plasmid contains a Zeocine resistance 
marker for selection in bacterial as well as in yeast cells. The vectors were linearized by PmeI 
before transformation of P. pastoris strain GS115 using the condensed transformation 
protocol described by Lin-Cereghino et al. [23].  
Purification of VHHs produced by Pichia pastoris 
Expression of VHH by transformed Pichia pastoris clones was first analyzed in 2 mL cultures. 
On day one individual transformants were used to inoculate 2 mL of YPNG medium (2% 
pepton, 1% Bacto yeast extract, 1.34% YNB, 0.1M potassium phosphate pH6, 0.00004% 
biotine, 1% glycerol) with 100 µg/mL Zeocin (Life Technologies) and incubated while shaking 
at 28°C for 24 hours. Next, cells were pelleted and the YPNG medium was replaced by YPNM 
medium (2% pepton, 1% Bacto yeast extract, 1.34% YNB, 0.1M potassium phosphate pH 6, 
0.00004% biotine, 1% methanol) to induce VHH expression. Cultures were incubated at 28°C 
while shaking for 48 hours. Fifty µL of 50% methanol was added to the cultures at 16, 24 and 
40 hours. After 48 hours, the yeast cells were pelleted and the supernatant was retained to 
assess the presence of VHH. To select VHHs with RSV-neutralizing activity, serial dilutions of 
the crude YPNM supernatant from individual Pichia pastoris transformants were tested in a 
plaque-reduction assay. 
Pichia pastoris transformants that yielded high levels of VHH in the medium and with high 
RSV-neutralizing activity were selected for scaling up using 100 mL Pichia cultures. Growth 
and methanol induction conditions and harvesting of medium were similar as mentioned 
above for the 2 mL cultures. The cleared medium was subjected to ammonium sulphate 
precipitation (80% saturation) for four hours at 4°C. The insoluble fraction was pelleted by 
centrifugation at 20,000 x g and solubilized in 10 mL HisTrap binding buffer (20 mM sodium 
phosphate, 0.5 M NaCl, 20 mM imidazole, pH 7.4) before purification on a 1 mL HisTrap HP 
column (GE Healthcare). Relevant fractions containing the VHH were pooled, and underwent 
concentration and buffer exchange to PBS with a Vivaspin column (5 kDa cutoff, GE 
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Healthcare) and the concentration was determined. The purified VHHs were aliquoted and 
stored at -80°C until further use.  
Cells and viruses 
HEp-2 cells (ATCC, CCL-23) and Vero cells (ATCC, CCL-81) were grown in Dulbecco's modified 
eagle medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 
mM L-glutamine, non-essential amino acids (Invitrogen, Carlsbad, California) and 1 mM 
sodium pyruvate at 37°C in the presence of 5% carbon dioxide. RSV A2, an A subtype of RSV 
(ATCC, VR-1540, Rockville), RSV B49, a B subtype of RSV (BE/5649/08 clinical strain, source 
described in [24], obtained from Prof M. Van Ranst) and RSV A Long (ATCC, VR-26, kind gift 
from Dr. Rik De Swart) were propagated on HEp-2 cells and quantified on Vero cells by 
plaque assay using goat anti-RSV serum (AB1128, Chemicon International).  
Plaque-reduction assay  
A dilution series of alpaca plasma or VHHs/palivizumab was prepared in Opti-MEM (Gibco), 
incubated with RSV for 30 minutes at 37°C and used to infect confluent Vero cells. After 
three hours, an equal volume of 1.2% avicel RC-851 (FMC Biopolymers) in DMEM medium 
supplemented with 2% FCS, 2 mM L-glutamine, non-essential amino acids and 1 mM sodium 
pyruvate was added to each well and the infection was allowed to continue at 37°C for three 
days. Viral infection was tested by immunostaining of the viral plaques with goat anti-RSV 
serum (AB1128, Chemicon International) and horseradish peroxidase-conjugated anti-goat 
IgG (SC2020, Santa Cruz). The plaques were visualized by applying TrueBlue peroxidase 
substrate (KPL, Gaithersburg).  
In vitro binding of VHHs to DS-Cav1 and postfusion F 
The binding of the purified VHHs to DS-Cav1 and postfusion F was tested in a direct ELISA. 
Microtiter plates (type II, F96 Maxisorp, Nunc) were coated with 100 ng DS-Cav1 or 100 ng 
postfusion F in PBS. After washing, the plates were blocked for one hour with 4% milk in PBS 
after which they were washed again with PBS once. A 1/3 dilution series of the VHHs was 
then applied to the protein-coated wells. After one hour, the plates were washed and a 
1/2000 dilution of anti-Histidine Tag antibody (AD1.1.10 AbD Serotec) in PBS was added for 
one hour. After washing and addition of HRP-linked anti-mouse IgG (1/2000 dilution) during 
one hour, the ELISA was developed in the same way as the PE-ELISA described above. 
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Mice 
Specific pathogen-free, female BALB/c mice were obtained from Charles River (Charles River 
Wiga, Sulzfeld, Germany). The animals were housed in a temperature-controlled 
environment with 12 h light/dark cycles; food and water were provided ad libitum. The 
animal facility operates under the Flemish Government License Number LA1400536. All 
experiments were done under conditions specified by law and authorized by the Institutional 
Ethical Committee on Experimental Animals (Ethical application EC2013-031). 
Prophylactic administration of VHHs and RSV A2 infection in mice 
Mice, seven weeks old, were randomly distributed in experimental groups of six animals. 
They were slightly anesthetized by isoflurane before intranasal administration of VHH, 
palivizumab or RSV challenge virus. VHH, palivizumab and RSV virus were administered 
intranasally in a total volume of 50 µL PBS. Each group received 30 µg of R1RSVF 71, 30 µg of 
R2RSVF 42, 30 µg of Ctrl-VHH or 30 µg of palivizumab four hours before infection with 106 
PFU of RSV A2. Mice were weighed daily.  
Determination of lung viral titers by plaque assay 
Six days after challenge, mice were euthanized, lungs were removed and homogenized in 1 
mL HBSS containing 20% sucrose and supplemented with 1% penicillin and 1% streptomycin. 
Lung homogenates were cleared by centrifugation at 4°C and used to titrate the virus by 
plaque assay. We set lung homogenates in which no virus was detected as the detection 
limit of the assay.  
Determination of lung viral titer by RT-qPCR 
To determine the lung RSV load by RT-qPCR, total RNA from the cleared lung homogenates 
was prepared by using the High Pure RNA tissue Kit (Roche) according to the manufacturer’s 
instructions. Next, cDNA was prepared by the use of random hexamer primers and the 
Transcriptor First strand cDNA synthesis kit (Roche). The relative levels of genomic RSV M 
cDNA were determined by RT-qPCR using primers specific for the RSV A2 M gene 
(5’TCACGAAGGCTCCACATACA3’ and 5’GCAGGGTCATCGTCTTTTTC3’) and a nucleotide probe 
(#150 Universal Probe Library, Roche) labeled with fluorescein (FAM) at the 5’-end and with 
a dark quencher dye near the 3’- end. The RT-qPCR data were normalized to actin mRNA 
levels. 
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Statistical analysis 
We used Graphpad Prism 6 for statistical analyses, and the two-sided Mann-Whitney U test 
to evaluate differences in lung viral titer between two groups and the one-way ANOVA to 
evaluate differences in relative body weight between all groups. 
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5.1 Abstract 
Human respiratory syncytial virus (RSV) is the main cause of lower respiratory tract 
infections in young children. The RSV fusion protein (F) is highly conserved and is the only 
viral membrane protein that is essential for infection. The prefusion conformation of RSV F is 
considered the most relevant target for antiviral strategies because it is the fusion-
competent form of the protein and the primary target of neutralizing activity present in 
human serum. Here, we describe two llama-derived single-domain antibodies (VHHs) that 
have potent RSV-neutralizing activity and bind selectively to prefusion RSV F with picomolar 
affinity. Crystal structures of these VHHs in complex with prefusion F show that they 
recognize a conserved cavity, formed by two F protomers. In addition, the VHHs prevent RSV 
replication and lung infiltration of inflammatory monocytes and T cells in RSV-challenged 
mice. These prefusion F-specific VHHs represent promising antiviral agents against RSV. 
5.2 Introduction 
Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract 
infections in children under the age of five throughout the world. It is estimated that RSV 
infects about 33.8 million children in this age group annually, of which more than 3 million 
require hospitalization due to severe bronchiolitis or pneumonia [1]. Reinfections occur 
regularly throughout life because natural infection offers only limited immunity [2]. RSV is 
also recognized as a major pathogen for the elderly, with a disease burden similar to that of 
seasonal influenza [3]. Thus, there is an urgent need for therapeutics that can reduce disease 
caused by RSV. 
Despite its medical importance and decades of intense research, there is still no licensed RSV 
vaccine nor an effective antiviral. The humanized monoclonal antibody (mAb) palivizumab 
(Synagis®) reduces hospitalizations when administered prophylactically, but its high cost and 
limited efficacy restrict its use to high-risk infants [4]. Palivizumab neutralizes RSV by binding 
to the fusion (F) protein and preventing fusion of the viral membrane with the host-cell 
membrane [5]. RSV F is a class I fusion protein that is expressed as an inactive precursor, F0, 
which is cleaved at two sites by a furin-like protease, leading to the formation of the 
covalently linked F2 (N-terminal) and F1 (C-terminal) subunits, which associate and trimerize 
to form the mature prefusion F protein [6]. Upon triggering, prefusion F partially refolds and 
inserts its hydrophobic fusion peptide into the membrane of the target cell. Fusion of the 
viral and host-cell membranes is facilitated by further refolding of the F protein into the 
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stable postfusion conformation. Small molecules that bind to RSV F and prevent its structural 
remodeling or F-specific antibodies that interfere with membrane fusion can block RSV 
infection [7, 8]. Such compounds are being clinically developed.  
Palivizumab binds to antigenic site II on RSV F, which is one of two well-characterized 
antigenic sites that are present on both the pre- and postfusion conformations. However, 
intensive screening for human mAbs that potently neutralize RSV has resulted in the 
isolation of prefusion F-specific antibodies with more robust neutralizing activity than 
palivizumab [9, 10]. Recently, RSV F was successfully stabilized in its prefusion conformation 
through the introduction of an intraprotomeric disulfide bond, cavity-filling mutations, and a 
trimerization motif. This reagent, called DS-Cav1 has been instrumental in revealing that the 
vast majority of RSV-neutralizing immunoglobulins in human sera selectively binds to F in its 
prefusion conformation [11-13].  
In addition to conventional antibodies, heavy-chain-only antibodies also exist in nature, e.g. 
in both camelids and sharks [14, 15]. The isolated antigen-recognition domains of these 
unusual antibodies are known as single-domain antibodies (VHHs). VHHs are very well suited 
for the development of therapeutics because of their small size, ease of production and 
physical stability that allows alternative routes of administration such as pulmonary delivery 
by nebulization [16]. A number of clinical trials are already ongoing with recombinant VHHs 
for the treatment of rheumatoid arthritis, cancer and infectious diseases [17, 18]. ALX-0171 
is an RSV-neutralizing VHH that binds to an epitope in RSV F that is similar to that of 
palivizumab [19]. In a phase I/IIa trial, hospitalized RSV-infected children were treated daily 
for three consecutive days with ALX-0171 delivered by an inhalation device. The treatment 
was safe and did not lead to any treatment-related serious adverse events. Interestingly, the 
study also revealed a trend towards a therapeutic effect, based on reduced viral loads in 
nasal swabs and clinical symptoms. In contrast, a similar trial with motavizumab—an affinity 
matured version of palivizumab—did not alter viral replication or improve clinical symptoms 
when administered after infection [20]. This different outcome might be explained by the 
direct delivery of ALX-0171 to the lungs whereas only about 0.2% of systemically 
administered antibody ends up in the lung lumen [21]. 
We hypothesized that a prefusion-specific VHH would have a much stronger antiviral effect 
than a conformation-independent VHH like ALX-0171. Here, we present the isolation and 
characterization of two llama-derived VHHs that potently neutralize RSV A and B subtypes 
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and selectively bind prefusion F with picomolar affinity. Structural studies reveal that these 
two VHHs bind to a conserved quaternary epitope composed of two F protomers. 
Furthermore, prophylactic treatment of mice with these VHHs potently controlled RSV 
infection and associated inflammation.  
5.3 Results  
Isolation of VHHs with exceptional RSV-neutralizing activity 
To obtain VHHs that selectively bind to the prefusion conformation of RSV F, a llama was 
immunized with recombinant F protein that was stabilized in the prefusion conformation, 
i.e. DS-Cav113. Plasma prepared after six weekly immunizations with prefusion F had potent 
RSV subtype A and B neutralizing activity (Supplementary Fig. 1). Peripheral blood 
mononuclear cells were isolated from the prefusion F-immunized llama and used to 
generate a VHH phage-display library. One round of panning on immobilized prefusion F 
protein resulted in a 140-fold enrichment in candidate prefusion F-binding phages. In a first 
approach to select RSV-neutralizing VHHs, we randomly selected 90 clones from this 
enriched population and tested binding to RSV F protein by ELISA. Thirty-seven clones 
expressed VHH that bound to either pre- or postfusion F protein (FΔFP) [22]; twenty-eight of 
these had a unique sequence and were subsequently expressed in Pichia pastoris. RSV A2-
neutralizing activity was present in the crude growth medium of P. pastoris clones 1, 4, 8, 13 
and 44, which were retained for further analysis (Supplementary Fig. 2a). 
In an alternative approach, the VHH cDNA inserts obtained after one round of panning on 
prefusion F were cloned as a pool into the P. pastoris expression vector and the resulting 
library was used to transform P. pastoris. The crude culture growth medium of individual P. 
pastoris transformants was then tested for RSV-neutralizing activity. One candidate, named 
F-VHH-L66, displayed clear RSV A2 neutralizing activity (Supplementary Fig. 2b). We purified 
the VHHs from the culture supernatant of the selected P. pastoris transformants for further 
analysis. All six purified VHHs (F-VHH-1, -4, -8, -13, -44 and -L66) neutralized RSV A and RSV B 
subtypes in vitro, with F-VHH-4 and F-VHH-L66 exhibiting the most potent neutralization, 
with an IC50 value below 0.1 nM for both RSV strains (Fig. 1a and b). These two VHHs were 
therefore selected for further characterization. Sequence analysis of F-VHH-4 and -L66 
revealed an identical complementarity-determining region (CDR) 1, a similar CDR2, but a 
very different CDR3 (Fig. 1c and Supplementary Fig. 3). F-VHH-4 and -L66 both have a 
cysteine residue at position 100c in the CDR3, and at position 50 in the CDR2. A disulfide 
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bond between the CDR3 and a residue at position 33 or 50 is a hallmark of a subclass of 
VHHs and helps to stabilize the extended CDR3 loop conformation [23].  
 
Figure 1. F-VHHs with potent RSV neutralizing activity. RSV neutralizing activity by F-VHHs. (a) RSV 
A2 (50 pfu/well) or (b) RSV B49 (40 pfu/well) was preincubated with different concentrations of VHH 
before infection of Vero cells. Three days later, the viral plaques were stained with polyclonal anti-
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RSV serum. (c) Predicted amino acid sequences of F-VHH-4 and F-VHH-L66 with Kabat numbering. 
The complementarity determining regions (CDRs) are boxed. Cysteines in CDR2 and CDR3 are in bold. 
(d) RSV A2 (30 pfu/well) plaque reduction activity of F-VHH-4 and F-VHH-L66 compared to mAbs. The 
Ctrl-VHH is specific for an irrelevant target. (e) IC50 values of F-VHHs and mAbs against RSV A2 and 
RSV B49 as determined by plaque reduction assay. Mean values ± SD from four (VHHs), three (D25) 
or two (palivizumab, motavizumab and AM22) repeat experiments are depicted for RSV A. Mean 
values ± SD from two experiments are depicted for RSV B. ND: Not determined. (f) Dilution series of 
VHHs and mAbs were added to HEp-2 cells that had been preincubated with RSV A2 (25 pfu/well) at 
4 °C for two hours, allowing viral attachment. After two hours at 37 °C, the VHHs or antibodies were 
washed away and infection was allowed during two days at 37 °C after which the plaques were 
stained. 65 is a mouse IgG2a monoclonal antibody that is specific for an irrelevant antigen. 
To assess the antiviral potency of the VHHs in more detail, RSV neutralization assays were 
performed in which F-VHH-4 and -L66 were compared with several F-specific mAbs 
(palivizumab, motavizumab, D25 and AM22) [9, 24, 25]. Remarkably, despite their 
monovalent character, F-VHH-4 and -L66 neutralized RSV A and B with picomolar IC50 values, 
which are similar to or lower than those for the bivalent prefusion F-specific mAbs D25 and 
AM22 (Fig. 1d and e). The VHHs were also tested in a neutralization assay against a set of 
clinical RSV isolates and a set of molecular clones built on the RSV Line 19 backbone, but 
with F and G derived from primary clinical isolates. These strains were as susceptible as the 
lab strains to neutralization by the VHHs (Supplementary Table 1 and Supplementary Fig. 4).  
In HEp-2 cells the F protein is involved in both viral attachment and membrane fusion [26-
30]. We therefore investigated if the VHHs could prevent infection after attachment of viral 
particles to the cells. Similar to palivizumab and D25, F-VHH-4 and F-VHH-L66 prevented 
infection when added after virion attachment (Fig. 1f). F-VHH-4 also efficiently inhibited 
syncytium formation in HEp-2 cells when added three hours after infection with RSV A2 
(Supplementary Fig. 5 and 6). However, mixing of RSV with the neutralizing VHHs prior to 
infection did not hinder viral attachment to HEp-2 target cells, indicating that F-VHH-4 and -
L66 inhibit RSV in vitro by blocking membrane fusion post-attachment (Supplementary Fig. 
7).  
VHHs bind a unique prefusion F-specific epitope 
To investigate whether the neutralizing VHHs specifically recognize the prefusion 
conformation of RSV F, the binding kinetics to recombinant pre- and postfusion F proteins 
were measured by surface plasmon resonance (SPR). The VHHs bound tightly to prefusion-
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stabilized F, whereas no binding to postfusion F could be detected (Fig. 2a and 
Supplementary Fig. 8). F-VHH-4 bound to immobilized prefusion RSV F with an equilibrium 
dissociation constant (KD) lower than 18 pM. The off-rate was extremely slow and outside 
the range measurable by SPR, therefore, the upper limit of the KD was estimated using the 
measured association rate constant (5.7 x 105 M-1s-1) and the lower limit of detection for the 
dissociation rate constant (1.0 x 10-5 s-1). F-VHH-L66 also bound to prefusion F with sub-
nanomolar affinity. However, compared to F-VHH-4, the F-VHH-L66 association rate constant 
was lower (3.3 x 105 M-1s-1) and the dissociation rate constant was higher (5.0 x 10-5 s-1), 
resulting in a KD of 154 pM. Binding of the VHHs to cells transfected with a codon-optimized 
F-expression plasmid and to RSV-infected cells was also observed (Supplementary Fig. 9 and 
Supplementary Fig. 10), demonstrating that the VHHs recognize full-length F in the context 
of biological membranes. 
 
Figure 2. F-VHH-4 and -L66 bind a similar epitope on prefusion F that partially overlaps with the 
epitopes of palivizumab, 101F, AM14 and MPE8. (a) Surface plasmon resonance (SPR) sensorgrams 
for the binding of F-VHH-4 (left) and F-VHH-L66 (right) to immobilized prefusion F. A buffer-only 
sample was injected over the prefusion F and reference flow cells, followed by 2-fold serial dilutions 
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of F-VHH-4 or F-VHH-L66 ranging from 5 nM to 39.1 pM, with a duplication of the 1.25 nM 
concentration. The data were double-reference subtracted and fit to a 1:1 binding model (red lines). 
(b) Prefusion F protein was immobilized on AR2G biosensors. The biosensors were dipped in 
competitor antibodies followed by analyte antibodies. Percent inhibitions were defined by comparing 
binding maxima of the analyte antibody in the absence and presence of each competitor. NB, no 
binding. 
To gain more insight into the epitopes that are targeted by F-VHH-4 and -L66, we performed 
cross-competition binding experiments using biolayer interferometry and a set of mAbs with 
known epitopes. This analysis revealed that the two VHHs competed with each other for 
binding to immobilized prefusion F and thus likely bound to overlapping epitopes (Fig. 2b). 
Binding by D25, which recognizes site Ø on prefusion F, was not hindered by F-VHH-4 or -
L66, which suggests that neither VHH bound to this site. In contrast, palivizumab, AM14 and 
MPE8 interfered with binding of the two VHHs to prefusion F and vice versa, suggesting that 
the VHH epitope is located in the vicinity of the binding sites of these three antibodies, 
approximately midway between the apex of the trimer and the viral membrane.  
To further narrow down the binding site of the VHHs, we selected for viruses resistant to F-
VHH-4 and -L66. Two rounds of selection in the presence of F-VHH-L66 and four rounds of 
selection in the presence of F-VHH-4 led to the isolation of a single type of escape mutant 
virus that had a threonine to asparagine change at position 50 in the F2 subunit. F-VHH-L66 
failed to neutralize this mutant virus, whereas this virus was still susceptible to inhibition by 
F-VHH-4, although this required 300-fold more F-VHH-4 compared to the parental virus (Fig. 
3). Thr50 resides at the floor of a cavity in prefusion F that is surrounded by the epitopes of 
palivizumab, AM14 and 101F [5, 31, 32], suggesting that both VHHs bind to this cavity. 
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Figure 3. Thr50Asn substitution in F2 enables viral escape from F-VHH-4 and F-VHH-L66 
neutralization. F-VHH-4 escape virus (left panel) or RSV A2 (right panel) (25 PFU) was incubated for 
30 minutes at 37 °C with different concentrations of the indicated VHH or mAb before addition to a 
monolayer of Vero cells. Three days later, cells were fixed and stained with polyclonal anti-RSV serum 
to visualize the plaques (enumerated in the Y axis). 
F-VHHs bind a cavity formed by two F protomers 
In order to precisely define the epitopes recognized by F-VHH-4 and -L66, their crystal 
structures in complex with prefusion F were determined to 3.3 and 3.8 Å resolution, 
respectively (Supplementary Table 2). Additionally, the crystal structure of unbound F-VHH-4 
was determined to 1.9 Å resolution (Supplementary Table 2 and Supplementary Fig. 11). The 
complex structures revealed that despite substantial differences in CDR3 sequence, F-VHH-4 
and -L66 bind in a nearly identical manner to a cavity formed by the boundary of two F 
protomers (Fig. 4a). This cavity is bordered by antigenic site II of one protomer and antigenic 
site IV of the neighboring protomer, and the location of this epitope between the binding 
sites of palivizumab, 101F and AM14 explains the ability of the VHHs to compete with each 
of these antibodies (Fig. 2b and Supplementary Fig. 12). This epitope has also been mapped 
by mutagenesis as the likely epitope for MPE8, which cross-neutralizes RSV, human 
metapneumovirus (hMPV) and pneumonia virus of mice (PVM) [10]. The VHHs, however, 
while being broadly neutralizing for RSV, did not neutralize hMPV (Supplementary Table 3) 
and could not bind to PVM-infected cells (Supplementary Fig. 13).  
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Figure 4. F-VHHs bind an epitope formed by two protomers of prefusion F. (a) Superposition of the 
crystal structures of three F-VHH-4s (blue) and three F-VHH-L66s (orange) bound to prefusion RSV F, 
viewed from the side and the top. (b) Close-up of the VHH-binding cavity, viewed from the side (left) 
and from the bottom (right). The VHH epitope is outlined with a dotted black line in the side view. 
The CDR2s and CDR3s of both VHHs are shown as tubes. 
F-VHH-4 and -L66 each bury nearly 1200 Å2 on prefusion F, with approximately 60% of the 
total buried surface area on one protomer and 40% on the adjacent protomer (Fig. 4b). The 
distribution of the VHH epitopes among the two protomers suggested that F-VHH-4 and -L66 
may be trimer-specific, which is a property that thus far has only been described for 
antibody AM14 [31]. To confirm the trimer-specificity of the VHHs, their binding kinetics for 
monomeric prefusion F were measured by SPR (Supplementary Fig. 14). The KD of F-VHH-4 
binding to monomeric prefusion F was 23 nM, which is over 1000-fold lower than the KD 
measured for trimeric prefusion F. No binding of F-VHH-L66 to monomeric prefusion F was 
detected, even at the highest concentration tested (500 nM) (Supplementary Fig. 14). Both 
VHHs were also able to bind and trap wild-type F protein ectodomain in the trimeric 
prefusion conformation (Supplementary Fig. 15). Therefore, both VHHs have a high 
selectivity for the trimeric state of prefusion F. 
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The CDR3s of F-VHH-4 and -L66 are submerged in the interprotomeric cavity and therefore 
mediate the majority of the interactions with RSV F (Fig. 5 and Supplementary Table 4). The 
main chain of both F-VHH-4 and -L66 forms a hydrogen bond with Thr50 of F2, the residue 
mutated in the escape viruses isolated for both VHHs. A number of hydrogen bonds are also 
formed between the CDR3 and the antiparallel β-strands that neighbor antigenic site IV. The 
CDR3 of each VHH is disulfide-linked to CDR2, which hydrogen bonds with the α7 helix of 
antigenic site II (Fig. 5). Upon membrane fusion, the domains of each RSV F protomer 
contacted by the VHHs undergo a rigid-body movement that causes their relative positions 
to change substantially between the prefusion and postfusion states. Superposition of the 
postfusion F structure onto the VHH-bound prefusion structures reveals a significant clash 
between the loop connecting α6 and α7 of postfusion F and the CDR3 of either VHH 
(Supplementary Fig. 16). Therefore, our structural data suggest that F-VHH-4 and -L66 
neutralize RSV and block fusion by preventing the movement of domains required for 
conversion of prefusion RSV F to the postfusion state. In addition, both VHHs bury 
approximately 100 Å2 on the β4 strand, which dramatically rearranges to become a portion 
of the α5 helix of postfusion F. Although the buried surface area in this region is relatively 
small, these contacts may also contribute to the prefusion specificity of the VHHs by 
preventing the refolding of β4 during the transition from prefusion to postfusion F. 
 
Figure 5. F-VHHs make direct contacts with residues on two neighboring protomers of prefusion F. 
Close-up of the CDR3 and CDR2 from (a) F-VHH-4 and (b) F-VHH-L66 bound to prefusion F. CDR2 and 
CDR3 are shown as tubes with the N- and C-termini labeled. Side-chains and main-chains involved in 
hydrogen bonding are shown as sticks, with hydrogen bonds depicted as black dotted lines. Residues 
of the F protein are labeled. 
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To assess which residues on the RSV F protein are most important for interaction with the F-
VHHs, T267A and L305R amino acid substitution mutations were introduced in a codon-
optimized F gene cDNA expression vector construct. These two positions were predicted to 
be important for VHH binding based on the co-crystal structure. Binding of F-VHH-4 and F-
VHH-L66 to these F mutants was evaluated by flow cytometry using transfected cells as 
targets (Supplementary Fig. 17). The T267A substitution had a greater impact on F-VHH-L66 
binding (low binding at 1 µg/ml and no binding detected at a concentration of 0.01 µg/ml 
compared to wild type F) than on F-VHH-4 binding (clear binding at 1 µg/ml and less binding 
at 0.01 µg/ml compared to wild type F). This mutant could still be bound by a set of control 
antibodies covering different epitopes (palivizumab, D25 and MPE8). Both VHHs failed to 
bind to the F protein containing the L305R substitution. While this substitution did not have 
an impact on the binding of palivizumab, D25 and goat anti-RSV serum, reduced binding was 
detected for MPE8 which is consistent with previously reported data [10].  
Among all RSV F-specific monoclonal antibodies, F protein cleavage dependency is a trait so 
far only described for antibody AM14 [31]. Therefore, we also determined if cleavage of the 
F protein is necessary for F-VHH-4 and -L66 binding. In this assay, dilution series of the 
cleaved or uncleaved F protein were tested for binding to coated antibody or VHH (as 
described in Gilman et al. [31]). While F-VHH-L66 failed to bind to prefusion F with mutated 
furin sites, F-VHH-4 could bind to this protein (Supplementary Fig. 18). This indicates that 
there is some difference in mode of binding between the two VHHs. As expected, D25 and 
MPE8 bound to both cleaved and uncleaved prefusion F, while AM14 could only bind to 
cleaved prefusion F.  
F- VHHs reduce replication of RSV in vivo 
In a final set of experiments, we evaluated the protective potential of F-VHH-4 and -L66 in 
vivo. Both F-VHHs strongly reduced virus replication when administered intranasally to 
BALB/c mice at a dose of 30 µg prior to challenge with RSV (Supplementary Fig. 19). We 
selected F-VHH-4 for subsequent animal experiments because it has a slightly higher 
neutralizing activity than F-VHH-L66. Intranasal administration of 10 µg F-VHH-4 or 
palivizumab to BALB/c mice four hours before challenge with 1x106 PFU of RSV A2 resulted 
in undetectable levels of virus in the lungs and the bronchoalveolar lavage on day five after 
challenge (Fig. 6a and Supplementary Fig. 20). This apparent lack of virus in the lungs of F-
VHH-4- or palivizumab-treated mice could be due to an in vitro effect of the remaining VHH 
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or antibody in the lung homogenates. Therefore, viral RNA was quantified by an RSV-specific 
RT-qPCR. The lungs of mice treated with F-VHH-4 were negative or borderline positive for 
RSV RNA, whereas the relative amount of RSV RNA indicated at least a 170-fold higher viral 
load in samples from palivizumab-treated mice compared to F-VHH-4-treated mice (Fig. 6b). 
Finally, we also assessed the effect of F-VHH-4 treatment on the influx of immune cells in the 
lungs of RSV A2-challenged mice five days after infection. In contrast to mice treated with 
Ctrl-VHH before challenge, mice treated with F-VHH-4 or palivizumab had significantly less 
alveolar influx of dendritic cells, monocytes, CD8+ and CD4+ T lymphocytes (Fig. 6c). Lowering 
the amount of F-VHH-4 to 1 µg per mouse resulted in the same protective effect 
(Supplementary Fig. 21). 
 
Figure 6. F-VHH-4 inhibits RSV A2 replication in mice. Groups of six BALB/c mice were treated 
intranasally with 0.5 mg/kg of F-VHH-4, palivizumab or Ctrl-VHH four hours before infection with 1 x 
106 RSV A2 or PBS (mock). Five days after infection, the pulmonary RSV load was determined by (a) 
plaque assay (dashed line represents the detection limit) or (b) by quantification of the amount of 
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lung viral RNA using RT-qPCR. Horizontal lines indicate medians. *P < 0.05, **P < 0.01 (Mann-
Whitney U-test). (c) Five days after infection, BAL fluid was prepared and the percentage of immune 
cells was determined by flow cytometry. Bars represent the average percentage of the indicated cell 
type ± SD (n=6) (AM, alveolar macrophages; DC, dendritic cells; Monoc, monocytes; CD4, CD4+ T cells; 
CD8, CD8+ T cells; Neutr, neutrophils; Eosino, eosinophils). *P < 0.05, **P < 0.01 (Mann-Whitney U-
test).  
5.4 Discussion  
Our aim was to obtain molecules with very high RSV-neutralizing activity that could be 
developed as a new therapeutic for the treatment of RSV infections. We describe a new class 
of VHHs that bind specifically to the prefusion conformation of the RSV F protein. Such VHHs 
were obtained by the immunization of a llama with a soluble prefusion-stabilized F protein 
combined with an RSV-neutralization-based screening strategy. The resulting VHHs display 
broad RSV-neutralizing activity, bind specifically and with high affinity to the prefusion 
conformation of F, and inhibit RSV replication in vivo. The potent RSV-neutralizing activity of 
the F-VHHs correlates with their ultra-high affinity for the prefusion F protein. By tightly 
binding to an epitope that is only present on the trimeric prefusion conformation, the VHHs 
presumably interfere with the transition of the F protein from the prefusion to the 
postfusion state, thereby preventing fusion with the host cell. 
F-VHH-4 and F-VHH-L66 have only 5 out of 15 amino acids in common in their CDR3. Yet, F-
VHH-4 and -L66 bind closely overlapping epitopes in a nearly identical way. On the 
nucleotide level, the VHHs are 94% identical, indicating that they probably emerged from the 
same recombined germline sequences. If so, it is remarkable that two very different paths of 
affinity maturation converge to highly similar modes of binding. Crystallization studies 
showed that the CDR3 of both VHHs bind into a cavity formed by two protomers. This 
illustrates the tendency of VHHs to preferably bind clefts or cavities whereas conventional 
antibodies in general bind either flat surfaces or extruding epitopes [33]. The epitope of F-
VHH-4 and F-VHH-L66 overlaps with the epitope mapped by mutagenesis for the broadly 
neutralizing antibody MPE8, which has neutralizing activity against human and bovine RSV, 
hMPV and PVM [10]. Nevertheless, the VHHs do not neutralize hMPV nor bind to PVM-
infected cells. RSV F has only 43 and 33% amino acid sequence identity with PVM an hMPV 
respectively [34], yet a substantial area of the surmised MPE8 epitope is conserved between 
the three viruses. Although the VHHs bind to a similar region, they make crucial contacts 
with a number of residues that are not conserved between RSV F, PVM F and hMPV F, 
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explaining the lack of hMPV neutralization and PVM-binding by the F-VHHs. Thus, in this case 
there appears to be a trade-off between the increased RSV-neutralizing activity of the VHHs 
and the breadth of MPE8. 
We addressed the in vitro escape potential of RSV in the presence of the VHHs. F-VHH-4 and 
F-VHH-L66 escape viruses had a single mutation resulting in a substitution of Thr50, which is 
located at the bottom of the cavity bound by the VHHs. Although resistant to F-VHH-L66, this 
virus could still be neutralized by F-VHH-4, albeit with 300-fold lower efficiency. The 
presence of three consecutive serine residues in the CDR3 of F-VHH-4 could lead to more 
flexibility of this loop compared to that of F-VHH-L66 and allow F-VHH-4 to bind to an altered 
conformation of prefusion F. Although the possibility of selecting for an escape mutant could 
raise concerns for the clinical use of these VHHs, the escape virus was severely attenuated as 
it was impossible to grow the virus to substantial amounts to make high-titer virus stocks. 
Analysis of all publically available F sequences derived from clinical isolates showed that the 
F-VHH-4 and –L66 epitope is highly conserved, indicating that variation in this region is not 
well tolerated. This greatly decreases the risk for development of resistant strains. 
Other VHHs against RSV F have been described recently [19, 35]. Nb017, for example, is a 
VHH developed by Ablynx that binds to antigenic site II of RSV F [19]. F-VHH-4 outperforms 
Nb017 by 15,000- and 180,000-fold on RSV A and RSV B neutralization respectively, 
reflecting the higher potency of prefusion-specific antibodies compared to antibodies that 
bind both conformations of F. In order to increase its neutralizing activity, Nb017 was re-
formatted into a trivalent VHH named ALX-0171. However, monovalent F-VHH-4 and -L66 
already display higher RSV A- and B- neutralizing activity than that reported for ALX-0171. In 
addition, the small size of monovalent VHHs may reduce its potential immunogenicity and 
facilitate penetration of the mucus layer that lines the respiratory epithelium to reach RSV-
infected cells. It is also straightforward to link a monovalent VHH to other carriers, such as a 
VHH that binds to another epitope in RSV or to a protein with an effector function of 
interest.  
A phase I/IIa clinical trial with inhaled ALX-0171 in hospitalized RSV-infected children 
indicated that the drug was safe. The trial also indicated that treatment with this trivalent 
pre- and postfusion F-reactive VHH could reduce viral replication and symptoms in the 
infected children. By selectively targeting prefusion F, for example with the VHHs described 
here, the antiviral impact in patients may be improved, which could result in a more robust 
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clinical benefit in a treatment setting of RSV-infected patients. As the vast majority of RSV-
infected infants are hospitalized at or after the peak of viral replication and disease, early 
RSV detection followed by rapid antiviral treatment remains key to reduce symptoms and 
prevent hospitalization of patients. Nebulization of F-VHH-4 as soon as possible after RSV 
confirmation offers the additional advantage that the antiviral is delivered directly to the site 
of infection. 
Developing new antibody-based drugs for respiratory infections in a VHH format has a 
number of advantages. Production and purification are inexpensive, straight-forward and 
can be performed in organisms that are generally regarded as safe and without the use of 
animal-derived products. In addition, due to their small size, high stability and solubility, 
VHHs can be easily administered via inhalation, directly to the site of viral infection. The in 
vitro and in vivo results reported here support further testing of F-VHH-4 and F-VHH-L66 as 
novel therapeutics against RSV.  
5.5 Materials and methods 
Study design 
It was our aim to develop efficient RSV-neutralizing VHHs that bind to the prefusion 
conformation of the F protein. Binding and neutralizing characteristics of the VHHs were 
analyzed on HEK293T cells, Vero cells, HEp-2 or A549 cells. In vivo assays were performed in 
BALB/c mice. All animal experiments were conducted with the approval of the Ethical 
committee of the faculty of Sciences (University of Ghent, Belgium, EC number 2015-019).  
Generation of prefusion F-specific VHHs 
A llama was immunized subcutaneously six times with 167 µg DS-Cav1 each time at weekly 
intervals. The animal facility operates under the Flemish Government License Number LA1 
700601. All experiments were done under conditions specified by law and authorized by the 
Institutional Ethical Committee on Experimental Animals (Ethical application 13-601-1).The 
DS-Cav1 protein was adjuvanted with poly (I:C) (Invivogen, 375 µg per injection) for the first 
two immunizations and with Gerbu LQ#3000 for the last four immunizations. One week after 
the last immunization 100 mL anticoagulated blood was collected for the preparation of 
peripheral blood lymphocytes. Total RNA from peripheral blood lymphocytes was used as 
template for first strand cDNA synthesis with oligodT primer. Using this cDNA, the VHH 
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encoding sequences were amplified by a nested PCR using first the call 01 and call 02 
primers (5’ GTCCTGGCTGCTCTTCTACAAGG3’, 5’GGTACGTGCTGTTGAACTGTTCC3’) and next 
the A6E and 38 primer (5’GATGTGCAGCTGCAGGAGTCTGGA/GGGAGG3’; 
5’GGACTAGTGCGGCCGCTGGAGACGGTGACCTGGGT3’). The resulting PCR fragment was 
digested with PstI and NotI, and cloned into the PstI and NotI sites of the phagemid vector 
pHEN4. Electrocompetent E. coli TG1 cells were transformed with the recombinant pHEN4 
vector. The resulting TG1 library stock was infected with VCS M13 helper phage to obtain a 
library of VHH-presenting phages. 
One round of panning was performed on 20 µg of immobilized prefusion F (DS-Cav1) in one 
well of a microtiter plate (type II, F96 Maxisorp, Nunc). After blocking the prefusion F-coated 
well and an uncoated well used as a negative control with SEA BLOCK blocking buffer 
(Thermo Scientific), phages (1 x 1012 particles) were applied to these wells and incubated for 
one hour at room temperature. After washing, the retained phage particles were eluted by 
applying a TEA-solution (14% triethylamine (Sigma) pH 10) for 10 minutes. Dissociated 
phages were transferred to a tube with 1 M Tris-HCl pH 8.0. Tenfold serial dilutions of the 
phages were used to infect TG1 cells, after which the bacteria were plated on LB agar plates 
with 100 μg/mL ampicillin and 1% glucose.  
Detection of F-specific VHHs in bacterial periplasm 
After a single round of panning, ninety colonies were randomly selected for further analysis 
by ELISA for the presence of F-specific VHHs in their periplasm. The colonies were used to 
inoculate 2 mL of Terrific Broth (TB) medium with 100 µg/mL ampicillin in 24-well deep well 
plates. After a five-hour incubation step at 37°C, VHH expression was induced by adding 
isopropyl β-D-1-thiogalactopyranoside (IPTG) at a concentration of 1 mM. The plates were 
subsequently incubated overnight at 37°C while shaking. The next day, bacterial cells were 
pelleted, resuspended in 200 µL TES buffer (0.2 M Tris-HCl pH 8, 0.5 mM EDTA, 0.5 M 
sucrose) and incubated at 4°C for 30 minutes. Next, periplasmic extracts were prepared by 
adding water to induce osmotic shock. After one-hour incubation at 4°C and subsequent 
centrifugation, the supernatants were collected. Microtiter plates were coated overnight 
with either 100 ng F protein in the postfusion conformation (FΔFP), 100 ng prefusion F (DS-
Cav1) or Bovine Serum Albumin (BSA, Sigma-Aldrich). The coated microtiter plates were 
blocked with 1% milk powder in phosphate-buffered saline (PBS) and 100 µL of the 
periplasmic extract was added to the wells. Bound VHHs were detected with anti-HA 
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(1/2000, MMS-101P Biolegend) mAb and horseradish peroxidase (HRP)-linked anti-mouse 
IgG (1/2000, NXA931, GE Healthcare). After washing, 50 µL of TMB substrate 
(Tetramethylbenzidine, BD OptEIA™) was added to every well. The reaction was stopped by 
addition of 50 µL of 1M H2SO4, after which the absorbance at 450 nM was measured with an 
iMark Microplate Absorbance Reader (Bio Rad). All periplasmic fractions for which the 
OD450 values obtained for prefusion or postfusion F were at least two times higher than the 
OD450 values obtained for BSA were selected and grown in 3 mL of LB medium with 1/2000 
ampicillin for plasmid isolation using the QIAprep Spin Miniprep kit (Qiagen). The cDNA 
sequence of the VHH was determined by Sanger sequencing using the M13RS primer 
(5’CAGGAAACAGCTATGACC3’). 
Expression of VHHs in Pichia pastoris 
To clone VHH sequences into a yeast expression vector, the VHH coding sequences were PCR 
amplified from the respective pHEN4 plasmids using the following forward and reverse 
primers (5’GGCGGGTATCTCTCGAGAAAAGGCAGGTGCAGCTGCAGGAGTCTGGG3’; 
5’CTAACTAGTCTAGTGATGGTGATGGTGGTGGCTGGAGACGGTGACCTGG3’). The resulting PCR 
products were digested with XhoI and SpeI and ligated into XhoI/SpeI-digested pKai61 
backbone. The origin of the pKai61 vector is described in Schoonooghe et al.[36]. The VHH 
sequences are cloned in frame with a slightly modified version of the S. cerevisiae a-mating 
factor signal sequence. The encoded genes contain a C-terminal 6XHis tag and are under 
control of the methanol inducible AOX1 promoter. The plasmid contains a Zeocine resistance 
marker for selection in bacterial as well as in yeast cells. The vectors were linearized by PmeI 
before transformation of P. pastoris strain GS115 using the condensed transformation 
protocol described by Lin-Cereghino et al.[37]. 
Purification of VHHs produced by Pichia pastoris 
Expression of VHH by transformed Pichia pastoris clones was first analyzed in 2 mL cultures. 
On day one individual transformants were used to inoculate 2 mL of YPNG medium (2% 
pepton, 1% Bacto yeast extract, 1.34% YNB, 0.1M potassium phosphate pH6, 0.00004% 
biotine, 1% glycerol) with 100 µg/mL Zeocin (Life Technologies) and incubated while shaking 
at 28°C for 24 hours. Next, cells were pelleted and the YPNG medium was replaced by YPNM 
medium (2% peptone, 1% Bacto yeast extract, 1.34% YNB, 0.1M potassium phosphate pH 6, 
0.00004% biotin, 1% methanol) to induce VHH expression. Cultures were incubated at 28°C 
while shaking for 48 hours. Fifty microliters of 50% methanol was added to the cultures at 
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16, 24 and 40 hours. After 48 hours, the yeast cells were pelleted and the supernatant was 
retained to assess the presence of VHH. To select VHHs with RSV-neutralizing activity, serial 
dilutions of the crude YPNM supernatant from individual Pichia pastoris transformants were 
tested in a plaque-reduction assay. 
Pichia pastoris transformants that yielded high levels of VHH in the medium and with high 
RSV-neutralizing activity were selected for scaling up using 100 or 300 mL Pichia cultures. 
Growth and methanol induction conditions and harvesting of medium were similar as 
mentioned above for the 2 mL cultures. The cleared medium was subjected to ammonium 
sulphate precipitation (80% saturation) for four hours at 4°C. The insoluble fraction was 
pelleted by centrifugation at 20,000 x g and solubilized in 10 mL HisTrap binding buffer (20 
mM sodium phosphate, 0.5 M NaCl, 20 mM imidazole, pH 7.4) before purification on a 1 mL 
HisTrap HP column (GE Healthcare). Relevant fractions containing the VHH were pooled, and 
concentrated with a Vivaspin column (5 kDa cutoff, GE Healthcare) and then subjected to 
size-exclusion chromatography (Superdex 75). Fractions containing the VHH were again 
pooled and concentrated and the concentration was determined. The purified VHHs were 
aliquoted and stored at -80°C until further use.  
Cells and viruses 
HEp-2 cells (ATCC, CCL-23), Vero cells (ATCC, CCL-81), HEK-293T cells (a gift from Dr. M. Hall) 
and A549 cells (ATCC, CCL-185) were grown in Dulbecco's modified eagle medium (DMEM) 
supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, non-
essential amino acids (Invitrogen, Carlsbad, California) and 1 mM sodium pyruvate at 37 °C in 
the presence of 5% carbon dioxide. RSV A2, an A subtype of RSV (ATCC, VR-1540, Rockville), 
RSV B49, a B subtype of RSV (BE/5649/08 clinical strain, source described in[38], obtained 
from Prof M. Van Ranst), RSV A Long (ATCC, VR-26, kind gift from Dr. Rik De Swart), 
MAD/GM2_2/12, MAD/GM2_12/12, MAD/GM2_13/12, MAD/GM2_14/12, 
MAD/GM3_10/14, MON/9/92 (primary RSV A strains, isolated in Madrid (MAD) or 
Montevideo (MON)) and MAD/GM3_7/13 (a primary RSV B strain isolated in Madrid) were 
propagated in HEp-2 cells and quantified on Vero cells by plaque assay using goat anti-RSV 
serum (AB1128, Chemicon International). Clinical isolates MAD/GM2_2/12, 
MAD/GM2_12/12, MAD/GM2_13/12, MAD/GM2_14/12, MAD/GM3_10/14 and MON/9/92 
represent at least 2 different genotypes of antigenic group A [39, 40]. 
 
125 
 
Plaque-reduction assay  
A dilution series of the VHHs/mAbs was prepared in Opti-MEM (Gibco), incubated with RSV 
for 30 minutes at 37 °C and used to infect confluent Vero cells. After three hours, an equal 
volume of 1.2% avicel RC-851 (FMC Biopolymers) in DMEM medium supplemented with 2% 
FCS, 2 mM L-glutamine, non-essential amino acids and 1 mM sodium pyruvate was added to 
each well and the infection was allowed to continue at 37 °C for three days. Viral infection 
was tested by immunostaining of the viral plaques with goat anti-RSV serum (AB1128, 
Chemicon International) and horseradish peroxidase-conjugated anti-goat IgG (SC2020, 
Santa Cruz). The plaques were visualized by applying TrueBlue peroxidase substrate (KPL, 
Gaithersburg). For the post-attachment neutralization assay, a dilution series of VHH/mAb 
was added to HEp-2 cells that had been preincubated with RSV at 4 °C for two hours. Control 
antibody 65 is a mouse IgG2a monoclonal antibody specific for the influenza matrix protein 
2[41].  
Recombinant mKate-RSV panel 
The pSynkRSV-line19F, a BAC system containing RSV cDNA was used to generate 
recombinant RSV antigenomes with matched G and F genes from various RSV strains to 
recover new infectious clones[42]. The panel of reconstructed recombinant mKate-RSV 
consists of five RSV subtype A and three RSV subtype B viruses which represent RSV lab 
strains and primary isolates from distinct temporal and geographic regions. The RSV subtype 
A panel comprises of A2/D46 and A2/L19 which are laboratory strains, and three primary 
strains: Riyadh 91/2009, 2-20 F/G and A1998/12-21. RSV subtype B panel comprises one lab 
strain B/18537 and two primary isolates TX11-56 and NH1276. 
Fluorescence plate reader neutralization assay  
Fluorescence plate reader neutralization assay was performed as previously described[13]. 
2.4 x 104 HEp-2 cells/well in 30μL culture medium were seeded in 384-well black optical 
bottom plate (Nunc 384-well plates, Thermo Scientific). Serum samples or antibodies (1 
mg/mL) were diluted four-fold for 12 dilutions starting from 1:10, equal volume of 
recombinant mKate-RSV (subtype A and subtype B) was added and mixed, incubated at 37°C 
for one hour, then 50 μL mixture of sample and virus was added to cells, and incubated at 
37°C for 22–24 hours. After incubation, assay plate was measured for fluorescence intensity 
in microplate reader at Ex 588 nm and Em 635 nm (SpectraMax Paradigm, molecular 
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devices). For the 96-well plate format, 5 x 104 cells/well in 100 μL of culture medium were 
seeded in a 96-well plate, 100 μL mixtures of sample and virus were added to the plate. 
Virus inhibition was measured as the reduction of fluorescence of samples comparing to 
virus control. Data was analyzed and EC50 was calculated by curve fitting with GraphPad 
Prism software (GraphPad Software Inc.).  
Attachment assay 
RSV A2 (1 x 107 PFU) was incubated with 1 µM VHH/antibody or 2.5 µM dextran sulphate 
(MP Biomedicals) for 30 minutes at room temperature. The mixtures were added to chilled 
HEp-2 cells and incubated for two hours at 4°C. The cells were washed five times with cold 
PBS with 0.5% BSA (PBS/BSA). Half of the cells were fixed with 2% PFA, stained with goat 
anti-RSV polyclonal serum (AB1128, Chemicon International) and subsequently with 
AlexaFluor 488 labeled donkey anti goat antibody (Invitrogen, 1/600 dilution). After washing, 
the cells were analyzed using a FACSCalibur flow cytometer. The other half of the cells was 
plated out and incubated at 37°C in DMEM with 2% FCS. After 48 hours, the cells were 
collected, fixed and analyzed as described above.  
Inhibition of syncytium formation 
HEp-2 cells were seeded in a 96-well plate (30,000 cells/well). The next day, the cells were 
washed with Opti-MEM (Gibco) and RSV A2 (35 PFU/well) was added to each well. In 
meanwhile a dilution series of VHHs/monoclonal antibodies was prepared in Opti-MEM 
supplemented with 1% penicillin and 1% streptomycin (1/3 dilution series). After three 
hours, the inoculum was removed and the cells were washed with Opti-mem. The dilution 
series of VHHs/monoclonal antibodies were applied to the cells after which the cells were 
incubated during two hours at 37°C. Next, 50 µl of 1.2 % avicel RC-851 (FMC Biopolymers) in 
DMEM medium supplemented with 2% heat-inactivated fetal calf serum (FCS), 2mM L-
glutamine, non-essential amino acids and 1 mM sodium pyruvate was added to each well 
and the incubation at 37°C was continued for three days. The cells were fixed for 30 minutes 
at room temperature by adding 50 µl of a 2% PFA solution to the wells. After fixation, the 
cells were washed twice with phosphate-buffered saline (PBS), permeabilized with PBS 
containing 0.2% Triton X-100 for 10 minutes and blocked with PBS containing 1% BSA. 
Subsequently, palivizumab was added (2 µg/ml in PBS containing 0.5% BSA and 0.001% 
Triton X-100 (PBS/BSA)). After three washes with PBS/BSA the cells were incubated with 
Alexa Fluor 594 goat anti-human IgG (Invitrogen) (1/600 in PBS/BSA) for 30 minutes. After 
127 
 
washing with PBS/BSA, fluorescent images were recorded with Olympus IMT 200 inverted 
fluorescence microscope. 
VHH binding to cells expressing F 
HEK293T were transfected with pCAGGS-F, which encodes a codon-optimized RSV F cDNA, 
with the FuGENE HD transfection reagent (Promega) according to the manufacturer’s 
protocol. To trace transfected cells, transfections were performed in the presence of peGFP-
NLS. Control transfections were performed with only peGFP-NLS. Forty-two hours after 
transfection the cells were detached, washed and blocked. Subsequently the cells were 
incubated with a 1/10 dilution series of VHH or mAb in PBS/BSA. One hour later the cells 
were washed and stained with mouse anti-Histidine Tag antibody (MCA1396, Abd Serotec) 
followed by anti-mouse IgG Alexa 633 (Invitrogen) (for the VHH samples) or anti-human IgG 
Alexa 633 (Invitrogen) (for the antibody samples). The stained cells were analyzed using a 
FACSCalibur flow cytometer. All procedures were performed on ice or at 4°C.  
Binding to infected cells was assessed in a similar manner. Vero cells were inoculated with 
RSV A2 at a MOI of 0.1 and after 48 hours the cells were collected and fixed with 2% PFA. 
The cells were stained with 1 µg/mL of VHH or antibody. The rest of the staining procedure 
was performed as described above.  
Immunostaining of infected cells  
A549 cells, grown on glass plates for confocal imaging or µ-Dish glass bottom dishes (ibidi) 
for TIRF-imaging, were mock-infected or infected with RSV A2 (MOI 1) for 24 hours and fixed 
with 2% PFA. The cells were blocked and stained with 1 µg/mL of F-VHH-4, F-VHH-L66 or 
Ctrl-VHH in PBS/BSA. One hour later the cells were washed and fixed again with 2% PFA and 
stained with polyclonal goat anti-RSV serum (or polyclonal rabbit anti-G serum (Sino 
Biological Inc. 11070-V08H) for the TIRF images) and mouse anti-Histidine Tag antibody. VHH 
binding was detected with anti-mouse IgG Alexa 488 and anti-RSV serum with anti-goat 
Alexa 633 (or anti-rabbit Alexa 568 for the TIRF images). After washing the samples were 
mounted and confocal images were recorded with a SP5 Leica confocal microscope. TIRF 
images were recorded with a Zeiss TIRF Observer. The recorded images were processed with 
Volocity software (Perkin Elmer). 
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Cross-competition analysis with biolayer interferometry 
Antibody cross-competition was performed as described previously [11] with some 
modifications. Briefly, DS-Cav1 protein (10 μg/mL) was immobilized in a random orientation 
on AR2G biosensors (ForteBio) pre-activated with N-hydroxysuccinimide (NHS) and 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDC) through amine coupling reaction in acetate 
buffer (pH 5.0). The reaction was quenched by 1 M ethanolamine (pH 8.0) and DS-Cav1-
immobilized biosensors were then equilibrated with assay buffer (PBS with 1% BSA). The 
biosensors were dipped in competitor antibodies (35 μg/mL in assay buffer) for 300 s 
followed by analyte antibodies (35 μg/mL in assay buffer) for 300 s with a short baseline step 
(60 s) in between the two antibody steps. All assays were performed at a set temperature of 
30 °C with agitation of 1,000 rpm in an Octet HTX instrument (ForteBio). Percent inhibition 
of antibody binding by competing mAbs was calculated with the following equation: 
Inhibition (%) = 100 - [(analyte antibody binding in the presence competitor mAb) / (analyte 
antibody binding in the presence of isotype control mAb)] x 100. 
F-VHH escape mutant viruses 
A dilution series of RSV A Long was used to infect Vero cells in the presence of a dose 
corresponding to 20, 80 or 320 times the IC50 of F-VHH-4 or F-VHH-L66. After six days of 
infection, the supernatant of the cells infected with the highest dilution of RSV for which 
virus could be detected (observed by plaque assay), was used to infect a subsequent series 
of Vero cells in the presence of VHH or palivizumab. After two and four passages in presence 
of F-VHH-L66 and F-VHH-4 respectively, single RSV isolates were obtained by serial dilution 
which were amplified on Vero cells. Total RNA was isolated from the resulting virus stocks, 
cDNA was prepared and the F gene was amplified and sequenced with following FW and RV 
primers (5’ATCAAGCTTTAACAATGGAGTTGCTAATCCTCA3’, 5’ 
AACCGCTCGAGTTTAGTTACTAAATGCAATAT3’). A plaque reduction assay with these virus 
isolates was performed. 
Surface plasmon resonance 
Purified DS-Cav1 with a C-terminal StrepTagII and 6X HisTag was captured on an NTA sensor 
chip to approximately 530 response units (RU) each cycle using a Biacore X100 (GE 
Healthcare). The NTA sensor chip was regenerated between cycles using 0.25 M EDTA 
followed by 0.5 mM NiCl2. A buffer-only sample was injected over the DS-Cav1 and reference 
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flow cells, followed by F-VHH-4 or F-VHH-L66 2-fold serially diluted from 5 nM to 39.1 pM in 
HBS-P+, with a duplication of the 1.25 nM concentration. The data were double-reference 
subtracted and fit to a 1:1 binding model using Scrubber. 
Protein production for crystallization 
Freestyle 293-F cells (Invitrogen) were transfected with plasmid encoding stabilized 
prefusion RSV F (DS-Cav1) [13]. Proteins were expressed in the presence of kifunensine (5 
μM) and purified from cell supernatants using Strep-Tactin resin (IBA). Tags were removed 
by thrombin digestion and glycans were removed by digestion with Endo H (10% w/w) for 2 
hours at room temperature. Purified DS-Cav1 was combined with a 1.5-fold and 2-fold molar 
excess of Pichia-expressed F-VHH-4 and F-VHH-L66, respectively, and separated from excess 
VHH using a Superose6 column (GE Healthcare Biosciences). For crystallization trials of the 
unbound VHHs, vectors encoding F-VHH-4 or -L66 with a C-terminal 3C cleavage site, Twin-
Strep-tag and 8X HisTag were transfected into FreeStyle 293-F cells. Proteins were purified 
from cell supernatants using Strep-Tactin resin before tag removal by HRV 3C digestion. 
VHHs were separated from cleaved tags using a Superdex 75 column.  
Crystallization and data collection 
F-VHH-4 crystals were produced by sitting-drop vapor diffusion by mixing 100 nL of F-VHH-4 
(9.45 mg/mL) with 50 nL of reservoir solution containing 3% (w/v) PEG 400, 2.2 M 
ammonium sulfate, 0.2 M sodium chloride and 0.1 M HEPES pH 7.5. Crystals were soaked in 
reservoir solution supplemented with 25% 2R,3R-butanediol and frozen in liquid nitrogen. 
Diffraction data were collected to 1.87 Å at SBC beamline 19-ID (Advanced Photon Source, 
Argonne National Laboratory).  
Crystals of F-VHH-4 in complex with DS-Cav1 were produced by hanging-drop vapor diffusion 
by mixing 2 μL of the complex (2.45 mg/mL) with 1 μL of reservoir solution containing 0.2 M 
ammonium citrate pH 4.5, 14.75% (w/v) PEG 3350, and 8.85% (v/v) isopropanol. Crystals 
were soaked in reservoir solution supplemented with 30% (v/v) ethylene glycol and frozen in 
liquid nitrogen. Diffraction data were collected to 3.3 Å at the GM/CA beamline 23-IDB (APS, 
Argonne National Laboratory).  
Crystals of F-VHH-L66 in complex with DS-Cav1 were produced by free-interface diffusion by 
mixing 2 µL of the complex (4.79 mg/mL) with 2 µL of 0.05 M potassium phosphate and 20% 
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(w/v) PEG 4000 in a Crystal Former Optimization Chip (Microlytic). Crystals were soaked in 
crystallization solution supplemented with 30% (v/v) ethylene glycol and frozen in liquid 
nitrogen. Diffraction data were collected to 3.8 Å at SBC beamline 19-ID. 
Structure determination, model building and refinement  
All data were indexed and integrated in iMOSFLM [43] and scaled and merged using 
AIMLESS [44]. F-VHH-4 crystals formed in space group P212121 with near-perfect pseudo-
merohedral twinning to appear as space group P41212. Diffraction data from F-VHH-4 
crystals were initially processed as P422 and a molecular replacement solution containing 
one VHH per asymmetric unit in space group P41212 was obtained using PHASER [45]. 
However, refinement resulted in suspiciously high Rwork/Rfree values, particularly given the 
high resolution of this data set. Evaluation of systematic absences revealed that 00l 
reflections were present for l=2n, which is compatible with a 42 or 21 screw axis, but not with 
the 41 axis found in the molecular replacement solution. Evaluation of the L- and H-tests 
revealed that the crystal was pseudo-merohedrally twinned (Supplementary Fig. 22a) with a 
twin fraction greater than 0.4 (Supplementary Fig. 22b). The data were subsequently 
reprocessed in space group P212121 and a molecular replacement solution was obtained 
containing two VHH molecules per asymmetric unit. After manual model building in Coot 
[46], the structure was refined in PHENIX [47] to an Rwork/Rfree of 17.0/20.8% using twin law 
kh-l and a refined twin fraction of 0.47.  
The F-VHH-4 and -L66 complexes formed crystals in space groups P3221 and P3121, 
respectively. The unbound F-VHH-4 structure and the previously solved prefusion F structure 
(PDB ID: 4MMS) were used as search models for molecular replacement. The F-VHH-4 and -
L66 structures were built manually in Coot and refined with PHENIX using NCS torsion 
restraints and reference-model restraints to an Rwork/Rfree of 18.5/23.4% and 25.3/28.8%, 
respectively. Complete data collection and refinement statistics are presented in 
Supplementary Table 2. 
HMPV microneutralization test 
Pre-determined amounts of GFP-expressing hMPV recombinant viruses (NL/1/00 A1 
sublineage or NL/1/99 B1 sublineage, a kind gift of Bernadette van den Hoogen and Ron 
Fouchier, Rotterdam, the Netherlands) or GFP-hRSV (A2 strain, a kind gift of Mark Peeples, 
Columbus, Ohio, USA) were mixed with serial dilutions of VHH or monoclonal antibodies 
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before being added to cultures of Vero-118 cells. Forty-eight hours later, the medium was 
removed, PBS was added and the amount of GFP per well was measured with a Tecan 
microplate reader M200. Fluorescence values were represented as percent of a virus control 
without antibody and IC50 values were calculated from the plotted curves. 
Binding to PVM-infected cells 
Vero cells were inoculated with lung homogenates from mice infected with PVM. Infection 
was continued at 32°C until day ten. PVM- and mock-infected cells were trypsinized, fixed 
with 1% PFA and blocked with 1% BSA. Cells were stained with 1 µg/ml MPE8 or 10 µg/ml 
VHH. One hour later the cells were washed and stained with mouse anti-Histidine Tag 
antibody (MCA1396, Abd Serotec) followed by anti-mouse IgG Alexa 633 (Invitrogen) (for the 
VHH samples) or anti-human IgG Alexa 633 (Invitrogen) (for the antibody sample). The 
stained cells were analyzed using a FACSCalibur flow cytometer. 
F mutagenesis  
F mutants were generated through fusion PCR with following primers based on the codon-
optimized F gene (amplifying the codon-optimized F gene in the pCAGGS vector FW and RV: 
5’ ATTGAATTCGCGGCCGCGCCACC3’, 5’GCCAGAAGTCAGATGCTCAAGG3’; T267A FW and RV 
mutagenesis primers: 5’ ACGACATGCCCATCGCCAACGACCAG3’, 5’ 
CTGGTCGTTGGCGATGGGCATGTCGT3’; L305R FW and RV mutagenesis primers: 5’ 
TGCAGCTGCCTCGGTACGGCGTGATCG3’, 5’ CGATCACGCCGTACCGAGGCAGCTGCA3’). These 
mutants were confirmed by sequencing. Binding to these mutants were tested in transiently 
transfected F HEK293T cells like described above.  
RSV F ELISA 
Binding to cleaved F was performed like described in [31]. Briefly 96-well plates were coated 
with either monoclonal antibody or VHH. After blocking, dilutions of purified F protein were 
added to plates, which were then washed before incubation with 101F antibody and 
peroxidase labeled anti-mouse IgG. After addition of o-phenylenediamine dihydrochloride 
(Sigma), reactions were stopped with 2 N sulfuric acid and absorbance was read at 490 nm.  
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Mice 
Specific pathogen-free, female BALB/c mice were obtained from Charles River (Charles River 
Wiga, Sulzfeld, Germany). The animals were housed in a temperature-controlled 
environment with 12 h light/dark cycles; food and water were provided ad libitum. The 
animal facility operates under the Flemish Government License Number LA1400536. All 
experiments were done under conditions specified by law and authorized by the Institutional 
Ethical Committee on Experimental Animals (Ethical application EC2015-019). 
Administration of VHHs and RSV A2 infection in mice 
Mice, seven weeks old, were randomly distributed in experimental groups of six animals. 
They were slightly anesthetized by isoflurane before intranasal administration of VHH, 
palivizumab or RSV challenge virus. VHH, palivizumab and RSV virus were administered 
intranasally in a total volume of 50 µL PBS. Each group received 10 µg of F-VHH-4, 10 µg of 
Ctrl-VHH or 10 µg of palivizumab four hours before infection with 106 PFU of RSV A2. The 
mock-infected group received 10 µg of Ctrl-VHH that is specific for a Junin virus protein. 
Determination of lung viral titers by plaque assay 
Five days after challenge, mice were euthanized, lungs were removed and homogenized by 
vigorous shaking with a Mixer Mill MM 2000 (Retsch) in the presence of a sterile metal bead 
in 1 mL HBSS containing 20% sucrose and supplemented with 1% penicillin and 1% 
streptomycin. Lung homogenates were cleared by centrifugation at 4 °C and used to titrate 
the virus by plaque assay. We set lung homogenates in which no virus was detected as the 
detection limit of the assay.  
Determination of lung viral titer by qRT-PCR 
To determine the lung RSV load by qRT-PCR, total RNA from the cleared lung homogenates 
was prepared by using the High Pure RNA Tissue Kit (Roche) according to the manufacturer’s 
instructions. Next, cDNA was prepared by the use of random hexamer primers and the 
Transcriptor First Strand cDNA Synthesis Kit (Roche). The relative levels of genomic RSV M 
cDNA were determined by qRT-PCR using primers specific for the RSV A2 M gene 
(5’TCACGAAGGCTCCACATACA3’ and 5’GCAGGGTCATCGTCTTTTTC3’) and a nucleotide probe 
(#150 Universal Probe Library, Roche) labeled with fluorescein (FAM) at the 5’-end and with 
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a dark quencher dye near the 3’- end. The qRT-PCR data were normalized to mRPL13A mRNA 
levels. 
Analysis of pulmonary cell infiltration 
The immune cell composition of bronchoalveolar lavages (BAL) was determined by analyzing 
surface expression of MHC-II, CD3e, SiglecF, CD4, CD8, CD11b and CD11c.  Briefly, high-
affinity Fc receptors (FcRs) were blocked by incubation with purified anti-mouse CD16/CD32 
(Fc Block, BD Pharmingen, 553142) for 30 minutes at 4°C. Subsequently the cells were 
stained with MHC-II-eFluor450 (eBioscience, 48-5321-82, 1/500), CD3e-AlexaFluor488 (BD 
Pharmingen, 557666, 1/300), SiglecF-PE (BD Pharmingen, 562068, 1/200), CD4-PerCP (BD 
Pharmingen, 553052, 1/300), CD8-PE-Cy7 (eBioscience, 25-0081-81, 1/300), CD11b-APC-Cy7 
(BD Pharmingen, 557657, 1/500) and CD11c-APC (BD Pharmingen, 550261, 1/200) for 1 hour 
at 4°C. After staining, samples were measured on an LSR II flow cytometer (BD Biosciences, 
San Jose, CA), and analyzed using FlowJo X (TreeStar) software. 
Testing lower doses of F-VHH-4 in mice 
BALB/c mice, seven weeks old, were slightly anesthetized by isoflurane before intranasal 
administration of VHH or RSV challenge virus. VHH and RSV virus were formulated in PBS 
and administrated in a total volume of 50 µL, which was distributed equally over the two 
nostrils. Each group of six mice received either 1, 3 or 10 µg of F-VHH-4 or 10 µg of Ctrl-VHH 
four hours before infection with 106 PFU of RSV A2. The mock-infected group received 10 µg 
of Ctrl-VHH.  
Statistical analysis 
We used Graphpad Prism 6 for statistical analyses, and the two-sided Mann-Whitney U test 
to evaluate differences between two groups.  
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5.8 Supplementary figures 
 
Supplementary Figure 1. Llama prefusion F immune plasma neutralizes RSV A2 and RSV B. RSV 
neutralizing activity in plasma isolated from a llama before and after 2 to 6 weekly immunizations 
with DS-Cav1 was determined by plaque reduction assay using RSV A2 (a) and RSV B (clinical strain 
RSV BE/5649/08) (b). Monolayers of Vero cells seeded in 96-well plates were infected with RSV A2 or 
RSV B (30 PFU/well) in the presence of serial dilutions of llama plasma. Three days after infection, the 
plaques in each well were stained and counted (Y-axis).  
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Supplementary Figure 2. RSV neutralizing activity in Pichia pastoris culture supernatants. pKai61-
VHH P. pastoris transformants were pre-cultured in 2 mL YPNG medium in a 24-well format for 24 
hours. Subsequently, the cells were transferred to YPNM medium for 48 hours to induce VHH 
expression. 1/60, 1/600 and 1/6000 dilutions of the cleared culture supernatant were tested for 
neutralizing activity by mixing with RSV A2 (30 PFU/well), which was used to inoculate a monolayer 
of Vero cells. Boxes indicate P. pastoris clones with neutralizing activity (i.e. no RSV plaques or a 
reduced number of RSV plaques in one or more wells compared to the other clones). (a) P. pastoris 
clones (numbered) obtained after transformation with a select set of unique pKai61-VHH plasmids. 
(b) P. pastoris clones obtained after transformation with pKai61 in which a library of candidate F-
specific VHHs was cloned. L3, L13, etc. refer to individual P. pastoris transformants.  
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Supplementary Figure 3. Nucleotide sequence of F-VHH-4 and F-VHH-L66. The sequences coding for 
the CDRs are labeled and boxed. 
  
F-VHH-4 CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCTCTGAGA
F-VHH-L66 CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCTCTGAGA
F-VHH-4 CTCTCCTGTGCAGCCTCTGGATTCACTTTGGATTATTATTACATAGGCTGGTTCCGC
F-VHH-L66 CTCTCCTGTGCAGCCTCTGGATTCACTTTGGATTATTATTACATAGGCTGGTTCCGC
F-VHH-4 CAGGCCCCAGGGAAGGAGCGCGAGGCAGTCTCATGTATTAGTGGTAGTAGTGGTAGC
F-VHH-L66 CAGGCCCCAGGGAAGGAGCGCGAGGGGGTCTCATGTATTAGTAGTAGTCATGGTAGC
F-VHH-4 ACATACTATCCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAG
F-VHH-L66 ACATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAG
F-VHH-4 AACACGGTGTATCTGCAAATGAACAGCCTGAAACCTGAGGACACGGCCGTTTATTAC
F-VHH-L66 AACACGGTGTATCTGCAGATGAACAGCCTGAAACCTGAGGACACGGCCGTTTATTAC
F-VHH-4 TGTGCGACAATTCGTAGTAGTA-GCTGGGGGGGTTGCGTGCACTACGGCATGGACTA
F-VHH-L66 TGTGCGACAGTA-GCTGTAGCACATTTCCGGGGTTGCGGAGTCGACGGCATGGACTA
F-VHH-4 CTGGGGCAAAGGGACCCAGGTCACCGTCTCCAGC
F-VHH-L66 CTGGGGCAAAGGGACCCAGGTCACCGTCTCCAGC
CDR1
CDR2
CDR3
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Supplementary Figure 4. Neutralization of clinical isolates of RSV by F-VHHs and mAbs. (a) RSV A2 
(60 PFU/well), primary RSV A isolates (b) MAD/GM2_2/12 (40 PFU/well), (c) MAD/GM2_12/12 (15 
PFU/well), (d) MAD/GM2_13/12 (27 PFU/well), (e) MAD/GM2_14/12 (20 PFU/well), (f) 
MAD/GM3_10/14 (17 PFU/well), (g) MON/9/92 (35 PFU/well) or primary RSV B isolate (h) 
MAD/GM3_7/13 (20 PFU/well) was preincubated with different concentrations of VHH or mAb 
before infection of Vero cells. Three days later, the viral plaques were stained with polyclonal anti-
RSV serum.  
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Supplementary Figure 5: F-VHHs inhibit syncytium formation. RSV A2 (35 PFU) was added to Hep-2 
cells, which were subsequently incubated for three hours at 37°C before the inoculum was washed 
away and 3 µg/ml of indicated VHH or antibody was added. Three days later, cells were fixed and 
stained with palivizumab to visualize the plaques. Scale bar represents 100 µm.  
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Supplementary Figure 6: F-VHH-4 inhibits syncytium formation at different concentrations. RSV A2 
(35 PFU) was added to Hep-2 cells, which were subsequently incubated for three hours at 37°C 
before the inoculum was washed away and a dilution series of F-VHH-4 or palivizumab was added. 
Three days later, cells were fixed and stained with palivizumab to visualize the plaques. The 
concentration of added F-VHH-4/palivizumab is indicated in ng/ml. Scale bar represents 100 µm. 
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Supplementary Figure 7. F-VHH-4 prevents fusion but not viral attachment. Left panel: RSV A2 (1 x 
107 PFU) was pre-incubated with 1 µM VHH (F-VHH-4 or Ctrl-VHH), 1 µM mAbs (palivizumab, D25 or 
ctrl mAb 65), 2.5 µM dextrane sulfate or PBS and then allowed to bind to HEp-2 cells for two hours at 
4°C. After washing, the cells were stained with polyclonal goat anti-RSV serum and analyzed by flow 
cytometry. Right panel: HEp-2 cells were treated as described above except that after the 2 hour 
incubation at 4°C and washing step, the cells were incubated for 48 hours at 37°C. Cells were then 
resuspended, stained with polyclonal goat anti-RSV serum and analyzed by flow cytometry. In both 
experiments the fluorescence intensity was compared to mock-infected cells.  
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Supplementary Figure 8. F-VHH-4 and -L66 do not bind to postfusion RSV F. Surface plasmon 
resonance (SPR) sensorgrams for the binding of (a) F-VHH-4 and (b) F-VHH-L66 to postfusion RSV F 
(RSV F ΔFP) coupled to a CM5 chip at approximately 450 RU. A buffer-only sample was injected over 
the postfusion F and reference flow cells, followed by 2-fold serial dilutions of F-VHH-4 or F-VHH-L66 
ranging from 1 μM to 500 nM for postfusion F. The data were double-reference subtracted.  
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Supplementary Figure 9. F-VHH-4 and -L66 bind to F-transfected and RSV-infected cells. (a) 
HEK293T cells were co-transfected with an RSV A2 F and GFP-NLS expression vector. Forty-two hours 
after transfection, the cells were immunostained with different concentrations of VHH or the 
indicated mAbs. Cells transfected with the GFP expression vector only, were stained with 1 µg/mL 
VHH or antibody. The graph shows the average ± SD of the median fluorescence intensity (MFI) value 
of the GFP positive cells determined by flow cytometry for the indicated VHH/antibody (n=3). (b) RSV 
A2- or mock-infected Vero cells were stained with VHHs or mAbs (1 µg/mL). The graph shows the 
average MFI value ± SD for the indicated VHH or antibody (n=3). Ctrl-VHH is specific for an irrelevant 
target and 65 is a mAb specific for an irrelevant antigen.  
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Supplementary Figure 10. F-VHH-4 and -L66 bind to RSV-infected cells. (a) Representative confocal 
images of RSV A2-infected or mock-infected A549 cells stained with 1 µg/mL F-VHH-4, F-VHH-L66, 
Ctrl-VHH or a polyclonal goat anti-RSV serum. Green signal: staining with VHH. Red signal: staining 
with goat anti-RSV serum. Scale bar = 20 µm. (b) Total internal reflection fluorescence (TIRF) 
microscopy image of RSV-A2- and mock-infected A549 cells stained with 1 µg/mL F-VHH-4 or Ctrl-
VHH. Red signal: staining with rabbit polyclonal anti-G serum. Green signal: staining with VHH. Scale 
bar = 10 µm. 
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Supplementary Figure 11. The bound and unbound conformations of F-VHH-4 are very similar. F-
VHH-4 from the prefusion F-bound structure (dark blue) was aligned to the 1.9 Å unbound structure 
(light blue). The conformations of the two states are very similar, with an RMSD of 0.7 Å for 125 
equivalent Cα atoms.   
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Supplementary Figure 12. Model of prefusion RSV F in complex with AM14, motavizumab, 101F 
and F-VHH-4. The AM14-motavizumab-prefusion F structure (PDBID: 4ZYP) and the F peptide-bound 
101F Fab structure (PBID: 3O41) were aligned with the F protein of the F-VHH-4 complex structure. 
The epitope of F-VHH-4, as well as that of F-VHH-L66, is located between those of AM14, 
motavizumab and 101F, and partially overlaps with each of these.  
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Supplementary Figure 13: F-VHHs do not bind to PVM-infected cells. Vero cells were either infected 
with lung homogenates from mice that had been infected with PVM or mock-infected. Ten days later 
the cells were fixed and stained with either 10 µg/mL of the indicated VHH or 1 µg/mL of MPE8. The 
graph shows the median fluorescence intensity (FI) value determined by flow cytometry of the 
indicated VHH/antibody.  
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Supplementary Figure 14. Binding of F-VHH-4 and -L66 to monomeric prefusion F. Surface plasmon 
resonance (SPR) sensorgrams for the binding of (a) F-VHH-4 and (b) F-VHH-L66 to monomeric 
prefusion F (DS-Cav1 lacking the foldon trimerization motif) coupled to a CM5 chip at approximately 
360 RU. A buffer-only sample was injected over the monomeric prefusion F reference flow cells, 
followed by 2-fold serial dilutions of F-VHH-4 or F-VHH-L66 ranging from 500 nM to 15.6 nM, with a 
duplication of the 62.5 nM concentration. The data were double-reference subtracted and fit to a 1:1 
binding model (red lines).  
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Supplementary Figure 15. F-VHH-4 and -L66 capture wild-type F ectodomain in the trimeric 
prefusion conformation. Overlaid elution profiles from a Superose6 16/70 column are shown for 
wild-type RSV F ectodomain expressed in the presence of F-VHH-4 or F-VHH-L66 (red and blue, 
respectively). Traces for prefusion-stabilized RSV F trimer unbound (grey) or bound by F-VHH-4 
(black) are also shown for comparison. The T4 fibritin trimerization motif (Foldon) was fused to the C-
terminus of the prefusion-stabilized RSV F protein to keep the protein trimeric.  
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Supplementary Figure 16. The cavity bound by the VHHs is constricted in the postfusion 
conformation of RSV F. The prefusion and postfusion RSV F structures are shown as molecular 
surfaces colored in pink, tan and light green. The insets show the two protomers involved in VHH 
binding as ribbons and the third promoter as a molecular surface. In prefusion F, the distance 
between antigenic site IV and antigenic site II is approximately 16 Å, whereas in the postfusion 
conformation this distance is reduced to ~11 Å, resulting in a substantial clash between the VHH 
CDR3 and antigenic site II.  
  
153 
 
 
Supplementary Figure 17: Binding of VHHs/mAbs to cells transfected with wild type or mutants of 
F. HEK293T cells were transfected with expression vectors for wild type, T267A mutant or L305R 
mutant RSV F in combination with a GFP-NLS expression vector (peGFP-NLS) or with the GFP-NLS 
expression vector alone. Cells were subsequently stained with (a) F-VHH-4, -L66 or Ctrl-VHH or (b) 
the indicated mAbs and analyzed by flow cytometry. The median fluorescence intensity (FI) value of 
the indicated VHH binding at the indicated concentration in µg/ml (or at 1 µg/ml for the antibodies) 
to GFP+ cells is shown in the graphs. 
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Supplementary Figure 18: Binding of F-VHH-4 and -L66 to cleaved and uncleaved prefusion F. 
Binding of F-VHH-4, -L66, Ctrl-VHH, motavizumab, D25 and AM14 to uncleaved monomeric RSV F 
(green circles), cleaved prefusion RSV F (black squares) and uncleaved prefusion RSV F (pink squares) 
was measured by ELISA. 
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Supplementary Figure 19. F-VHH-4 and -L66 prevent RSV replication in lungs of RSV-challenged 
mice. A 1.5 mg/kg dose of F-VHH-4, F-VHH-L66, palivizumab or Ctrl-VHH was administered 
intranasally four hours before infection of BALB/c mice (n = 5 per group, except the palivizumab 
group: n = 4) with 1 x 106 RSV A2. Five days after infection, the RSV load in cleared lung homogenates 
was determined by (a) plaque assay (dashed line represents the detection limit) or (b) RT-qPCR. 
Horizontal lines indicate medians. **P < 0.01 (Mann-Whitney U-test).   
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Supplementary Figure 20. Prophylactic F-VHH-4 administration reduces viral titer in BAL fluid. A 0.5 
mg/kg dose of F-VHH-4, palivizumab or Ctrl-VHH was administered intranasally four hours before 
infection of BALB/c mice (n = 6 per group) with 1 x 106 RSV A2 or PBS (mock). Five days after 
infection, the RSV load in the bronchoalveolar lavage (BAL) fluid was determined by plaque assay 
(dashed line represents the detection limit). Horizontal lines indicate medians. **P < 0.01 (Mann-
Whitney U-test).   
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Supplementary Figure 21. F-VHH-4 prevents RSV replication and immune cell infiltration in lungs of 
RSV-challenged mice. A dose of 1, 3 or 10 µg F-VHH-4 or 10 µg Ctrl-VHH was administered 
intranasally four hours before infection of BALB/c mice (n = 3 per group) with 1 x 106 RSV A2 PFU or 
PBS (mock). Five days after infection, mice were euthanized and the pulmonary RSV load was 
determined by plaque assay. (a) Viral titer. Horizontal lines indicate medians. (b) The percentage of 
different immune cells in the BAL fluid as determined by flow cytometry. Bars represent the average 
percentage of the indicated cell type ± SD (n=3) (AM, alveolar macrophages; DC, dendritic cells; 
Monoc, monocytes; CD4, CD4+ T cells; CD8, CD8+ T cells; Neutr, neutrophils; Eosino, eosinophils).  
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Supplementary Figure 22. F-VHH-4 crystal exhibited a high degree of twinning. (a) Cumulative 
probability distribution function N(|L|), with the expected distribution for untwinned data shown in 
blue, perfectly twinned data shown in green, and the observed data shown in red. The observed data 
has a distribution similar to that expected for a highly twinned data set. (b) Cumulative probability 
distribution function N(|H|), with theoretical curves for a twin fraction of α = 0 (blue), 0.1 (green), 
0.2 (yellow), 0.3 (orange) and 0.4 (red). The observed data are shown in grey, with an initial slope and 
predicted α value of greater than 0.4. 
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5.9 Supplementary tables 
Supplementary Table 1. Neutralization of recombinant mKate-RSV laboratory and primary 
strains by F-VHH-4 and -L66 (IC50 µg/mL).  
Isolate type Subtype Strain F-VHH-4 F-VHH-L66 
Lab A A2 0.003 0.005 
 A L19 0.002 0.004 
Primary A Riyadh 91/2009 0.004 0.007 
 A 2-20F/G MS 0.007 0.011 
 A A1998-12-21 0.004 0.008 
Lab B 18537 0.003 0.002 
Primary B TX11-56 0.007 0.004 
 B NH1276 0.001 0.001 
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Supplementary Table 2. Crystallographic data collection and refinement statistics.  
 
F-VHH-4 
F-VHH-4– 
prefusion F 
F-VHH-L66– 
prefusion F 
PDB ID    
    
Data collection    
Space group P212121 P3221 P3121 
Cell constants    
  a, b, c (Å) 
  α, β, γ (°) 
47.7, 47.8, 149.8 
90, 90, 90 
173.2, 173.2, 153.3 
90, 90, 120 
138.9, 139.9, 221.9 
90, 90, 120 
Wavelength (Å) 0.9793 1.0332 0.9793 
Resolution (Å) 
34.5–1.9  
(1.92–1.87) 
38.0–3.3 
(3.43–3.30) 
50.4–3.8 
(4.06–3.80) 
Unique reflections 29,019 (1,853)  40,311 (4,477) 25,035 (4,457) 
Rmerge 0.118 (1.125) 0.188 (1.081) 0.332 (1.246) 
Rpim 0.050 (0.515) 0.073 (0.415) 0.157 (0.581) 
I / σI 11.1 (2.1) 9.2 (2.1) 5.2 (1.5) 
CC1/2 0.995 (0.465) 0.995 (0.545) 0.975 (0.549) 
Completeness (%) 100.0 (100.0) 99.9 (100.0) 99.9 (100.0) 
Redundancy 6.6 (5.6) 7.4 (7.5) 5.3 (5.5) 
Wilson B-factors 20.6 78.0 98.3 
    
Refinement    
Resolution (Å) 
34.5–1.9  
(1.94–1.87) 
38.0–3.3 
(3.38–3.30) 
50.4–3.8 
(3.95–3.80) 
Unique reflections 28,958 (2,824) 40,277 (2,821) 24,981 (2,726) 
Rwork / Rfree (%) 17.0/20.8 18.5/23.4 25.3/28.8 
No. atoms    
  Protein 1910 14082 13949 
  Ion (PO4) 0 0 5 
  Glycan (NAG) 0 42 42 
  Water 143 0 0 
B-factors    
  Protein 25.7 107.9 123.3 
  Ion (PO4) - - 155.9 
  Glycan (NAG) - 112.4 120.3 
  Water 29.4 - - 
R.m.s. deviations    
  Bond lengths (Å) 0.007 0.005 0.006 
  Bond angles () 0.81 1.20 1.04 
Ramachandran    
  Favored (%) 97.2 96.5 96.7 
  Allowed (%) 2.9 3.3 2.9 
  Outliers (%) 0.0 0.2 0.4 
 Values in parentheses are for the highest-resolution shell. 
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Supplementary Table 3. Lack of hMPV neutralization by F-VHH-4 and -L66. 
 IC
50
 (ng/mL) hMPV-A1-
GFP 
hMPV-B1-
GFP 
RSV-A2-GFP 
F-VHH-4 >30,000 >30,000 0.47 
F-VHH-L66 >30,000 >30,000 0.59 
Crtl-VHH ND* >30,000 >30,000 
MPE8 ND 108 47 
101F 216 783 124 
MF14** 249 319 ND 
Motavizumab ND ND 33 
 
*ND, not determined 
**MF14, monoclonal antibody specific for the hMPV F glycoprotein. This mAb does not 
neutralize RSV.  
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Supplementary Table 4. Prefusion F residues involved in hydrogen bonds with F-VHH-4 and 
-L66. 
PreF Residue F-VHH-4 Residue F-VHH-L66 Residue CDR hMPV 
Gln270 Tyr33 Tyr33 
1 
Gln 
Gly307 Tyr33 Tyr33 Gly 
Asn428 Arg45 Arg45 - Arg 
Asp269 Ser54  
2 
Gly 
Thr267  Ser56 Ser 
Asn268 Ser56 Ser56 Ala 
Asp269 Ser56 Ser56 Gly 
Thr267  Thr57 Ser 
Asn268 Thr57 Thr57 Ala 
Thr423 Arg96  3 Ser 
Asn345 Ser98  3 Asn 
Asn454 Ser98  
3 
Asn 
Ser451 Ser99  Thr 
Gly453  His99 Asp 
Thr50 Trp100 Phe100 
3 
Thr 
Gln270 Trp100  Gln 
Pro265 Cys100c Cys100c Pro 
Ser186 Tyr100f  Arg 
Ile431 Asp101 Asp101 
3 
Arg 
Ser425 Asp101 Asp101 Gly 
Asn428  Trp103 Arg 
 
Supplementary Table 4 shows all residues involved in hydrogen bonds between the side-
chain or main-chain of prefusion F with either the side-chain or main-chain of the two VHHs. 
Residues located in the protomer distal to the membrane (with respect to the VHH binding 
site) are not highlighted, whereas residues in the membrane proximal protomer are 
highlighted in grey.  
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Chapter 6 
Assessing therapeutic potential of RSV-neutralizing single-domain 
antibodies in the mouse model 
 
 
 
 
 
 
Author contributions: Xavier saelens, Bert Schepens, Jason McLellan and Iebe rossey 
designed and discussed the experiments. All experiments were performed by Iebe Rossey.  
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6.1 Introduction 
Respiratory syncytial virus (RSV) is an important respiratory pathogen both in the very young 
and the elderly. Every year 3.4 million children below the age of five are hospitalized due to 
a severe RSV infection [1]. Currently, only supportive care is provided to relieve these 
children. There is a high need for an effective antiviral which can be used to treat RSV-
infected patients. A potent antiviral which can be directly applied to the lung via inhalation 
could greatly reduce the burden caused by RSV infections. The single-domain antibodies 
(VHHs) described in the previous chapter might be good candidates for such a therapy. The 
high stability of VHHs allows direct pulmonary administration via nebulization. Combined 
with their potent antiviral activity, these VHHs might lead to a new therapeutic approach to 
treat RSV-infected patients. So far it has only been shown that F-VHH-4 and -L66 effectively 
inhibit viral infection when administered prophylactically. This chapter describes the in vivo 
testing of F-VHH-4 in a therapeutic setup and the further optimization of the F-VHHs. 
6.2 Results 
Testing retention time of VHHs in mouse lung environment 
First, a small pilot experiment was conducted to evaluate how long a monovalent or bivalent 
VHH is retained in the lung after intranasal administration. Hereto, a mixture of two 
monovalent VHHs (R1RSVF 11 and R1RSVF 74) and one bivalent VHH (N1-3-VHHb directed 
against influenza NA [2]) was administered intranasally to sedated BALB/c mice. BAL fluid 
samples were isolated at different time points after administration and analyzed by western 
blot (Fig. 1). All three VHHs are still clearly detectable in BAL isolated at 12 hours after 
administration. When using longer western blot exposure times, faint bands representing 
the VHHs R1RSVF 74 and N1-3-VHHb appear, indicating that a very small amount of VHH is 
still present at 24 hours after administration.  
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Figure 1: VHH remains in lung for at least 12 hours. Five mice received a mixture of 50 µg R1RSVF 
11, 50 µg R1RSVF 74 and 20 µg of Nb3.biv intranasally. At the indicated time points, BAL fluids were 
taken and analyzed on western blot using mouse anti-Histidine tag antibody. The three lanes on the 
right were loaded with the indicated amounts of R1RSVF 74 for comparison. 
Therapeutic potential of F-VHH-4 in vivo 
Subsequently, three experiments were performed to assess the therapeutic effect of the F-
VHHs upon RSV A2 infection. In a first experiment, 30 µg of F-VHH-4, -L66 or palivizumab 
was administered either four hours before infection (prophylactic set-up) or 24 hours after 
infection (therapeutic set-up) (Fig. 2). While the VHHs had a clear prophylactic effect, no 
effect could be discerned for the therapeutic strategy at all. Palivizumab treatment did have 
a major effect on viral load based on plaque assay. This however seemed to be an in vitro 
artifact from remaining antibody in the lung as only a minor reduction in viral RNA was 
observed by the RSV-specific RT-qPCR.  
One dose of VHH might be too little to obtain a therapeutic effect. In the next set-up, mice 
were therefore treated intranasally with 3 µg of F-VHH-4 or palivizumab every day starting 
from day two until day five after infection. Instead of the intranasal treatment, one group of 
mice received an intraperitoneal injection with 15 mg/kg palivizumab, the dose children 
receive during palivizumab prophylaxis. None of the treatments had any effect on viral titers 
or on cell influx in the lung (Fig. 3). 
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Figure 2: F-VHHs inhibit RSV replication in mice when administered prophylactically. Groups of five 
BALB/c mice were treated intranasally with 1.5 mg/kg of F-VHH-4, F-VHH-L66, palivizumab or Ctrl-
VHH four hours before (prophylactic) or 24 hours after (therapeutic) infection with 1*106 RSV A2. 
Five days after infection, the pulmonary RSV load was determined by (a) plaque assay (dashed line 
represents the detection limit) or (b) by quantification of the amount of lung viral RNA using RT-
qPCR. Horizontal lines indicate medians. **P < 0.01, ***P < 0.001 (One-way ANOVA).  
 
Figure 3: VHH or palivizumab treatment does not inhibit RSV replication or immune cell influx. (a) 
Groups of six BALB/c mice were treated intranasally with 0.15 mg/kg of F-VHH-4, palivizumab or Ctrl-
VHH daily on day two to five after infection with 1 x 106 RSV A2. One group (palivizumab IP) received 
a single dose of palivizumab (15 mg/kg) at day two after infection. Six days after infection, the 
pulmonary RSV load was determined by quantification of the amount of lung viral RNA using RT-
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qPCR. Horizontal lines indicate medians. No significant difference was found between the different 
groups. (b) Six days after infection, BAL fluid was prepared and the percentage of immune cells was 
determined by flow cytometry. Bars represent the average percentage of the indicated cell type ± SD 
(n=6) (AM, alveolar macrophages; DC, dendritic cells; Monoc, monocytes; CD4, CD4+ T cells; CD8, 
CD8+ T cells; Neutr, neutrophils; Eosino, eosinophils). **P < 0.01, **** P < 0.0001 (One-way ANOVA).  
Next, we decided to use a different mouse model because RSV replicates very poorly in wild 
type BALB/c mice. Immunocompromised mice are considered to be a better model for RSV 
infection, allowing enhanced and/or more prolonged RSV replication [3, 4]. Therefore we 
tested the efficacy of the F-VHHs in SCID mice.  
First we evaluated at what time point the treatment would have the highest chance of 
succeeding, i.e. the moment where the viral titer starts to increase. A preliminary 
experiment was conducted to follow viral replication after infection (Fig. 4).  
 
Figure 4: Replication of RSV A2 in SCID mice. Ten SCID mice were infected with 1 x 106 RSV A2. 
Pulmonary RSV load of two mice at indicated time points after infection were determined by (a) 
plaque assay (dashed line represents the detection limit) or (b) by quantification of the amount of 
lung viral RNA using RT-qPCR. Horizontal lines indicate medians. At day zero, samples were taken 
four hours post infection.  
Viral levels remained low until day two and peaked on day four after infection, therefore we 
opted to administer 10 µg of VHH or palivizumab both on day two and day three post 
infection. While treatment with palivizumab resulted in a modest tree-fold reduction in 
relative RSV RNA level, treatment with F-VHH-4 was not associated with reduced viral titers 
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(Fig. 5). Also no reduction of replicating virus could be observed by plaque assay indicating 
that there was no F-VHH-4 remaining in the lung which could have had an in vitro effect.  
 
Figure 5: F-VHH-4 treatment does not lower RSV load in SCID mice. Groups of six BALB/c mice were 
treated intranasally with 0.5 mg/kg of F-VHH-4, palivizumab or Ctrl-VHH on day two and three after 
infection with 1 x 106 RSV A2. Five days after infection, the pulmonary RSV load was determined by 
(a) plaque assay (dashed line represents the detection limit) or by (b) quantification of the amount of 
lung viral RNA using RT-qPCR. Horizontal lines indicate medians. *P < 0.05, **P < 0.01 (One-way 
ANOVA) 
Formatting F-VHH-4 as bivalent construct to try to enhance potency 
To increase the in vivo efficacy of the F-VHHs, they were further optimized. To test if avidity 
could lead to an increase in functional affinity, as was observed with VHHs targeting 
influenza NA or the palivizumab epitope of RSV F [2, 5], we investigated if head-to-tail fusion 
of two identical F-VHH-4s with a flexible (Gly4Ser)3 linker would enhance the neutralizing 
potency of the VHH. However in this case, linking two F-VHH-4 VHHs did not lead to an 
increase of neutralizing activity (Fig. 6) (IC50 of monovalent F-VHH-4 is 0.020 nM, IC50 of 
bivalent F-VHH-4 is 0.019 nM). If bivalency leads to an enhanced protection in vivo has not 
been determined yet. 
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Figure 6: Bivalent F-VHH-4 and monovalent F-VHH-4 have comparable RSV-neutralizing activity. 
RSV A2 (35 PFU) was incubated for 30 minutes at 37°C with different concentrations of the indicated 
VHH or monoclonal antibody before addition to a monolayer of Vero cells. Three days later, cells 
were fixed and stained with a polyclonal anti-RSV serum to visualize the plaques.  
Another strategy for VHH optimization was to link F-VHH-4 and -L66 to a VHH which binds to 
rat surfactant protein A (SPA) (Nb17 described in [6]), which is secreted by type II alveolar 
epithelial cells. We hypothesized that by linking our F-binding VHHs to this SPA-VHH, the 
VHHs would be targeted to alveolar pneumocytes and the retention time in the lung would 
be increased. To test if fusion with an SPA-VHH would interfere or not with the neutralizing 
activity of the F-VHHs, we compared the in vitro neutralizing activity of the monovalent F-
VHHs with the bispecific VHHs. The F-VHHs were linked to the SPA-VHH with a flexible 
(Gly4Ser)3 linker. The addition of the SPA-VHH did not affect the neutralizing activity of the 
VHHs (IC50s of 0.10 nM, 0.12 nM, 0.14 nM and 0.276 nM for F-VHH-4, VHH SPA-4, F-VHH-L66 
and VHH SPA-L66 respectively) (Fig. 7). Whether these bispecific VHHs are more efficacious 
in vivo still has to be evaluated in the mouse model.  
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Figure 7: Bispecific F-VHHs are as potent as monovalent F-VHHs. RSV A2 (35 PFU) was incubated for 
30 minutes at 37°C with different concentrations of the indicated VHH before addition to a 
monolayer of Vero cells. Three days later, cells were fixed and stained with a polyclonal anti-RSV 
serum to visualize the plaques. Note that F-VHH-4 and F-VHH-L66 are half the size of the other VHHs 
tested. 
6.3 Discussion 
While F-VHH-4 can provide protection against RSV infection when administered to the mice 
prophylactically, it failed to provide protection when administered therapeutically. 
Intranasal treatment with palivizumab could induce a limited reduction of RSV viral RNA in 
both wild type BALB/c and SCID mice. This might be associated with the longer retention 
time of the antibody in the lung or the Fc-dependent effector functions (antibody dependent 
cell mediated cytotoxicity and phagocytosis). Providing such effector functions to the VHH, 
by linking it to an Fc-tail or a VHH which activates human and mouse Fcγ-receptors, might 
enhance the VHH's RSV-neutralizing activity in vivo.  
Formatting F-VHH-4 to a bivalent VHH did not increase its in vitro neutralizing activity. 
Previously reported prefusion F-specific antibodies such as AM22 and D25 also don’t benefit 
from an avidity effect as the Fab fragments of these mAbs have similar neutralizing activity 
as the intact immunoglobulin format [7]. We only tested one type of linker to connect the 
two F-VHH-4 moieties. It is possible that longer linkers or linkers with a different sequence 
have a different effect. The linker length in particular is worthwhile exploring because it is 
unknown if the 15 amino acid long linker used here facilitates intra or inter-F trimer binding 
of F-VHH-4. Although no enhanced activity was discerned in vitro, these bivalent VHHs still 
might have increased functionality in vivo. Further research will have to point this out. 
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Bispecific VHHs targeting both the F and the SPA protein were also developed. Such VHHs 
would be targeted to the SPA-producing alveolar epithelial cells and might be retained 
longer in the lung. Adding the SPA-VHH could also have a direct antiviral effect by targeting 
the F-VHH-bound virions to the surfactant protein which has an important host defense role 
against RSV [8]. On the other hand, these SPA-VHH-based bispecific VHHs might possibly 
enhance viral infection in the mouse lung by targeting RSV to the alveolar pneumocytes, 
which are readily infected by RSV. This could be tested by an in vitro neutralization assay in 
mouse lung epithelial cells (MLE-15 cells), which produce pulmonary surfactant proteins [9]. 
If the SPA-VHH does not affect the binding between the SPA and its receptor, the SPA-VHH 
could also possibly target RSV to the alveolar macrophages which have a receptor for SPA 
[10, 11]. This interaction could possibly lead to the enhanced clearance of RSV in the mouse 
lung and would not necessarily rely on an RSV-neutralizing VHH as long as tight enough 
binding to RSV virions is achieved by the VHH. More research is needed to assess the 
effectiveness of the bispecific VHHs in the mouse model.  
Optimization of the VHH format, dose, timing of administration and mouse model will be 
necessary to be able to demonstrate a therapeutic effect.  
6.4 Materials and methods 
Testing VHH retention time in the mouse lung 
Five mice were slightly anesthetized with isoflurane before intranasal administration of 50 
µg R1RSVF 11, 50 µg R1RSVF 74 and 50 µg bivalent N1-3-VHHb in 50 µl PBS. BAL fluid 
samples (1 mL) were taken at 1.5, 3, 6, 12 and 24 hours after administration. Samples (40 µl) 
were loaded on a 15% SDS-PAGE gel next to a dilution series of VHH R1RSVF 74. Samples 
were blotted to a nitrocellulose membrane. Staining was performed with mouse anti-
Histidine Tag antibody (1/2000) followed by an HRP-linked anti-mouse IgG antibody (1/2000, 
NXA931, GE Healthcare). The blot was developed with ECL Western Blotting substrate 
(Promega). 
Testing therapeutic efficacy of F-VHHs in mice 
 Set-up 1 
Mice, seven weeks old, were randomly distributed in experimental groups of five animals. 
They were slightly anesthetized by isoflurane before intranasal administration of VHH, 
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palivizumab or RSV challenge virus. VHH, palivizumab and RSV virus were administered 
intranasally in a total volume of 50 µL PBS. Each group received 30 µg of F-VHH-4, 30 µg of F-
VHH-L66, 30 µg of Ctrl-VHH or 30 µg of palivizumab four hours before or 24 hours after 
infection with 106 PFU of RSV A2. Five days after challenge, lung viral titers were determined 
by plaque assay or RT-qPCR.  
 Set-up 2 
Mice, seven weeks old, were randomly distributed in experimental groups of six animals. 
They were slightly anesthetized by isoflurane before intranasal administration of VHH, 
palivizumab or RSV challenge virus. VHH, palivizumab and RSV virus were administered 
intranasally in a total volume of 50 µL PBS. Each group received 3 µg of F-VHH-4, 3 µg of Ctrl-
VHH or 3 µg of palivizumab on day two, three, four and five after infection with 106 PFU of 
RSV A2. One group received an injection of 0.3 mg palivizumab intraperitoneally at day 2 
after infection. Six days after challenge, lung viral titers were determined by RT-qPCR and 
cellular influx was determined via analysis of BAL fluid.  
 Set-up 3 
Preliminary experiment: eleven SCID mice (C.B.-17/IcrHan Hsd-Prkdc-scid), seven weeks old, 
were randomly distributed in six groups (one mouse as mock control). They were slightly 
anesthetized with isolfurane before intranasal administration of 106 PFU of RSV A2 in 50 µl 
PBS. Four hours, one day, two days, 4 days and 8 days after infection lung viral titers were 
determined by plaque assay and RT-qPCR. 
Actual experiment: SCID mice (C.B.-17/IcrHan Hsd-Prkdc-scid), seven weeks old, were 
randomly distributed in experimental groups of six animals. They were slightly anesthetized 
by isoflurane before intranasal administration of VHH, palivizumab or RSV challenge virus. 
VHH, palivizumab and RSV virus were administered intranasally in a total volume of 50 µL 
PBS. Each group received 10 µg of F-VHH-4, 10 µg of Ctrl-VHH or 10 µg of palivizumab on day 
two and three after infection with 106 PFU of RSV A2. Five days after challenge, lung viral 
titers were determined by plaque assay and RT-qPCR. 
Construction of a bivalent F-VHH-4 construct 
The gene coding for the VHH was amplified with following FW and RV primers 
(5’GGGGTATCTCTCGAGAAAAGGCAGGTGCAGCTGGTGGAGTCTGGG3’, 
173 
 
5’AGACTCCTGCAGCTGCACCTGACTACCGCCGCCTCCAGATCCACCTCCGCCACTACCGCCTCCGCCG
CTGGAGACGGTGACCTGGG3’), thereby removing a PstI site from the beginning of the VHH 
gene and adding a the (Gly4Ser)3 linker and the beginning of the VHH gene with a PstI site at 
the end of the sequence. The resulting PCR fragment was digested with XhoI and PstI and 
ligated into an XhoI and PstI digested VHH containing vector, thereby creating a homo- or 
heterobivalent construct. This bivalent VHH was expressed and purified as outlined above.  
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Chapter 7 
Adaptation of human respiratory syncytial virus to the murine host 
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7.1 Introduction 
To advance fundamental and applied human respiratory syncytial virus (RSV) research, a 
proper animal model is needed. Mice are often the lab animal of choice because they are 
easy to handle, small and available at low cost. Experimenting with mice is also facilitated by 
the wide range of mouse-specific immunologic reagents available and the expertise held by 
many researchers. Laboratory mice are hence widely used to study RSV-host interactions. 
However, this in vivo model is poorly relevant for RSV replication and associated disease in 
humans. Mice are poorly permissive for RSV which means that some degree of RSV 
replication can only be achieved by inoculation with high virus inocula (> 105 plaque forming 
units (PFU)). To obtain some form of RSV-induced morbidity, inocula as high as 107 PFU are 
required [1, 2]. Even after instillation of these exceedingly high RSV doses, very limited virus 
replication is observed in the mouse lungs. Immediately following infection, the amount of 
replication competent RSV in the mouse lungs drops dramatically and on day 3-5 after 
challenge typically only 1-5% of the original inoculum can be recovered [2]. The requirement 
for a very high inoculum dose followed by very poor replication in the mouse lung differs 
dramatically from RSV replication kinetics in man. In children, RSV replicates robustly in the 
respiratory tract, leading to cell damage in the lung epithelium [3]. As a result, plugs that 
consist of shed infected cells, infiltrating immune cells, fibrin and mucus start to form and 
these obstruct the narrow airways of the infants and thereby cause difficulty breathing and 
hypoxia [3-5]. The tropism of RSV differs between mice and humans: in mice, RSV mainly 
infects the alveolar epithelium, whereas in humans both bronchiolar and alveolar epithelium 
are infected [3, 6]. In addition, RSV-associated disease correlates with different host 
responses in mouse and human. In humans, CD8+ T cells are associated with viral clearance 
and protection whereas in mice, these cells are associated with lung pathology [7-9].  
Here, we applied extensive passaging in laboratory mice to select for an RSV A2-derived 
strain that is better adapted to mice. We obtained a mouse-adapted RSV strain that 
replicates better in this model, and thus better recapitulates RSV infection in man.  
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7.2 Results 
Development of a mouse-adapted RSV strain 
Of all inbred mice, BALB/c mice are considered one of the most RSV-permissive mice strains 
[10]. RSV A2 was first passaged 16 times in cyclophosphamide (CP)-treated BALB/c mice. 
Treatment with CP induces an immunocompromised status which facilitates prolonged RSV 
replication [11]. Next, passaging was continued in untreated BALB/c mice to reduce the risk 
of selecting an RSV virus that had become overadapted to immunocompromised mice at the 
expense of fitness in normal mice. Passaged RSV virus is named CP16+x (16 passages in CP-
treated mice, x passages in untreated mice). Every passage, two mice were anaesthetized 
and 0.5-1*106 PFU of RSV was administered intranasally. Four or five days later, the lung 
viral titer was determined by plaque assay and the lung-derived virus was propagated on 
HEp2-cells. The in vitro propagated virus was then used to inoculate the next pair of mice. 
During seven passages the resulting lung viral titer ranged from 49,000 to 1,064,000 (10%-
106% of the inoculum) (Fig.1). On average a tenfold higher titer than the viral titer typically 
found in BALB/c mice that have been infected with the parental RSV A2 virus (hereafter 
referred to as WT RSV A2). This illustrates that over the course of passages in mice a pool of 
RSV viruses with enhanced viral replication emerged. The high viral replication of the CP16 
RSV suggested that this pool of RSV had already emerged before passaging in untreated, 
immunocompetent BALB/c mice.  
 
Figure 1: Replication efficiency of mouse-passaged RSV A2. Every passage, two mice were infected 
with 106 PFU (or 500,000 PFU of the CP16+2 RSV) of the indicated HEp2-grown ex vivo RSV 
preparations. At day five post infection, the pulmonary RSV load in total lung was determined by 
plaque assay. Horizontal lines represent medians.  
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Because CP16+1 RSV replicated to higher viral titers in the lungs of mice than WT RSV A2, we 
directly compared the replication and associated body weight change in BALB/c mice of 
CP16+1 RSV and WT RSV A2. Therefore, BALB/c mice were infected with 106 PFU of either 
virus or mock-infected, and their weights were followed during 33 days (Fig.2).  
 
Figure 2: CP16+1 RSV induces greater morbidity than RSV A2 in mice. On day 0, two mice were 
infected with 106 PFU of WT RSV A2, 106 PFU of CP16+1 RSV or PBS (mock). Body weights were 
recorded up to 33 days after infection and shown as averages with standard deviations of the body 
weight of individual mice relative (in percentage) to day 0. 
While the mice infected with the WT RSV A2 only lost 10% of their bodyweight, up to 25% of 
body weight loss was noted in the mice that had been challenged with the CP16+1 virus, 
indicating that the passaged virus can induce substantial morbidity. This morbidity was also 
characterized by ruffled fur, a symptom that was not observed in mice infected with the RSV 
A2 lab strain. All mice recovered from the infection and convalescent sera isolated 33 days 
after infection from CP16+1 RSV-infected mice contained about twofold more RSV-
neutralizing serum antibodies than serum from WT RSV A2-infected mice (Fig. 3).  
 
Figure 3: RSV-neutralizing activity in mouse sera. Sera (pool of two mice) from mice that had been 
challenged with the indicated virus or PBS (mock) were isolated at day 33 post infection. WT RSV A2 
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was preincubated with dilution series of mouse sera from the indicated groups before infection of 
Vero cells. Three days later, the viral plaques were stained with polyclonal anti-RSV serum. 
To test if additional passaging in immunocompetent BALB/c mice further increased the 
virulence of RSV, mice were infected with 106 PFU of CP16+6 or WT RSV A2. The body weight 
was monitored until day 15 after infection (Fig.4). Mice infected with the CP16+6 virus lost 
15-23% of bodyweight, while mice infected with RSV A2 did not lose any body weight in this 
experiment. Compared to mice that had been infected with CP16+1 virus (Fig.2), no clear 
increase in pathogenicity was observed and passaging was discontinued. At last a CP16+7 
virus stock was made by propagating the lung virus from CP16+6 virus-infected mice on 
HEp2-cells. 
 
Figure 4: CP16+6 induces greater morbidity than RSV A2 in mice. Two mice were infected with 106 
PFU of WT RSV A2 or 106 PFU of passaged CP16+6 RSV at day 0. Averages with standard deviations of 
the body weight of individual mice relative (in percentage) to day 0 are shown. 
A dose of 30*106 PFU of the resulting CP16+7 mouse-adapted RSV (maRSV) could induce 
severe morbidity and mortality in BALB/c mice at day 6-7 post infection, whereas only a 
limited loss of body weight was observed in the mice infected with the same dose of RSV A2 
(Fig.5 a and b). Lowering the inoculum dose to 5*106 PFU still induced mortality (Fig. 5 c and 
d). 
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Figure 5: MaRSV induces severe body weight loss and mortality. (a and b) Three mice were infected 
with 30*106 PFU of RSV A2 or CP16+7 RSV. (a) Body weights were monitored until day 9 post 
infection. Averages with standard deviations of the body weight of individual mice relative (in 
percentage) to day 0 are shown. (b) Survival curve. (c and d) Two mice were infected with 15*106 
PFU, 5*106 PFU or 1.7*106 PFU of CP16+7 RSV. (b) Body weights were monitored until day 11 post 
infection. Averages with standard deviations of the body weight of individual mice relative (in 
percentage) to day 0 are shown. (c) Survival curve. 
Characterization of mouse-adapted virus 
After 16 passages in CP-treated and 7 passages in untreated BALB/c mice, the resulting RSV 
strain was considered to be at least partially adapted to mice. The obtained maRSV is likely a 
mixture of viruses derived from the WT RSV A2 virus. To evaluate the genetic variation in 
these 'quasispecies', the genome of CP16+7 maRSV was subjected to deep sequencing. 
CDNA was prepared from RNA which was extracted from the supernatant of maRSV-infected 
HEp2-cells or from HEp2-cells infected with the WT RSV A2 virus. Fifteen primer pairs were 
used to amplify the complete 15kb RSV genome using this cDNA template (primer sequences 
obtained from [12] in supplementary table 1). Remarkably, the PCR reaction (reaction five) 
covering part of the G gene, did not result in a detectable PCR product (Fig. 6). To determine 
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whether the forward or reversed primer is responsible for this unexpected result, the 
primers used for reaction five were combined with the primers from the adjoining fragments 
(Fig. 7). For comparison, the same PCR reactions were performed on cDNA derived from RNA 
from supernatant of cells infected with the WT RSV A2.  
 
Figure 6: Amplification of the maRSV genome through fifteen PCR reactions. Fifteen PCR reactions 
covering the RSV genome were performed on cDNA prepared from RNA from the supernatant of 
maRSV-infected HEp2-cells with RSV specific primers. PCR products were loaded on a 1% agarose gel 
next to a 1 kb DNA ladder. 
 
Figure 7: Primer RV5 cannot anneal to the maRSV template. PCR with either FW4/FW5 and RV5/RV6 
primers was performed on cDNA derived from RNA isolated from the supernatant of maRSV- or RSV 
A2-infected HEp2-cells, obtained with either RSV specific primers (first two reactions of each 
template) or random hexamer primers (last two reactions of each template). PCR products were 
loaded on a 1% agarose gel next to a 1kb DNA ladder.  
No PCR product was obtained from the PCR in which primers FW4 and RV5 on the maRSV 
cDNA were used. Remarkably the PCR product from the reaction using primers FW5-RV6 was 
smaller than the same product derived from the RSV A2-infected cells. These results suggest 
that the maRSV genome contains a deletion in the G gene, including the region that confers 
binding of the RV5 primer. 
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PCR products 1-15 (PCR product 5 was replaced with the product obtained from the reaction 
with primers FW5 and RV6) were combined, purified, sheared and analyzed by Illumina 
MiSeq deep sequencing. The resulting sequences were compared to the sequences derived 
from the WT RSV A2 virus. The mutations found in the maRSV PCR products, together with 
their relative frequency are shown in Table 1. 
Table 1: Mutations, and their relative frequency in maRSV. 
Position*  Mutation  Gene  AA change Frequency (%) 
900 C>A NS2 F91L >99.5 
4046 C>T M (3’ UTR) none >99.5 
4729 A>T G E14D >99.5 
5160-5369 deletion G 158-227 del >99.5 
15088 T>/ trailer none >99.5 
9266 G>A L E257K 87.17 
2422 G>A P G26D 84.35 
6940 A>G F K427R 54.95 
3023 G>A P none 36.5 
150 G>T NS1 D18Y 22.12 
13832 A>G L I1779V 22.00 
13480 A>C L K1661N 15.43 
9266 A>G L K257E 12.83 
1241 T>C N none 11.92 
1235 T>C N none 11.87 
1251 T>C N Y38H 11.82 
1559 A>G N none 11.75 
8703 C>T L S69F 11.42 
12932 G>A L A1479T 11.10 
14131 G>A L none 10.80 
8206 T>C M2-2 none 8.34 
8119 A>G M2-1 T172A 8.24 
9407 G>A L G304R 6.58 
3149 C>T P (3’ UTR) none 5.88 
4753 T>C G none 5.82 
1083 T>G NS2 (3’ UTR) none 5.76 
4772 T>A G C29S 5.68 
*Position in WT RSV A2 
Five of the observed mutations occur at a frequency of more than 99.5%, suggesting that 
almost all individual viral genomes in the maRSV stock contain these mutations. Three of 
these mutations result in an amino acid change:  
 An F91L substitution in the non-structural protein 2 (NS2). NS2 suppresses the human 
antiviral interferon (IFN) response [13, 14]. 
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  An E14D substitution in the attachment protein G. G is responsible for binding to the 
host cell and has some immune evasive functions [15, 16]. 
 The removal of amino acids 158-227 of the G protein. 
The deletion in the G gene is the most dramatic change, resulting in the removal of the 
central conserved domain, the CX3C motif and the heparin-binding domain (HBD). The E14D 
substitution in the G protein is probably less important. This substitution was also observed 
in 26% of the viruses in the parental stock. Two mutations in non-coding regions of the 
maRSV genome were found: one in the 3’ untranslated region (UTR) of the gene coding for 
matrix protein M, and one in the trailer region of the genome. Other mutations were also 
present in most viruses in the maRSV stock, yet were not fully penetrant (E275K in the 
polymerase protein (L), G26D in the phosphoprotein (P) and K427R in the fusion protein (F)).  
Evolution of mouse adaptation  
To evaluate at what steps of the RSV serial passaging in mice these mutations appeared, RNA 
was isolated from the supernatant of cells that had been infected with viruses obtained 
during the different steps of mouse adaptation. PCR reactions were performed on the cDNA 
to specifically amplify the G and the NS2 genes. The PCR reactions covering the NS2 gene 
were analyzed by Sanger sequencing. The C>A mutation in the NS2 gene could not be 
observed in the CP8 virus, yet it was already present in the CP10 virus, indicating that the 
mutation occurred during the 9th or the 10th passage in CP-treated mice. Pinpointing the 
moment of the deletion in the G gene was more difficult. This seems to have happened early 
in the mouse adaptation, and infection of HEp2-cells with the viruses derived from mice 
from the beginning of the mouse adaptation was not very successful, resulting in low 
amounts of cDNA and PCR product (Fig. 8). The FW5-RV6 PCR product derived from the CP2 
virus seemed to run lower than the PCR product derived from RSV A2, indicating that the 
deletion in G already occurred in the first two passages in CP-treated mice. 
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Figure 8: Deletion in G gene occurred before CP-passage three. PCR with FW5/RV6 primers was 
performed on cDNA derived from RNA isolated from the supernatant of passaged RSV-infected or 
RSV A2-infected HEp2-cells. PCR products were loaded on a 1% agarose gel next to a 1kb DNA ladder. 
(a) First trial of PCR reactions with primers FW5/RV6. (b) Second trial of PCR reaction with primers 
FW5/RV6 with slightly adapted annealing temperature. 
Analysis of clonal maRSV isolates 
Through limiting dilution, two viral isolates could be separated from the maRSV pool. These 
were named D6 and D7. Sequencing showed that only D6 is a pure 'clonal' isolate; D7 is a 
mixture of two viruses (Table 2).  
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Table 2: Presence of maRSV mutations in isolate D6 and D7. 
Position*  Mutation  Gene  AA change Frequency (%) Present in D6 Present in D7 
900 C>A NS2 F91L >99.5 X X 
4046 C>T M (3’ UTR) none >99.5 X X 
4729 A>T G E14D >99.5 X X 
5160-5369 deletion G 158-227 del >99.5 X X 
15088 T>/ trailer 
 
>99.5  X 
9266 G>A L E257K 87.17  X 
2422 G>A P G26D 84.35  X 
6940 A>G F K427R 54.95  X 
3023 G>A P none 36.5 X X 
150 G>T NS1 D18Y 22.12  50/50 
13832 A>G L I1779V 22.00  50/50 
13480 A>C L K1661N 15.43   
9266 A>G L K257E 12.83   
1241 T>C N none 11.92 X  
1235 T>C N none 11.87 X  
1251 T>C N Y38H 11.82 X  
1559 A>G N none 11.75 X  
8703 C>T L S69F 11.42   
12932 G>A L A1479T 11.10 X  
14131 G>A L none 10.80 X  
8206 T>C M2-2 none 8.34   
8119 A>G M2-1 T172A 8.24   
9407 G>A L G304R 6.58   
3149 C>T P (3’ UTR) none 5.88   
4753 T>C G none 5.82 X  
1083 T>G NS2 (3’ UTR) none 5.76   
4772 T>A G C29S 5.68 X  
*Position in WT RSV A2 
MaRSV D6 and -D7 were compared with the original maRSV stock and the WT RSV A2 strain 
in an in vivo infection experiment. Groups of six mice were infected with 106 PFU of either 
virus. Five days after infection, lungs were isolated and lung viral titers were determined (Fig. 
9). Infection with the original maRSV (CP16+7) resulted in an average pulmonary titer of 
500,000 PFU per lung, which is 35-fold higher than infection with RSV A2 (15,000 PFU/lung). 
Infection with isolate D6 and D7 resulted in an average titer of 200,000 PFU/lung and 
100,000 PFU/lung respectively, confirming their mouse-adapted phenotype.  
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Figure 9: maRSV infection results in more viral replication and morbidity compared to RSV A2. Six 
BALB/c mice were infected with 106 PFU of WT RSV A2, CP16+7, CP16+7 D6, CP16+7 D7 RSV or mock-
infected. Five days after infection, the pulmonary RSV load was determined by plaque assay. 
Horizontal lines represent medians. Dashed line represents the detection limit. *P < 0.05,**P < 0.01, 
**** P < 0.0001 (One-way ANOVA).  
7.3 Discussion 
Because of the very low permissiveness of mice for RSV infection, it is not straightforward to 
adapt RSV to the mouse as host. In contrast to the mouse-adaptation of most influenza 
viruses, where mice can be directly infected by lung homogenates from infected mice [17], 
the process of mouse-adapting RSV in immunocompetent mice is slow. It is required to 
propagate the virus first on cell culture between every passage, thereby increasing the titer 
and removing the antiviral cytokines induced in the mouse lung. In this work, the first 16 
rounds were performed in CP-treated mice. Treatment with CP, a chemotherapeutic drug 
which reduces peripheral blood leukocytes and lung macrophages, renders mice 
immunocompromised, thereby creating an environment where RSV can replicate for 
prolonged time [11, 18]. In these mice it was not necessary to propagate the virus on cell 
culture before starting a new passage. To avoid overadaptation to these immunodeficient 
mice, additional passages were performed in untreated BALB/c mice. After seven additional 
passages, passaging was stopped. 
Sequencing showed that the resulting maRSV contained a large deletion in the G gene, 
resulting in the ablation of the most important domains of the G protein: the central 
conserved domain, the CX3C motif and the HBD. A large deletion in the G gene has already 
been reported by Karron et al. in a cold-passaged RSV strain, which was attenuated in vivo 
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[19, 20]. RSV lacking most of the G protein was also observed in nature, in an HIV-exposed 
and an HIV-infected infant in South Africa [21]. HIV-status of the former two-month-old child 
was being tested because of the HIV-seropositive status of the mother. The authors 
speculated that the compromised immune system of these children allowed the RSV virus 
variant that lacks most of the G-coding region to use other proteins for binding and 
replication. While the G protein is necessary for efficient replication in mice, the central 
domain seems to be of less importance. Teng et al., reported that RSV lacking the central 
conserved domain and the cysteine noose could still replicate efficiently in mice, be it with a 
3-10-fold reduction in viral titers compared to WT virus [22]. However, CP16+7, in which 
next to the conserved domain and the cysteine noose also the HBD is removed, clearly 
replicates much more efficiently than the WT virus in mice. These observations leave us with 
the question whether the CP16+7 strain is mouse-adapted despite or thanks to this deletion 
in the gene coding for G. The E14D substitution is probably not relevant for the mouse-
adapted phenotype because this substitution was also observed in the WT RSV A2 strain.  
The CP16+7 virus also contained a mutation in the NS2 gene resulting in a phenylalanine to 
leucine change at position 91. NS2, together with NS1, counteracts the innate antiviral 
response on multiple levels. It interferes with the innate immune response by decreasing 
Stat2 levels [23] and by suppressing the activation of the interferon regulatory factor 3 (IRF-
3) [24]. Interestingly, murine Stat2 is much less sensitive to NS1 and NS2 than human Stat2 
[23]. Further research is required to determine if this is still the case with the NS2 from the 
maRSV strain. NS1 and NS2 are also involved in inhibition of early apoptosis of the infected 
cells, thereby increasing the viral yield [25]. Strangely, NS2 activity is also associated with 
more effective clearance of RSV infection by inducing rounding of the infected columnar 
airway epithelial cells which then start to shed and obstruct the distal airways [4]. In this 
way, NS2 may directly contribute to RSV-induced morbidity. NS2 is at least partially 
functional in mice. Infection of mice with a recombinant RSV strain without this gene 
resulted in a substantially elevated pulmonary cytotoxic T lymphocyte (CTL) response 
compared to mice infected with either WT RSV or a mutant missing the NS1 gene [26]. This 
CTL response however did not impact the viral replication because the peak of the CTL 
response occurs some days after the peak of the viral replication in mice. Although in vitro 
assays show that RSV does not decrease Stat1 expression (in contrast to Stat2) [23], the CTL 
suppressive effect was attributed to the suppression of the type I interferon (IFN) response 
due to an effect on Stat1. In Stat1 knockout mice, the levels of induced CTLs was not 
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different between mice infected with NS2-missing RSV or WT RSV [26]. So, rather than 
inactivating, the F91L substitution in NS2 might enhance the NS2 function in mice, 
suppressing the mouse antiviral response more efficiently. It has already been observed that 
the host specificity of bovine RSV depends in part on the NS proteins [27]. Therefore, the 
mutation in NS2 in maRSV could be a step in switching the host specificity from human to 
mouse.  
Two noncoding mutations are present in almost all viruses in the CP16+7 stock. These could 
contribute to the mouse-adapted phenotype by modulating the transcription of the viral 
genes or the replication of the viral genome. The deletion at position 15088 is part of the 
trailer region of the RSV genome, which contains the antigenomic promoter. It was shown 
that the last 36 nucleotides of this trailer region are sufficient for synthesis of full-length 
genomes, but including nucleotide 37-155 increased promoter activity [28]. The nucleotide 
at position 15088, nucleotide 135 relative to the 5' end, is thus located in a region that is 
important for genome replication. Still, this deletion probably does not have a major effect 
on viral replication in mouse as viral isolate D6, which does not contain this deletion, still 
replicated far more efficiently than RSV A2. In more than 80% of the maRSV viruses, a 
mutation is present in the L and/or P gene, both coding for proteins from the viral 
polymerase complex. These mutations also possibly affect the viral transcription and/or 
replication process.  
Infection with the CP16+7 isolates D6 and D7 both led to relatively high lung RSV titers, 
despite the different pattern of mutations present in their genomes. They have five 
mutations in common, the mutation in the gene coding for NS2, the deletion and mutation 
in the gene coding for G, the mutation in the 3’ UTR of the gene coding for M and a silent 
mutation in the gene coding for P. To fully understand the contribution of each of these 
mutations to the mouse-adapted phenotype from the CP16+7 virus strain, they should be 
analyzed separately. This is possible by either expressing the mutated proteins 
recombinantly, and testing their function in vitro or by making recombinant RSV strains, 
containing one or more of the described mutations, and testing these viruses in vivo. 
In summary, after 16 passages in CP-treated and 7 more in non-treated mice, a virus is 
obtained which replicates more than thirty fold better than the RSV A2 lab strain. At a dose 
of 106 PFU of maRSV significant morbidity characterized by ruffled fur and weight loss is 
observed in BALB/c mice, whereas the same dose of WT RSV A2 hardly causes disease. More 
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research is still needed to understand the mechanisms of the increased pathogenicity 
exhibited by this virus. This will allow us to learn more about the viral proteins which 
determine the host specificity of RSV. This mouse-adapted virus could lead to an improved 
RSV-mouse model, which is of major importance for both fundamental research and the 
development of new RSV antivirals and vaccines. 
7.4 Materials and methods 
Cells and viruses 
HEp-2 cells (ATCC, CCL-23) and Vero cells (ATCC, CCL-81) were grown in Dulbecco's modified 
eagle medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 
mM L-glutamine, non-essential amino acids (Invitrogen, Carlsbad, California) and 1 mM 
sodium pyruvate at 37°C in the presence of 5% carbon dioxide. RSV A2, an A subtype of RSV 
(ATCC, VR-1540, Rockville), was propagated on HEp-2 cells and quantified on Vero cells by 
plaque assay using goat anti-RSV serum (AB1128, Chemicon International).  
Mice 
Specific pathogen-free, female BALB/c mice were obtained from Charles River (Charles River 
Wiga, Sulzfeld, Germany). The animals were housed in a temperature-controlled 
environment with 12 h light/dark cycles; food and water were provided ad libitum. The 
animal facility operates under the Flemish Government License Number LA1400536. All 
experiments were done under conditions specified by law and authorized by the Institutional 
Ethical Committee on Experimental Animals (Ethical application EC2013-030). 
Passaging RSV and evaluating mouse adapted phenotype. 
Each passage, two female BALB/c mice were anesthetized and infected intranasally with 106 
PFU of passaged and HEp-2 grown RSV (500,000 PFU of CP16+2 RSV was administered to the 
mice, because this stock was not concentrated enough). Four or five days after infection, 
mice were euthanized, lungs were isolated and homogenized in 1 ml of HBSS containing 20% 
sucrose and supplemented with 1% penicillin and 1% streptomycin. Lung homogenates were 
cleared by centrifugation at 4°C and used to titrate the virus by plaque assay. The lung virus 
was propagated on HEp-2 cells and titrated on Vero cells before start of a new passage. For 
the evaluation of the mouse-adapted phenotype, two mice were infected with 106 PFU of 
the passaged RSV virus, RSV A2 or mock (PBS). To assess if the CP16+7 RSV could induce 
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mortality, three female BALB/c mice were infected with 30*106 PFU of CP16+7 RSV or RSV 
A2. To determine the lethal dose of CP16+7 RSV, three mice were infected intranasally with 
either 15*106, 5*106 or 1.7*106 PFU of CP16+7 RSV. 
Determination of lung viral titers by plaque assay 
Four or five days after challenge, mice were euthanized, lungs were removed and 
homogenized like before. Lung homogenates were cleared by centrifugation at 4°C and used 
to titrate the virus by plaque assay. A dilution series of lung homogenate was prepared in 
Opti-MEM (Gibco) and used to infect confluent Vero cells. After three hours, the cells were 
washed and 0.6 % avicel RC-851 (FMC Biopolymers) in DMEM medium supplemented with 
2% FCS, 2 mM L-glutamine, non-essential amino acids and 1 mM sodium pyruvate was 
added to each well and the infection was allowed to continue at 37°C for three days. Viral 
infection was tested by immunostaining of the viral plaques with goat anti-RSV serum 
(AB1128, Chemicon International) and horseradish peroxidase-conjugated anti-goat IgG 
(SC2020, Santa Cruz). The plaques were visualized by applying TrueBlue peroxidase substrate 
(KPL, Gaithersburg). We set lung homogenates in which no virus was detected as the 
detection limit of the assay.  
Plaque-reduction assay 
A dilution series of the mouse serum was prepared in Opti-MEM, incubated with RSV for 30 
minutes at 37°C and used to infect confluent Vero cells. After three hours, an equal volume 
of 1.2% avicel RC-851 in DMEM medium supplemented with 2% FCS, 2 mM L-glutamine, 
non-essential amino acids and 1 mM sodium pyruvate was added to each well and the 
infection was allowed to continue at 37°C for three days. Viral plaques were detected by 
plaque assay like described above. 
Deep sequencing 
RNA was isolated from the supernatant of HEp2-cells infected with either CP16+7 passaged 
RSV or RSV A2 passages once in BALB/c mice with the High Pure RNA Isolation Kit (Roche). 
CDNA was prepared with the Transcriptor First Strand cDNA Synthesis Kit (Roche) using 
either the random hexamer primers included in the kit or a mixture of the 15 RSV specific 
primers from [12] (supplementary table 1). The RSV genome was amplified in 15 reactions 
with the primers described in [12] (see below). Samples from each virus were purified from 
solution and mixed. Deep sequencing was performed by the VIB facility Nucleomics core. 
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Briefly, 150 ng of each sample was sheared with an M220 focused-ultrasonicator (Covaris) 
set to obtain peak fragment lengths of 300-400 bp. Next, the NEBNext Ultra DNA Library 
Preparation kit (New England Biolabs) was used to repair the ends and to add the Illumina 
MiSeq-compatible barcode adapters to 100 ng of fragmented DNA. The resulting fragments 
were size-selected using Agencourt AMPure XP bead sizing (Beckman Coulter). Afterwards, 
indexes were added in a limited-cycle PCR (10 cycles), followed by purification on Agencourt 
AMpure XP beads. Fragments were analyzed on a High Sensitivity DNA Chip on the 
Bioanalyzer (Agilent Technologies). The multiplex sample was heat denatured for 2 min at 
96°C before loading on the Illumina MiSeq chip. After the 2×250 bp Illumina MiSeq paired-
end sequencing run, the data were base called and reads with the same barcode were 
collected and assigned to a sample on the instrument, which generated Illumina FASTQ files 
(Phred +64 encoding). 
Isolation of single maRSV isolates 
Single maRSV isolates were obtained by diluting out the CP16+7 stock, and infecting 
confluent HEp-2 cells with these dilutions. Three days after infection, supernatants were 
transferred to a new plate and the plaques were stained. The supernatant of the wells were 
only one plaque could be seen was used to infect fresh HEp-2 cells and virus stocks were 
made five days later.RNA was isolated from the HEp-2 supernatant, cDNA was prepared and 
the viral genome was amplified like described above. PCR reactions were purified from 
solution and sent for sequencing. 
Statistical analysis 
We used Graphpad Prism 6 for statistical analyses, and the one-way ANOVA test to evaluate 
differences between two groups. 
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7.7 Supplementary tables 
Supplementary table 1: Primers used for cDNA preparation and whole genome sequencing 
Primer 5’-3’ sequence Start End 
FW1 ACGCGAAAAAATGCGTACAAC 1 21 
RV1 TGGATGGTGTATTTGCTGGA 1197 1216 
FW2 ATTTCAACACAAKAKTCACACAA 1003 1025 
RV2 TTCAGGAGCAAACTTTTCCAT 2346 2366 
FW3 AAAAATTGGGTGGWGAAGCA 2014 2033 
RV3 CCCTTGGGTGTGGATATTTG 3441 3460 
FW4 AACCTRTTGGAAGGGAATGA 3018 3037 
RV4 AGGCCAGAATTTGCTTGAGA 4331 4350 
FW5 CAGATCATCCCAAGTCATTG 4153 4172 
RV5 GCTGCATATGCTGCAGGGTAC 5198 5218 
FW6 AAGTCAACCCTGCAATCCAC 5054 5073 
RV6 GCATTAACACTAAATTCCCTGGT 6360 6382 
FW7 GTGAACAAGCAAAGCTGC 6279 6296 
RV7 GTGTGACTGGTGTGCTTCTGG 7315 7335 
FW8 CCCATTAGTRTTCCCCTCTG 7097 7116 
RV8 TCCATTAATAATGGGATCCATT 8497 8518 
FW9 GATTGCCAGCAGACGTATTGAAG 8057 8079 
RV9 GGCTAATATCTTTCCATGTC 9307 9326 
FW10 CAATGCAACATCCTCCATCA 9084 9103 
RV10 GGTTGCATTGCAAACATTCTA 10375 10395 
FW11 CGTGAGTTTCGGTTGCCTA 10064 10082 
RV11 GGGATCACCACCACCAAATA 11448 11467 
FW12 AGTGGGACCGTGGATAAACA 11164 11183 
RV12 TGACTGTAAGGCGATGCAA 12506 12524 
FW13 TGGACATCAAATATACWACAAGCA 12180 12203 
RV13 TTAACAACCCAAGGGCAAAC 13361 13380 
FW14 AAAAAGATTGGGGAGAGGGATA 13041 13062 
RV14 TGCAYTTTCTTACATGCTTGC 14355 14375 
FW15 GGTGAAGGAGCAGGGAATTT 14054 14073 
RV15 ACGAGAAAAAAAGTGTCAAAAACT 15199 15222 
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General conclusions and discussion 
 
This PhD thesis describes the development of a new antiviral therapy against RSV and of a 
better mouse model for RSV-related research. Both are urgently needed. Children, 
hospitalized with a severe RSV infection, only receive merely supportive care as an RSV-
specific antiviral is lacking. An RSV-specific treatment which could reduce RSV-related 
morbidity and mortality, would significantly reduce both humane and economic costs. To 
develop such a treatment, an easy-to-use, cost-efficient and biologically relevant animal 
model would be ideal. Because the mouse model is often the animal model of choice in 
biomedical research, obtaining an RSV virus with increased replication efficiency in this 
model would boost RSV-related research.  
Immunization of a llama with adjuvanted, purified recombinant prefusion F followed by 
panning and functional screening, eventually led to the isolation of two prefusion F-specific 
VHHs with powerful in vitro neutralizing activity. To our knowledge, this is the first time that 
VHHs specifically binding the prefusion conformation of F are described. These VHHs, 
although differing in sequence, bind to the same quaternary epitope located at the side of 
the F trimer. This epitope was not described before, meaning that no co-crystal structure of 
an antibody that binds to this epitope has been reported yet. Based on mutational analysis it 
is likely that the epitope in F that is recognized by the prefusion F-specific VHHs reported 
here overlaps with the MPE8 epitope. Based on co-crystal structures it is clear that the 
epitope is bordered by the binding sites of the monoclonal antibodies palivizumab, AM14 
and 101F. By tightly binding this epitope it is likely that the VHHs lock the F protein in the 
prefusion conformation and thereby prevent viral fusion. Prophylactic administration of the 
VHHs potently inhibited RSV infection and associated inflammation in mice. 
To try to obtain an RSV virus that is better adapted to laboratory mice, we serially passaged 
the conventional RSV A2 laboratory strain 23 times in mice: 16 passages in CP-treated and 7 
passages in untreated BALB/c mice. The obtained virus could cause significant weight loss at 
an inoculum dose that did not at all induced morbidity with the parental virus. Deep 
sequencing revealed that the mouse-adapted virus consisted of many quasispecies 
containing different mutations. Five mutations were apparent in almost all of the viruses of 
this pool. Of those, a mutation in NS2 is probably the most relevant for the mouse-adapted 
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phenotype because NS2 has a key function in counteracting the host immune response. 
Further research will have to point out what the relative contribution of each mutation is.  
One prefusion F protein is not the other 
In this project, two camelids were immunized with prefusion-stabilized F. An alpaca was 
immunized with Cav1 and a llama was immunized with DS-Cav1. DS-Cav1 immunization led 
to a 17-fold higher level of neutralizing antibodies in the hyperimmune serum than Cav1. 
This difference can be attributed to several factors. An important element is the enhanced 
physical stability acquired by the added disulfide bond in DS-Cav1 compared to Cav1. 
Immunization with DS-Cav1 was also reported to elicit threefold higher levels of neutralizing 
activity in mice than Cav1 [1]. It is known that over time the Cav1 protein spontaneously 
converts to postfusion F. Therefore, possibly a portion of the Cav1 protein used to immunize 
lost its prefusion F shape, diffusing the immune response to both conformations. Another 
contributing factor which could have an effect on the differing immune response is the used 
adjuvant. While Gerbu is the standard adjuvant for llama or alpaca immunization, 
stimulating induction of antibodies binding to conformational epitopes [2], the first two 
injections of DS-Cav1 were performed using poly (I:C) as adjuvant, which had already been 
successfully used to elicit neutralizing titers upon DS-Cav1 immunization in mice and 
macaques [1]. Another factor might be a difference in immune response between llamas and 
alpacas. There are differences in the humoral immune response among camelids. For 
example, the serum of camels typically consists for 75% out of heavy chain-only antibodies, 
while in llamas and alpacas this is only 45 and 50% respectively [3, 4]. Lengths of CDR3 loops 
also vary among species. The average length of a CDR3 in llamas is 14.9 amino acids, in 
alpacas this is 17.8 amino acids [4, 5]. We observed CDR3 lengths varying between 5 and 21 
amino acids for the alpaca and 10 and 21 amino acids for the llama, indicating a large variety 
within one animal. At last, the difference in immune response could be due to natural 
variation as each time only one animal was immunized. 
To conclude, although both stabilized in the prefusion conformation, Cav1 and DS-Cav1 
differ significantly in the antibody response they induce. The unstable nature of RSV F 
requires manipulations on different levels to prevent the protein from flipping to the more 
stable postfusion state. The trimerization domain, the cavity-filling mutations combined with 
the disulfide bonds seem to ensure that prefusion F stability in DS-Cav1, which is therefore 
the preferred immunogen to induce prefusion F-specific antibodies. The use of a different 
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adjuvant and animal however complicates the direct comparison between the two 
immunizations. 
Prefusion F has many epitopes 
Upon development of the stabilized prefusion F protein, it was suggested that the F trimer 
apical epitope Ø was the major site for prefusion-specific antibodies. Immunization with the 
prefusion F protein, in which this site was occluded with either D25 or AM22 could not raise 
substantially higher RSV-neutralizing response than postfusion F [1]. Since then other potent 
prefusion F-specific antibodies were discovered which do not bind to this site. MPE8, AM14, 
2E1 and F-VHH-4 and -L66 are all prefusion specific and bind to the side of the F trimer. 
These antibodies (or antibody fragments) all have neutralizing activities in about the same 
range as the site Ø-targeting D25 and AM22. Upon a natural infection, it could be more likely 
that most of the prefusion F-specific immunity is directed against the prefusion F apex, as 
this is the most accessible region. However, the relative contribution of site Ø-specific 
antibodies to the overall neutralizing activity in human serum appears to be highly individual 
varying from almost nothing to 100% [6].  
In conclusion, this study again confirms that site Ø is not the only region to which highly 
neutralizing prefusion F-specific antibodies can bind. The great transformation during the 
transition from prefusion to postfusion F probably disrupts many conformational epitopes in 
the prefusion F protein. F-VHH-4 and -L66 bind one of them, a site possibly not accessible for 
full-size conventional antibodies. 
In vivo therapeutic protection is not easy to demonstrate in the RSV mouse model 
The aim of this project was to develop powerful RSV-neutralizing VHHs which could suppress 
RSV replication in the mouse model efficiently. The obtained VHHs have outstanding in vitro 
neutralizing characteristics and can potently prevent RSV infection when administered 
prophylactically to RSV-challenged mice. Demonstrating a therapeutic effect in the RSV A2 
mouse model was not successful so far. The low permissiveness of RSV in rodents makes it 
very hard to show a therapeutic effect of a drug in this model. Some studies demonstrate a 
therapeutic effect based on reduction of viral load determined by plaque assay [7, 8]. These 
results however are questionable as remaining antibody in the lung samples can influence 
the result. Using RT-qPCR to determine the amount of viral RNA is a more trustworthy read-
out. Still, establishing a reduction in the amount of viral RNA by treatment is very hard as in 
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mice the amount of RSV genome does not increase above the background inoculum after 
infection [9]. While therapeutic administration of an anti-RSV antibody frequently is 
successful in reducing the amount of replicating virus based on plaque assay, often no 
reduction in viral RNA can be discerned. This is illustrated by a study by Meijas et al., who 
reported that intraperitoneal administration of palivizumab or motavizumab on day two 
after infection efficiently reduced the amount of replicating virus, yet did not lower the 
amount of viral RNA [10]. A possible solution could be to use an immunodeficient mouse 
model, in which RSV replicates more efficiently. Corti et al. for example could show a 
therapeutic effect of MPE8 and palivizumab when administered intravenously in Stat1-
deficient mice at day one post infection [11]. Treatment at day two after infection could not 
significantly reduce the amount of viral RNA, highlighting the importance of timing of 
treatment. In our study, we opted for the SCID mouse model in which viral RNA was shown 
to increase upon inoculation indicating active viral replication. Administration of 10 µg 
palivizumab intranasally at day two and three after infection could lower viral RNA load in 
the lung threefold compared to the Ctrl-VHH treatment. The reduction in replicating virus 
observed through plaque assay was far greater, yet heavily influenced by the remaining 
antibody in the lung. Treatment with F-VHH-4 did not have an effect on either read-out, 
indicating that there was no VHH remaining in the lung at the moment of sampling. The in 
vivo efficacy of F-VHH-4 might be enhanced by either increasing the local half-life of the 
VHHs or by adding effector functions. The local half-life can be enhanced by increasing the 
size of the VHHs for example by formatting the VHH in a multivalent structure. Multiple F-
VHH-4 molecules linked together could obtain increased efficacy by engaging in intra or 
inter-F trimer binding. Creating bispecific VHHs could be advantageous in other ways. Linking 
F-VHH-4 to a VHH specific for surfactant protein A (SPA) might result in enhanced 
effectiveness by bringing the VHH-bound virion together with the surfactant protein which 
has an immediate antiviral effect [12, 13]. This antiviral effect has been shown by studies in 
SPA-deficient mice [13]. These mice experienced greater immune cell influx upon RSV 
infection and RSV could replicate to higher titers in these hosts. These effects were not 
present when RSV was coadministrated with purified SPA. The antiviral effect of SPA is 
suggested to be linked to opsonization of RSV and its macrophage-activating activity [13, 14]. 
Adding Fc-receptor dependent functions could be established by adding an Fc-tail or a VHH 
that activates human and mouse Fcγ-receptors [15]. These molecules could enable antibody 
dependent cell mediated cytotoxicity and phagocytosis (ADCC and ADCP) and complement-
dependent reactions, resulting in faster clearance of RSV-infected cells. Several studies show 
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that these mechanisms could be of importance for protection against RSV. A study with a 
mutant MPE8 which lacks complement and Fc-receptor binding showed that this MPE8 
variant was severely less efficient in protecting mice from PVM-associated mortality in a 
prophylactic setting [11]. However, in a therapeutic setting, this mutant MPE8 was as 
effective as the original antibody. The role of Fc-receptor mediated functions is also 
exemplified by the protection against RSV conferred by antibodies targeting the ectodomain 
of the SH protein. This protective effect is solely based on clearance of RSV-infected cells via 
ADCC and ADCP, indicating that these processes alone can be sufficient for reduction of RSV 
replication [16]. A last demonstration of the importance of antibody effector functions in the 
control of RSV infections is a study in which a glycan variant of palivizumab was made in a 
plant-based expression system [17]. This variant had augmented antibody effector functions 
and was more successful in reducing RSV titers in the cotton rat lung compared to the 
conventional palivizumab. PEGylation at last not only increases the size of the VHH, it also 
shields the molecule from proteolytic enzymes and reduces potential immunogenicity [18-
20].  
The lack of therapeutic effect observed here could be attributed to the low replication of 
RSV A2 in the mouse model. The maRSV model might be a more powerful model to test the 
therapeutic efficacy of an RSV antiviral. 
Assessing the in vivo protective effect of an antibody is not so straightforward as assessing 
its neutralizing potency in vitro. In order to demonstrate a therapeutic effect, it is necessary 
to optimize factors like animal model, timing and route of administration, dose and half-life 
of the molecule.  
Mouse-adapted virus does not need the central domain of the G protein 
The last chapter describes the development of a maRSV strain through various passages in 
CP-treated and wild type (WT) mice. While the resulting virus is not completely adapted to 
the mouse as host, still a high inoculum is needed to induce morbidity, it has gained great 
vigor in this model compared to the parental RSV A2 strain. 
Five mutations were discerned, present in the majority of the maRSV quasispecies. The most 
remarkable one, a deletion of the central region of the G protein, is probably not the most 
significant one for the mouse-adapted phenotype. It has been demonstrated that viruses 
lacking G or a part of G replicate somewhat less efficiently in vivo [21, 22]. The mutation in 
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NS2 is more likely to be the major contributor to the mouse-adapted phenotype because 
NS2 has an essential role in the repression of the host antiviral response. The mouse-
adapted phenotype can probably be ascribed to a more efficient immune evasion rather 
than enhanced infection efficiency. The non-coding mutations, together with the mutations 
in the genes involved in the polymerase machinery might as well be of importance in the 
increased viral replication of the maRSV. 
The maRSV strain forms a great improvement for the RSV mouse model, as this virus can 
replicate to much higher titers compared to the commonly used RSV A2 laboratory strain. 
This enhanced viral replication results in increased morbidity which manifests in body weight 
loss in the mice. This reflects the human situation, where high viral titers are associated with 
severe disease [23, 24]. Further characterization of the infection process of maRSV in mice is 
necessary to elucidate if other features of human RSV infection, like shedding of infected 
epithelial cells and strong lung neutrophil influx, are also present in this mouse model. 
The maRSV model could be valuable to evaluate novel therapeutics and vaccines. However, 
as this virus lacks an important part of the G protein, it cannot be used to test G-binding 
antibodies such as antibody 131-2G which binds the central region of RSV G. If further 
research shows that the deletion in G does not contribute to the mouse-adapted phenotype, 
a recombinant maRSV strain with wild type G could form an improved model to test such 
antibodies. 
Perspectives 
The VHHs directed against the prefusion conformation of F were developed as a possible 
new therapeutic to treat RSV infections. F-VHH-4 can potently prevent RSV infection in mice 
yet a therapeutic effect has not been observed yet. Further optimization is required to 
evaluate the F-VHH's potential in mice. As the limited half-life of the VHH in the lung seems 
to be problematic, increasing the dosage and optimizing the timing of administration might 
be helpful. So far only the single-domain format of F-VHH-4 has been tested in vivo. Further 
research will point out if the bivalent and bispecific format (where the F-VHHs are linked to a 
VHH binding surfactant protein A), which were already developed during this thesis, has 
improved functionality in the mouse model. Further exploration of other formats (e.g. 
linking the F-VHHs to an Fc-tail or an Fcγ-receptor activating VHH, optimizing the linkers,...) 
would possibly lead to further optimization of the VHHs developed in this study. 
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As the mouse model for RSV possibly impedes the testing of therapeutic effectiveness, it 
would be interesting to test the therapeutic potential of F-VHH-4 in the maRSV mouse 
model. In this model it would be possible to use reduction in morbidity and mortality as 
read-out, in addition to reduction of viral titers.  
Once a therapeutic effect can be established, several more steps will be needed before the 
VHH can be considered for clinical testing. To minimize the risk of immunogenicity, it will be 
necessary to humanize the VHH sequence. The stability of the VHH under different 
circumstances will have to be determined. It is especially important to investigate if the VHH 
is able to withstand the process of nebulization, which would be the preferred method of 
administration to the patients. At last, the in vivo potential of the VHH will have to be 
validated in a different animal model, for instance the cotton rat or the neonatal lamb 
model. 
Further characterization of the other RSV-neutralizing VHHs picked up after DS-Cav1 
immunization might be an interesting line of research still to pursue. Epitope determination 
of these VHHs could be useful in the elucidation of other antigenic sites on the fusion protein 
which are targeted by antibodies elicited by DS-Cav1 immunization. Testing neutralization 
versus affinity of VHHs targeting different epitopes might demonstrate the presence of 
epitopes that are more sensitive than others. For example, epitopes containing secondary 
structures that undergo dramatic changes upon triggering compared to epitopes that do not 
contain such regions. This might provide insight in the fusion process for which we only 
know the beginning (prefusion conformation) and the end (postfusion conformation) but not 
what happens in between. 
Concerning the maRSV, a further functional analysis of the individual mutations is needed. At 
this moment it is still unclear what the relative contribution is of each of the observed 
mutations to the mouse-adapted phenotype. The function of the concerned proteins could 
be observed individually, by overexpression and functional assays, or in the context of a 
complete virus by creating recombinant RSV strains with one or a few of the found 
mutations through reverse genetics. This research could be valuable in the understanding of 
fundamental processes in RSV biology. Next it is still necessary to assess in how far the 
maRSV infection process resembles that in man. Although the improved viral replication is 
already an important parameter, it still needs to be determined if this maRSV strain also 
induces other more human-like infection characteristics. These characteristics include a high 
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neutrophil influx in the lung, epithelial cell shedding, infection of the bronchiolar epithelium, 
decreased levels of oxygen saturation and an increased respiratory rate. It would also be 
interesting to investigate if the observed loss of body weight is mediated by T cell influx 
(typical for mice) or not (typical for human) via T cell depletion. The obtained virus strain will 
have to be validated as a good model for analyzing antivirals and vaccines against RSV. 
Palivizumab and the SHe-based vaccine developed in our research group would be good 
candidates to validate the testing of such compounds in the maRSV model. Once validated, 
this model could be of great use for development of new RSV-specific antiviral strategies and 
vaccines.  
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Abstract 
Human respiratory syncytial virus (HRSV) was first discovered in the 1950s, but despite 
decades of research, a licensed vaccine against it is not available. Epidemiological studies 
indicate that antibodies directed against the fusion protein (F) partially correlate with 
protection. In addition, an F-specific monoclonal antibody is licensed as a prophylactic 
treatment in children who are at high risk of developing complications following HRSV 
infection. Therefore, most HRSV-oriented vaccination strategies focus on inducing a humoral 
immune response against F. In the quest for the development of a safe HRSV vaccine, the 
induction of a T cell immune response has received a lot less attention. T cell immunity 
directed against HRSV has not been associated unequivocally with protection against HRSV 
and CD4+ T helper cell responses may even worsen disease due to HRSV. However, many 
studies support a protective role for CD8+ T cells in clearance of HRSV from the lungs. In this 
review we highlight the clinical and experimental evidence in favor of a CD8+ T lymphocyte-
based vaccination strategy to protect against HRSV. First, we describe how T cell responses 
and T cell memory are induced in the lungs upon respiratory viral infection. HRSV has 
evolved mechanisms that hamper CD8+ T cell priming and effector functions. We appraise 
the information on HRSV-specific CD8+ T cell immunity gained from laboratory mouse 
studies, taking into account the advantages and limitations of this animal model and, where 
possible, the accordance with clinical evidence. Finally, we focus on recent efforts to develop 
T cell based vaccines against HRSV.  
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Introduction 
Infection with human respiratory syncytial virus (HRSV) is a major cause of severe 
pneumonia and bronchiolitis in new-born babies and young children [1]. Almost every child 
has been infected with HRSV before the age of two and will be re-infected several times 
more later on [2]. Each year, over 30 million infections with HRSV result in acute lower 
respiratory infections in children younger than five years, of whom 1-2% require 
hospitalization [3]. With an estimated annual death toll of 200,000 children younger than 
five years, mostly in developing countries, HRSV is a major killer [3]. HRSV infection does not 
result in long-lasting, protective immunity and re-infections are common [2]. In healthy 
adults HRSV (re)infections mostly result in symptoms resembling the common cold [4]. 
Remarkably, these re-infections occur in the absence of overt antigenic variation of the virus, 
suggesting that the levels of neutralizing antibodies and memory T cells induced by natural 
infections with HRSV do not provide long lasting protection [5]. It should be noted that 
severe disease due to HRSV infection is associated with high replication of this virus in the 
lower respiratory tract. Infection of the lower respiratory tract occurs more often in young 
infants and in the elderly. In these age groups, T cell immunity against HRSV is absent (the 
very young) or inadequate (in the elderly, due to immune senescence). 
The disease burden caused by HRSV clearly justifies research efforts to develop prevention 
and treatment strategies. The only available virus-specific preventive measure consists of 
monthly intramuscular injections of a monoclonal antibody (Palivizumab) directed against 
the fusion protein (F) of HRSV. This costly intervention reduces hospitalization by 50% [6]. 
Developing a safe and effective vaccine that prevents severe HRSV-associated disease would 
meet an important medical need.  
Here we focus on the role of CD8+ T cells directed against HRSV because there is 
considerable evidence that these immune effectors contribute to the control of disease 
caused by HRSV.  
Activation and proliferation of CD8+ T cells 
 Activation of CD8+ T cells starts with antigen-presenting cells (APCs), such as dendritic cells 
(DCs), which present peptides loaded on MHC class I molecules to the T cell receptor (TCR) 
of the naïve CD8+ T cell. Peptides can be uploaded in the MHC class I molecules of an APC in 
three ways: by direct presentation, with peptides derived from a protein expressed in the 
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APC itself; by cross presentation, where peptides come from extracellular proteins taken up 
by the APC; or by cross-dressing, meaning the exchange of MHC class I molecules, already 
uploaded with a peptide, from one APC to another one [7]. 
In the lung, DCs reside in the interstitium, where they sample the respiratory lumen with 
their dendrites. DCs are subdivided in conventional DCs (cDCs; CD11c+ MHC-II+) and 
plasmacytoid DCs (pDCs; CD11clow/B220+) [8]. cDCs are further divided into CD11b+CD103- 
DCs (CD11b+ DCs) and CD11b-CD103+ DCs (CD103+ DCs). Following HRSV infection, CD11b+ 
and CD103+ DCs migrate to the lung-draining lymph nodes (LNs) and present antigen to CD4+ 
and CD8+ T cells, respectively [9, 10]. It is not clear if direct or cross presentation is the main 
mechanism responsible for the display of HRSV-derived peptides by CD103+ DCs to the CD8+ 
T cells in the LN. Two reports proposed that, in mice, lung CD11b+ and CD103b+ DCs 
migrating to the mediastinal LNs are infected by HRSV, suggesting direct presentation (Figure 
1) [9, 10]. However, this was based on the presence of HRSV RNA or a GFP reporter in these 
cells, while the presence of viral RNA or GFP could also reflect the uptake of infected cells by 
these DCs, as has been observed for influenza [11]. 
Recognition by naive T cells of MHC/peptide complexes on APCs by a high affinity TCR 
interaction is generally referred to as “signal one”. APCs also have to provide two additional 
signals to activate CD8+ T cells. Signal two consists of the binding of B7 (also known as 
CD80/86), CD70 or OX-40L on APCs to CD28, CD27 or OX-40, respectively, on T cells, which 
triggers their clonal expansion [12, 13]. A third signal shapes the overall magnitude of the 
primary response and the formation of memory. This signal consists of cytokines, such as IL-
12, type I interferons and IL-15 [14]. In vitro, HRSV infection of human DCs impairs their 
capacity to activate T cells. This impairment is not due to a lack of DC maturation or antigen 
presentation but may rather involve a soluble factor [15]. Impaired T cell activation by HRSV-
infected mouse DCs was caused by inadequate immune synapse formation characterized by 
a lack of Golgi apparatus polarization in the T cells despite DC-T cell contact, rather than IL-
10 or another soluble factor [16]. A recent study by Gupta et al., suggests that depending on 
the type of myeloid DCs that are infected by HRSV, either Th1, Th2 or Tregs are activated 
[17]. In aggregate, DCs that become infected with HRSV seem to lose their natural capacity 
to activate T cells.  
HRSV encodes two nonstructural proteins NS1 and NS2, which suppress type I IFN 
production and signaling [18, 19]. This not only has a profound effect on the innate immune 
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response to HRSV but also on the induction of a CD8+ T cell response, which was proven in 
vivo by Kotelkin et al. (Figure 1) [20]. An in vitro study suggests that NS1 could also have a 
suppressive effect on CD8+ T cells independent of the type I IFN suppression [21].  
 
Fig. 1. The immune modulatory effect of HRSV in the induction of CD8+ T cells and the influx of 
antigen-specific CD8+ T cells into the lungs during HRSV infection. Based on the presence of HRSV 
RNA or GFP derived from a recombinant HRSV reporter virus in the CD11b+ and CD103+ cDCs, it has 
been suggested that HRSV can infect these cells. This may lead to direct presentation of HRSV 
antigens to the CD8+ T cells in the LN. PD-L1 is induced in the RSV infected bronchial epithelial cells. 
PD-L1 binds to PD-R1, present on CD8+ T cells, inhibiting the local activation of these CD8+ T cells. The 
HRSV proteins NS1/NS2 antagonize the type I IFN response, which leads to suppression of the 
activation and the effector activity of the CD8+ T cells. HRSV hampers the influx of CD8+ T cells (which 
are CX3CR1+) with the secreted variant of its G protein. This G protein contains a conserved CX3C 
motif, mimicking fractalkine, and reduces the migration of CX3CR1+ T cells to the lung. 
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Migration, effector functions and control of CD8+ T cells 
Once activated, T cells migrate from the LN to the site of infection, where they can exert 
their effector functions. The chemokine receptor CXCR3 governs the migration of CD8+ T 
cells from the LN into the lung parenchyma. CXCR3-/- mice show reduced leukocyte migration 
to the lungs after influenza A virus infection [22]. Inhibition of CXCL10, a CXCR3 ligand, 
results in exacerbated disease, impaired viral clearance and reduced numbers of HRSV 
specific CD8+ T cells in the lungs upon HRSV infection [23]. HRSV seems to directly counteract 
the migration of T cells to the lung through its G protein, which is involved in virion 
attachment to the host cell and is produced as a secreted variant by infected cells. HRSV G 
protein has a conserved CX3C motif that mimics fractalkine, a CX3C type chemokine, and 
reduces the migration of CX3CR1+ T cells to the lung following HRSV infection (Figure 1) [24, 
25].  
Cytotoxic T cells (CTLs) kill infected cells by lysing them through the perforin-dependent 
release of granzyme-containing granules or the induction of apoptosis of infected epithelial 
cells through interaction of Fas with Fas-Ligands [26]. When activated CD8+ T cells encounter 
target cells, they also produce pro-inflammatory cytokines such as IFN-γ, IL-2 and TNF-α. 
Even at this executioner phase, HRSV deploys inhibitory steps. HRSV infection of primary 
human bronchial epithelial cell induces Programmed Death Ligand 1 (PD-L1). Interaction of 
this ligand with Programmed Death Receptor 1 (PD-R1) that is present on CD8+ T cells, 
inhibits local activation of these cells and may contribute to delayed clearance of HRSV-
infected cells (Figure 1) [27]. In mice, it was found that an HRSV infection can actually 
suppress T cell effector function and the establishment of a long-lived lung memory 
response [28]. However, this reported functional impairment of lung CD8+ T cell effector 
activity is likely not unique to HRSV but rather is specific for the lungs, since it was also 
observed after infection with influenza and even in CD8+ T cells that had migrated from the 
periphery into the lungs after intradermal infection with vaccinia virus [29].  
The mammalian immune system has evolved mechanisms that balance the effector 
functions of cytotoxic CD8+ T cells. Regulatory T cells (Treg, CD4+ CD25+ Foxp3+ cells) do just 
that [30, 31]. Following HRSV infection, Tregs proliferate and rapidly accumulate in the 
mediastinal LNs and lungs. Depletion of Tregs from mice before HRSV infection results in 
exacerbated disease marked by increased weight loss, enhanced airway resistance and 
increased cellular influx into the lungs. Whether Treg depletion affects HRSV replication is 
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unclear. Some groups reported a delay in early CD8+ T cell influx in the lungs and virus 
clearance upon Treg depletion [30, 31]. In contrast, others observed enhanced pulmonary 
CD8+ T cell influx and increased viral clearance from the lungs upon Treg depletion [32]. This 
inconsistency might be explained by the different methods used for Treg depletion. Still, the 
consensus from these studies is that Tregs ameliorate disease following HRSV infection. 
Foxp3+ T regs and CD4+ and CD8+ effector T cells in the respiratory tract produce the anti-
inflammatory cytokine IL-10 following acute HRSV infection, with maximum production 
corresponding to the peak of the virus-specific T cell response [33, 34]. Even though T cells 
are an important source of IL-10 during HRSV infection in mice, many other cell types also 
produce IL-10. These include myeloid DCs, monocytes and macrophages [35-37]. Production 
of IL-10 limits inflammation that, at least in part, results from the HRSV-specific effector 
functions of these cells [33, 38]. This seems in line with findings in HRSV-infected IL-10 
deficient mice, which show more weight loss, delayed recovery and enhanced immune cell 
infiltration into the respiratory tract compared to normal mice, even though virus clearance 
is intact [32]. Interfering with IL-10 signaling by injection of an IL-10 receptor antagonist 
alters the activated T cell subsets during primary HRSV infection and results in more IL-17 
producing CD4+ T cells and fewer Foxp3+ Tregs. The resulting disease outcome is 
characterized by increased body weight loss and airway resistance [33]. This critical role for 
IL-10 in controlling disease due to HRSV had already been suspected from genetic studies in 
humans: certain polymorphisms in the IL-10 gene are associated with the development of 
severe bronchiolitis in HRSV infected infants [39, 40]. 
Characteristics of memory CD8+ T cells 
After elimination of the pathogen-infected cells, the effector phase is followed by a 
contraction phase where the vast majority of effector T cells will die. However, a subset of 
these effector T cells will further differentiate into memory T cells [13, 41]. Originally, these 
memory T cells (both CD4+ and CD8+ T cells) were divided in two subsets based on their 
homing properties and phenotype [42]. Central memory T cells (TCM, CD45RA
-CCR7+ 
(human)) circulate in lymphoid tissues, have proliferative capacity and effector function. 
Effector memory T cells (TEM, CD45RA
-CCR7- (human)) circulate in lymphoid tissues and 
peripheral tissues and have immediate effector function. In the last years evidence for a 
third type of memory T cells, tissue resident memory T cells (TRM), is rising [43-45]. In 
contrast to the circulating TCM and TEM, TRM are tissue specific and do not circulate. TRM are 
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distinguished from the circulating memory T cells by the expression of CD69 [46]. Although 
the exact origin of the TRM and the relationship with TCM and TEM is unclear, lung TRM play an 
important role in immunity against respiratory pathogens (e.g. influenza virus, HRSV) [46-
50]. 
Memory CD8+ T cells, generated after vaccination or after an encounter with the same 
pathogen, can rapidly clear a secondary infection. This is partially a matter of numbers. 
Whereas only 100 to 1000 CD8+ T cells specific for a given epitope are present in naive mice, 
the antigen specific memory CD8+ T cell population after infection is at least 100 to 500 
times larger [51, 52]. A secondary HRSV infection in mice induces an accelerated lymphocyte 
response (both CD4+ and CD8+) involving a greater number of T cells compared to a primary 
infection [53-56]. In addition, these epitope-specific memory CD8+ T cells have 
characteristics that distinguish them from naive CD8+ T cells. First, they can rapidly produce 
cytokines such as IFN-γ, TNF-α and IL-2. Second, target cell killing by memory CD8+ T cells 
does not require prior co-stimulation, and memory CD8+ T cells are more cytotoxic due to 
their heightened expression of granzyme B [13]. Finally, memory CD8+ T cells can reside in 
peripheral tissues, such as the lung, close to the site of pathogen invasion [57]. It is also 
important to note that pre-existing antibodies in individuals who already experienced HRSV 
infection, can increase secondary CD4+ and reduce CD8+ T cell responses. Both neutralizing 
and non-neutralizing IgG augment HRSV-specific CD4+ T cell responses in the presence of life 
HRSV, presumably by increasing MHC-II restricted antigen presentation through the 
formation of immune complexes. In contrast, HRSV neutralizing antibodies lowered the CD8+ 
T cell responses, most likely by reducing infection of APCs [58]. 
 An intriguing feature of HRSV infection is the susceptibility of previously infected individuals 
to reinfection with antigenically closely related viruses or even an identical virus strain [2]. In 
a human challenge model, almost 50% of adults with high levels of circulating neutralizing 
antibodies could be re-infected with HRSV of the same serotype within two months of 
natural infection [5]. This suggests that the duration of protective immunity to HRSV is short-
lived and that long-lived memory T cell formation might be weak. The latter assumption is 
supported by a study in healthy elderly people where the researchers analyzed the CD8+ T 
cell subsets specific against the immunodominant epitopes in the matrix protein (M229-237) 
and the nucleoprotein (NP306-314). They found that compared to influenza A specific CD8
+ T 
cells, there are much less HRSV specific CD8+ T cells present in the peripheral blood [59]. 
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In healthy adults the frequency of memory CD8+ T cells specific for different HRSV epitopes 
in peripheral blood mononuclear cells (PBMCs) is low [60]. Low levels of HRSV specific CD8+ T 
cells were also observed in PBMCs of infants [61, 62]. Moreover, HRSV reinfection does not 
boost the levels of HRSV specific CD8+ T cells in circulation in infants [63]. However 
compared to those in the peripheral blood, the frequencies of HRSV- and influenza-specific 
memory CD8+ T cells (specific against the immunodominant peptides of HRSV-M229-237 or 
influenza-M158-66 or NP44-52) in the lungs of adults are much higher [50]. The HRSV-M specific 
CD8+ T cells found in the lungs of these healthy adult volunteers also have a more advanced 
differentiation state (lower expression profile of CD27 and CD28) than the ones present in 
the circulation [50, 59]. Recently, Turner et al. found that influenza specific memory CD4+ 
and CD8+ T cells (influenza NP366-374 and PA224-233 (mice) and influenza M158-66 (human)) 
accumulate in the lung as TRM after influenza virus infection in mice and in human donor 
samples [49]. For HRSV, a similar mechanism might apply, although it needs to be 
determined if the lung TRM provide (partial) protection against challenge.  
Control of HRSV by CD8+ T cells: do mice fool us? 
CD8+ T cells with a TCR directed against viral epitopes presented in an MHC class I context on 
the surface of infected cells can clear cells infected with respiratory viruses such as HRSV 
[64]. Clear evidence for such a role of CD8+ T cells came from adoptive transfer studies. 
Transfer of HRSV-primed T cells derived from the spleens of HRSV infected mice to athymic 
nu/nu BALB/c mice or immunodeficient gamma-irradiated mice results in HRSV clearance by 
day 15 after infection, much faster than in recipients of unprimed T cells [65]. Clearance can 
be achieved by transfer of either CD4+ or CD8+ T cells separately, or by the combination of 
both. However CD4+ T cells are less efficient in clearing HRSV than CD8+ T cells. 
The mode of action of cytotoxic CD8+ T cells inevitably implies some degree of tissue damage 
and at least local inflammation. Therefore, it is not always clear whether these cells also 
contribute to lung damage. Importantly, the effects of CD8+ T cells probably differ between 
laboratory mice and humans. Mouse studies support a critical role of CD8+ T cells in HRSV 
clearance, although this might come at a cost of concomitant lung pathology. For example, 
transfer of monoclonal CD8+ T cells specific for an uncharacterized epitope of HRSV into 
gamma irradiated mice rapidly cleared the virus from the lungs of persistently infected mice. 
This clearance was associated with significant weight loss, ruffled fur, respiratory disease 
(tachypnea, cyanosis) and a high mortality rate [66]. Similar results were observed in 
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immune-competent mice [66]. A reciprocal experimental approach, using in vivo T cell 
depletion, largely confirmed the critical role of CD8+ T cells in both virus clearance and lung 
pathology [67].  
These findings in mice contrast substantially with results observed in humans, for whom 
there is no clear evidence for a CD8+ T cell role in lung pathology [68]. The most vulnerable 
group of HRSV patients are infants younger than six months. Unfortunately, we know very 
little about the lung resident immune responses in this age group. The generally accepted 
paradigm is that the infant immune system develops and reacts to a variety of infections 
differently and less effectively than the adult immune system [69, 70]. In children suffering 
from severe disease caused by HRSV, the number of effector CD8+ T cells in the blood and 
bronchoalveolar lavage (BAL) does not correlate with disease severity [68]. This suggests 
that the CD8+ T cell response in itself does not necessarily contribute to disease [68]. In fact, 
there is evidence that CD8+ T cell responses correlate with recovery from disease. This is 
supported by a study by Lukens et al., who monitored HRSV viral load in the lungs and the 
CD8+ T cell numbers in the blood of hospitalized infants [71]. Viral load peaked during the 
first days of hospitalization, and it correlated with disease severity two to three days after 
admission. In contrast, the levels of CD8+ T cells in the blood were maximal around day 11–
15 after onset of the primary symptoms, i.e. during the recovery phase [71]. Moreover, fatal 
cases of HRSV infections are characterized by high viral titers and near absence of pulmonary 
infiltration of T cells or the cytokines they produce [72]. Finally, children with T cell 
deficiencies shed virus for months instead of 7-21 days in otherwise healthy children [73]. In 
conclusion, human CD8+ T cells seem to contribute to HRSV clearance but not to lung 
pathology. 
CD8+ T cell-based HRSV vaccines 
The development of an HRSV vaccine has been hampered by the unfortunate outcome of 
the formalin inactivated (FI) HRSV-vaccine trial conducted in the 1960s. Although this 
vaccine did lead to a high HRSV specific antibody titer, it was not effective at all: instead of 
preventing HRSV-associated disease, it actually exacerbated disease in HRSV-naïve infants 
[74]. The antibodies induced by the FI-vaccine were not able to neutralize the virus nor 
inhibit fusion, while a normal HRSV infection does lead to such protecting antibodies [75]. It 
has been proposed that the formalin treatment altered the epitopes of the F and G protein, 
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which lead to induction of low-avidity non-neutralizing antibodies causing immune complex 
deposition and enhanced inflammation upon an HRSV infection [76]. Another observation 
that contributed to the exacerbated disease was an exaggerated CD4+ T cell response [77] 
which is associated with a distorted Th1/Th2 balance towards the Th2 response, suggesting 
that an allergy-like condition developed during infection [78]. 
It is generally accepted that HRSV vaccines should induce a Th1-polarized immune response 
to limit the risk of immune pathology upon infection. In mice, vaccine-induced virus-specific 
CD8+ T cells downregulate the Th2 response following HRSV challenge [79]. An additional 
argument for avoiding a Th2-type of response in the case of vaccine strategies that rely on 
CD8+ T cell effector mechanisms is that IL-4 and IL-13 (typical Th2 cytokines) can decrease or 
alter the cytotoxic activity of these cells [80, 81]. 
The prime target groups for a prophylactic HRSV vaccine are very young infants and the 
elderly, because most of the patients that develop severe disease after HRSV infection are 
present in these age groups. Very early in life, maternal-derived HRSV neutralizing antibodies 
offer some protection. Therefore, maternal immunization aimed at inducing neutralizing 
antibodies may improve protection of the very young against HRSV [82, 83]. To induce 
protective T cells in very young infants is a major challenge given the relatively 
underdeveloped adaptive immune system of newborns and a predisposition to a Th2 
response [84]. Moreover, the innate response to HRSV infection is much weaker in 
newborns compared to that in adults. Indeed, infection of pDCs derived from cord blood 
with HRSV results in much lower interferon-α levels [85].  
HRSV infection in the elderly causes mild to severe respiratory disease, with a high chance 
for complications [4, 86]. Yet surprisingly it was found that the induction of an HRSV-specific 
humoral response doesn’t seem to decline with age, it even seemed to be more vigorous 
than in younger people [87]. On the other hand, cellular immunity does diminish with 
increasing age, reflected for example in lower CTL generation [59, 88, 89]. Increased 
pathology upon HRSV infection is probably due to an age-related shift from a Th1-like to a 
Th2-like cytokine response [90, 91]. A vaccine inducing neutralizing antibodies, while tipping 
over the Th1/Th2 balance towards a Th1-like response could do the trick in this aged target 
group.  
Several groups focused on CD8+ T cell-based approaches. Voges and colleagues used 
recombinant Sendai virus (a respirovirus) expressing HRSV F protein (SeV F) or soluble HRSV 
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F protein (SeV sF) as a potential vaccine [92]. These recombinant Sendai viruses induced 
both an antibody response and a CTL response to the F protein and protected mice against 
an HRSV challenge given three weeks after vaccination. Remarkably, vaccination with SeV F 
and Sev sF also protected B cell-deficient MB1 mice from HRSV challenge, indicating that T 
cells are sufficient to provide protection, at least early after vaccination. Whether this Sendai 
vectored CD8+ T cell antigen delivery induced robust memory T cell formation and provided 
protection later on was not examined. In adult BALB/c mice, infection with vaccinia virus 
expressing the HRSV M2 protein induces a robust CD8+ T cell response, directed 
predominantly against a single M2-derived peptide (M282-90). This CD8
+ T cell response 
promotes HRSV clearance following challenge. Furthermore, this enhanced virus clearance 
was even obtained by a vaccinia vector expressing M282-90 as the sole heterologous 
“antigen”, illustrating that this HRSV epitope represents a vulnerable HRSV target for CTLs, at 
least in the mouse model [93, 94]. Several other studies also focused on a single CTL epitope 
of the HRSV M2 protein. A plasmid containing a minigene encoding HRSV M282-90 was 
assessed as a DNA vaccine in mice. Intradermal injection with this plasmid induced an M282-
90 specific CD8
+ T cell response that provided significant reduction in viral load upon HRSV 
challenge three weeks later [95]. Intranasal administration of this DNA formulated in 
nanoparticles composed of chitosan also induced a protective M282-90 specific CD8
+ T cell 
response [96]. However, HRSV challenge was performed only 14 days after the last 
vaccination and the memory response induced by this DNA vaccine was not assessed. 
For the induction of a long-lasting memory response, a peptide consisting of the same M282-
90 CD8
+ T cell epitope was formulated with different adjuvants. Upon administration of the 
M282-90 peptide together with the enterotoxin-based adjuvant LTK63, the CD8
+ T cells 
remained detectable in the spleen for more than 100 days after vaccination [97]. 
Unfortunately, resistance to HRSV afforded by this vaccine upon an HRSV infection was 
accompanied with greater weight loss, illustrating the downside of unbalanced T cell 
immunity against HRSV in mouse. Simmons et al. proposed that excessive TNF (a cytokine 
that can induce cachexia) production during viral infection, which is partly driven by IFN- 
producing CTLs, was responsible for the enhanced weight loss. Alternatively, immunization 
with a fusion protein composed of the M282-90 epitope fused to the carrier protein DsbA 
(disulphide bond isomerase) of E. coli or the measles virus F1 protein induced CD8+ T cells 
that correlated with protection against challenge and remained detectable in the spleen 
until four months after vaccination [98]. These CD8+ T cells possessed ex vivo cytolytic 
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activity, but the ability to protect against an HRSV challenge at this later time point was not 
examined. In contrast to the previous study challenge of DsbA-M282-90 vaccinated mice was 
not associated with enhanced weight loss. Possibly the difference in outcome is attributable 
to the challenge dose used: the 30-fold lower dose with HRSV-A long, which is also less 
pathogenic in BALB/c mice than HRSV-A2, used in the Simmons study [99]. Controlling the 
relatively low challenge dose of a poorly pathogenic strain would only require a limited CD8+ 
T cell response.  
Only three vaccines have been licensed for administration at the time of birth or within the 
first few weeks of life: Hepatitis B vaccine, Oral Polio Vaccine (OPV) and BCG (Bacillus 
Calmette–Guérin). Bueno et al. used BCG as a vector to induce T cell immunity against the 
M2 and nucleocapsid (N) proteins [100]. BCG is used in newborns to protect against 
tuberculosis, and the immune responses induced by this vaccine are considered Th1 
oriented. Immunization of BALB/c mice with recombinant BCG expressing M2 or N indeed 
resulted in HRSV-specific T cells that predominantly produced IL-2 and IFN-, and it was 
associated with ameliorated disease and reduced lung virus load following challenge with 
HRSV. Adoptive transfer experiments demonstrated that both CD4+ and CD8+ T cells from 
BCG-N immunized mice were needed for protection [101]. Whether long term protection 
was achieved by this method is again not clear because the study employed challenge within 
three weeks after immunization.  
A vaccine named TriVax, consisting of a peptide representing the immunodominant M282-90 
CD8+ T cell epitope, the Toll-like receptor agonist poly(I·C), and a costimulatory anti-CD40 
antibody, was used as a T cell vaccine [102]. It induced HRSV-specific effector and memory 
CD8+ T cells in BALB/c mice. Vaccinated mice were protected against HRSV infection, as they 
efficiently cleared HRSV four days after challenge. However, HRSV challenge was performed 
only six days after vaccination, which is when CTL numbers are still expanding as a result of 
vaccination. In addition, protection against HRSV challenge by memory T cells was only 
partial: an HRSV challenge 42 days after TriVax vaccination reduced the viral lung titer 4 days 
after challenge only tenfold. In a model of aged BALB/c mice, impairment of HRSV specific 
CD8+ T cell responses upon TriVax vaccination correlated with the absence of protection 
against a subsequent HRSV challenge [103]. Protection was partially restored by 
simultaneous administration of an agonistic anti-CD137 mAb, which enhanced HRSV specific 
CD8+ T cell responses in the lungs of these old mice. 
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To explore the possibility of inducing a CD8+ T cell response against HRSV using a live viral 
vector, we constructed a recombinant influenza virus carrying the HRSV F85-93 CTL epitope in 
the stalk of the influenza neuraminidase (PR8/NA-F85-93 virus). Infection of mice with this 
virus showed effective induction of an HRSV specific CTL response upon HRSV challenge 28 
or 50 days after the vaccination, and that these CTLs correlated with significantly reduced 
virus replication in the lungs [104]. Presumably, live (attenuated) influenza virus is needed as 
a vector for the delivery of a protective HRSV response, because an approach that was based 
on a replication-incompetent influenza virus to deliver HRSV F did not induce detectable 
HRSV-specific antibodies and was associated with enhanced disease upon HRSV challenge 
[105]. 
How can vaccination strategies be optimized to elicit better HRSV-specific CD8+ T cell 
responses and improve immune memory formation, in particular in very young infants? One 
possibility is to try steering the co-stimulatory signals between the APC and the CD8+ T cell. 
In neonatal mice the hierarchy of the CD8+ T cell response is profoundly different and the 
resulting CD8+ T cell responses functionally much weaker than in adult mice. This difference 
is likely due to limited costimulation of CD28 on the T cell during antigen presentation [9]. 
Therefore, a possible strategy to drive the CD8+ T cell responses into a more protective 
adult-like response could be the use of life-vectors or genetic vaccines that are engineered 
to express CD28 together with the HRSV antigens. Another possibility to optimize a CD8+ T 
cell inducing HRSV vaccine is to specifically induce the HRSV-specific TRMs, by specific routes 
of vaccination and/or adjuvants. TRMs are present close to the site of infection, where they 
could provide protection early on in the infection.  
Conclusions 
It will probably take a long time to develop a safe and effective HRSV vaccine. There is 
sufficient evidence that human CD8+ T cells play an important role in viral clearance and 
probably in control of disease. But a long lasting T cell memory after natural HRSV infection 
is lacking. Therefore, we believe that increasing the CD8+ T cell memory response will be 
essential for effective protection against HRSV. Several strategies for the induction of CD8+ T 
cells against HRSV by vaccination have been explored. The induction of a T cell response per 
se is no longer a challenge, but rather the formation of a long-lasting protective memory 
CD8+ response. Therefore, to develop a safe and effective HRSV vaccine, a better 
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understanding of the formation of the memory response to HRSV CTL epitopes is necessary. 
Ideally, an HRSV vaccine should be administered to the infant as early as possible. Since the 
potential use of a non-replicating HRSV vaccine is still being held back in this age population, 
a replicating vaccine is currently the best option. BCG and OPV are administered at or within 
a first few weeks after birth, and live attenuated vaccines against rotavirus, measles virus, 
mumps virus and rubella virus are routinely used in early childhood (from one year onwards 
in most countries) vaccination programs, which might facilitate the acceptance of a potential 
live attenuated HRSV vaccine in the early childhood vaccination program. 
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